

**CUMULATIVE
SUPPLEMENT 10
OCTOBER 2002**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

22nd EDITION

Department of Health and Human Services

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2002

RM
301.45
.A66
2002
Oct.
suppl.

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

1.0 INT
1.1
1.2
1.3
1.4
1.5
1.6
1.7
DRUG

P

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

22ND EDITION

Cumulative Supplement 10

October 2002

CONTENTS

	PAGE
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes	iv
1.3 Waived Exclusivity	vi
1.4 Tramadol Hydrochloride Tablets	vi
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Change Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

Library Use Only

THE UNIVERSITY OF
MICHIGAN LIBRARY

ANN ARBOR, MICHIGAN

48106-1000

300 N ZEEB

ANN ARBOR, MI 48106-1000

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

22ND EDITION

CUMULATIVE SUPPLEMENT 10
October 2002

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 22nd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 22nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 23rd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

DANBURY PHARMACEUTICALS INC
(DANBURY PHARMA)

DURAMED PHARMACEUTICALS INC
(DURAMED)

DERMIK LABORATORIES INC
(DERMIK LABS)

DERMIK LABORATORIES INC SUB RORER
(DERMIK LABS)

JANSSEN RESEARCH FDN
(JANSSEN)

JANSSEN RESEARCH FDN DIV
JOHNSON AND JOHNSON
(JANSSEN)

JOHNSON AND JOHNSON PHARMACEUTICAL
RESEARCH AND DEVELOPMENT LLC
(JOHNSON AND JOHNSON)

MCNEIL CONSUMER HEALTHCARE DIVISION
(MCNEIL CONS)

MOVA PHARMACEUTICALS CORPORATION
(MOVA)

NMC LABORATORIES INC

PARKE DAVIS PHARMACEUTICALS LTD
(PARKE DAVIS PHARMS)

RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE
(JOHNSON RW)

RW JOHNSON PHARMACEUTICAL RESEARCH
INSTITUTE DIV ORTHO PHARMACEUTICAL CORP
(JOHNSON RW)

THAMES PHARMACAL COMPANY INC
(THAMES)

WHITEHALL LABORATORIES INC DIV AMERICAN HOME
PRODUCTS CORP
(WHITEHALL LABS)

WHITEHALL ROBINS HEALTHCARE
(WHITEHALL LABS)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

WATSON LABORATORIES INC
(WATSON LABS)

DURAMED PHARMACEUTICALS INC SUB OF BARR
LABORATORIES INC
(DURAMED PHARM BARR)

DERMIK LABORATORIES DIVISION OF AVENTIS
PHARMACEUTICALS INC
(DERMIK LABS)

DERMIK LABORATORIES DIVISION OF AVENTIS
PHARMACEUTICALS INC
(DERMIK LABS)

JANSSEN PHARMACEUTICA PRODUCTS LP
(JANSSEN PHARMA)

JANSSEN PHARMACEUTICA PRODUCTS LP
(JANSSEN PHARMA)

ORTHO MCNEIL PHARMACEUTICAL INC
(ORTHO MCNEIL PHARM)

MCNEIL CONSUMER AND SPECIALTY PHARMACEUTICALS
DIVISION MCNEIL PPC
(MCNEIL CONS SPECT)

CLONMEL HEALTHCARE LTD
(CLONMEL HLTH)

ALPHARMA US PHARMACEUTICAL DIV
(ALPHARMA US PHARM)

PFIZER PHARMACEUTICALS LTD
(PFIZER PHARM LTD)

ORTHO MCNEIL PHARMACEUTICAL INC
(ORTHO MCNEIL PHARM)

ORTHO MCNEIL PHARMACEUTICAL INC
(ORTHO MCNEIL PHARM)

TARO PHARMACEUTICALS NORTH AMERICA INC
(TARO PHARMS US)

WYETH CONSUMER HEALTHCARE
(WYETH CONS)

WYETH CONSUMER HEALTHCARE
(WYETH CONS)

1.3 WAIVED EXCLUSIVITY

Waived exclusivity - If a new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the expiring patent or exclusivity listed in the Orange Book.

However, the holder of the NDA may waive its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waives its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The application referencing this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity.

1.4 TRAMADOL HYDROCHLORIDE TABLETS. Tramadol Hydrochloride 50 mg tablet products approved under section 505(j) are marked with a (*) because there are special considerations governing the substitution of these products. The tramadol hydrochloride 50 mg tablets marked with a (*) are therapeutically equivalent to RW Johnson's Ultram (Tramadol Hydrochloride) 50 mg tablets. However, because of RW Johnson's exclusivity and patent protection for the 25 mg titration dosing regimen, tramadol hydrochloride drug products approved under section 505(j) may not carry the labeling for the 25 mg titration dosing regimen. Ultram 50 mg tablets are scored for use in the 25 mg titration schedule; tramadol hydrochloride 50 mg tablets approved under section 505(j) are not scored. Prescribers and dispensers should be aware of this scoring difference between Ultram and other tramadol hydrochloride tablets and take it into account when writing a prescription or practicing drug product selection.

1.5 AVAILABILITY OF THE EDITION

The 22nd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is \$105.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at <http://www.fda.gov/cder/orange/adp.htm>.

The Internet version of the hard copy monthly supplement is at <http://www.fda.gov/cder/orange/supplement/cspreface.htm>. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 22nd annual edition of the 2001 Orange Book Patent and Exclusivity List is at <http://www.fda.gov/cder/orange/22bookpub.pdf>.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at <http://www.fda.gov/cder/orange/docket.pdf>. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at: <http://www.fda.gov/cder/orange/patdecl.pdf>
<http://www.fda.gov/cder/orange/patdecl.html>

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2001) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product

activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2001</u>	<u>MAR 2002</u>	<u>JUN 2002</u>	<u>SEP 2002</u>
DRUG PRODUCTS LISTED	10166	10357	10193	10329
SINGLE SOURCE	2665 (26.2%)	2645 (25.5%)	2400 (23.5%)	2399 (23.2%)
MULTISOURCE	7391 (72.7%)	7602 (73.4%)	7687 (75.4%)	7824 (75.8%)
THERAPEUTICALLY EQUIVALENT	7105 (69.9%)	7309 (70.6%)	7402 (72.6%)	7549 (73.1%)
NOT THERAPEUTICALLY EQUIVALENT	286 (2.8%)	293 (2.8%)	285 (2.8%)	275 (2.7%)
EXCEPTIONS ¹	110 (1.1%)	110 (1.1%)	106 (1.0%)	106 (1.0%)
NEW MOLECULAR ENTITIES APPROVED	10	1	5	5
NUMBER OF APPLICANTS	574	574	574	582

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to cu
>D>. The pro
display only th
year will be lis

The change co

NEWA
CAHN
CDFR
CFTG
CMFD

CPOT
CRLD
CTEC
CTNA
DISC

WDAG

WDRP

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.



ACEBUTOLOL HYDROCHLORIDE

	CAPSULE; ORAL				
	SECTRAL				
AB	ESP PHARMA	EQ 200MG BASE	N18917 001	DEC 28, 1984	JUL CAHN
AB +		EQ 400MG BASE	N18917 003	DEC 28, 1984	JUL CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

	CAPSULE; ORAL				
	ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE				
AB	VINTAGE PHARMS	325MG;50MG;40MG;30MG	N75929 001	APR 22, 2002	APR NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

	CAPSULE; ORAL				
	PHENAPHEN W/ CODEINE NO. 2				
	@ ROBINS AH	325MG;15MG	N84444 001		MAY DISC
	SOLUTION; ORAL				
	ACETAMINOPHEN AND CODEINE PHOSPHATE				
AA +	ALPHARMA	120MG/5ML;12MG/5ML	N85861 001		MAY CRLD
	TYLENOL W/ CODEINE				
	@ JOHNSON RW	120MG/5ML;12MG/5ML	N85057 001		MAY DISC
	TABLET; ORAL				
	ACETAMINOPHEN AND CODEINE PHOSPHATE				
AA	ABLE	300MG;30MG	N40452 001	AUG 01, 2002	AUG NEWA
AA		300MG;60MG	N40459 001	AUG 01, 2002	AUG NEWA
	@ PUREPAC PHARM	300MG;60MG	N86683 001		MAY DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

	SOLUTION; ORAL				
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
AA	KV PHARM	500MG/15ML;7.5MG/15ML	N40366 001	JAN 23, 2002	JAN NEWA
	TABLET; ORAL				
AA	ABLE	325MG;7.5MG	N40464 001	OCT 23, 2002	OCT NEWA
AA		325MG;10MG	N40464 002	OCT 23, 2002	OCT NEWA
AA		650MG;10MG	N40476 001	OCT 23, 2002	OCT NEWA
AA		750MG;7.5MG	N40469 001	OCT 25, 2002	OCT NEWA
AA +	MALLINCKRODT	660MG;10MG	N40084 003	JUL 29, 1996	JUL CTNA
AA		750MG;10MG	N40468 001	OCT 31, 2002	OCT NEWA
AA	UCB	500MG;10MG	N40210 001	AUG 13, 1997	JUN CAHN
	+ WATSON LABS	750MG;10MG	N40094 004	MAR 22, 1999	OCT CFTG
AA +		750MG;10MG	N40094 004	MAR 22, 1999	OCT CFTG
	NORCO				
AA +	WATSON LABS	325MG;5MG	N40099 001	JUN 25, 1997	MAY CTNA

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

	TABLET; ORAL				
	ACETAMINOPHEN AND PENTAZOCINE HCL				
AB	AMIDE PHARM	650MG;EQ 25MG BASE	N76202 001	AUG 02, 2002	AUG NEWA

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

	TABLET; ORAL				
	DARVOCET				
	@ AAIPHARMA LLC	325MG;32.5MG	N16844 001		JUN CAHN

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL		DARVOCET-N 100	
AB +	AAIPHARMA LLC	650MG;100MG	N17122 002 JUN
DARVOCET-N 50		AAIPHARMA LLC	
AB		325MG;50MG	N17122 001 JUN

ACYCLOVIR

TABLET; ORAL		ACYCLOVIR	
AB	NEOSAN PHARMS	400MG	N74946 001 NOV 19, 1997 JUL
AB		800MG	N74946 002 NOV 19, 1997 JUL

ADEFOVIR DIPIVOXIL

TABLET; ORAL		HEPSERA	
+	GILEAD	10MG	N21449 001 SEP 20, 2002 SEP

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION		CHROMALBIN	
	@ ISO TEX	100uCi/VIAL	N17835 001 JUN

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION		RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125	
	@ MALLINCKRODT	6.67uCi/ML	N17844 003 JUN
	@	100uCi/ML	N17844 002 JUN

ALBUTEROL

AEROSOL, METERED; INHALATION		PROVENTIL	
BN +	SCHERING	0.09MG/INH	N17559 001 JUN

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION		PROVENTIL-HFA	
BX +	3M	EQ 0.09MG BASE/INH	N20503 001 AUG 15, 1996 MAR
VENTOLIN HFA		GLAXOSMITHKLINE	
BX +		EQ 0.09MG BASE/INH	N20983 001 APR 19, 2001 MAR
TABLET, EXTENDED RELEASE; ORAL		ALBUTEROL SULFATE	
AB	SIDMAK LABS	EQ 4MG BASE	N76130 002 SEP 26, 2002 SEP
AB		EQ 8MG BASE	N76130 003 SEP 26, 2002 SEP
VOLMAX		MURO	
AB +		EQ 4MG BASE	N19604 002 DEC 23, 1992 SEP
AB +		EQ 8MG BASE	N19604 001 DEC 23, 1992 SEP

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION		ALFENTA	
AP +	GD SEARLE LLC	EQ 0.5MG BASE/ML	N19353 001 DEC 29, 1986 JUL

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

@ GENZYME

10 UNITS/ML

N20057 004 MAY 08, 1992 JUN DISC

JUN CAHN

JUN CAHN

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALOPRIM

+ DSM PHARMS

EQ 500MG BASE/VIAL

N20298 001 MAY 17, 1996 JUN CAHN

JUL CAHN

JUL CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN;
DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE
SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

INJECTABLE; INJECTION

INFUVITE ADULT

+ SABEX 2002

2 IU/ML; 20MG/ML; 12UGM/ML; 40
 IU/ML; 1UGM/ML; 3MG/ML; 80UGM/ML; 8MG/M
 L; 0.8MG/ML; 0.72MG/ML; 0.6MG/ML; 600
 IU/ML

N21163 001 MAY 18, 2000 AUG CTNA

SEP NEWA

MULTI-12

+ SABEX 2002

2 IU/ML; 20MG/ML; 12UGM/ML; 40
 IU/ML; 1UGM/ML; 3MG/ML; 80UGM/ML; 8MG/M
 L; 0.8MG/ML; 0.72MG/ML; 0.6MG/ML; 600
 IU/ML

N21163 001 MAY 18, 2000 APR CAHN

JUN DISC

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

PHARMACIA AND UPJOHN

0.01MG/VIAL

N21212 001 JUN 11, 2002 JUN NEWA

0.02MG/VIAL

N21212 002 JUN 11, 2002 JUN NEWA

JUN DISC

JUN DISC

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

AMANTADINE HCL

AA CAROLINA MEDCL

50MG/5ML

N75819 001 SEP 11, 2002 SEP NEWA

JUN CRLD

AMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

@ MEDIMMUNE ONCOLOGY

375MG/VIAL

N20221 002 SEP 10, 1999 JUN DISC

MAR CTEC

MAR CTEC

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 7%

@ ABBOTT

7% (7GM/100ML)

N17673 002

JUN DISC

SEP NEWA

SEP NEWA

AMINOSYN 8.5%

@ ABBOTT

8.5% (8.5GM/100ML)

N17673 004

JUN DISC

SEP CFTG

SEP CFTG

AMINOSYN II 3.5%

@ ABBOTT

3.5% (3.5GM/100ML)

N19438 001 APR 03, 1986

JUN DISC

BRANCHAMIN 4%

@ BAXTER HLTHCARE

4% (4GM/100ML)

N18678 001 SEP 28, 1984

JUN DISC

JUL CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

>A>		AMIODARONE HCL							
>A>	AP	ABBOTT	50MG/ML	N75955 001	OCT 18, 2002	OCT	NEWA		
>A>	AP	AM PHARM PARTNERS	50MG/ML	N75761 001	OCT 15, 2002	OCT	NEWA		
>A>	AP	BEDFORD	50MG/ML	N76018 001	OCT 15, 2002	OCT	NEWA		
>A>	AP	BEDFORD LABS	50MG/ML	N76299 001	OCT 24, 2002	OCT	NEWA		
>A>	AP	BEN VENUE	50MG/ML	N76088 001	OCT 15, 2002	OCT	NEWA		
>A>	AP	FAULDING	50MG/ML	N76108 001	OCT 15, 2002	OCT	NEWA		
>A>	AP	PHARMAFORCE	50MG/ML	N76217 001	OCT 15, 2002	OCT	NEWA		

CORDARONE

>D>	+	WYETH AYERST	50MG/ML	N20377 001	AUG 03, 1995	OCT	CFTG		
>A>	AP	+	50MG/ML	N20377 001	AUG 03, 1995	OCT	CFTG		

TABLET; ORAL

AMIODARONE HCL

>D>		EON	400MG	N75315 002	JUN 30, 2000	OCT	CRLD		
>A>	+		400MG	N75315 002	JUN 30, 2000	OCT	CRLD		

CORDARONE

>D>	AB	+	WYETH AYERST	200MG	N18972 001	DEC 24, 1985	OCT	CRLD	
>A>	AB			200MG	N18972 001	DEC 24, 1985	OCT	CRLD	

AMLEXANOX

PASTE; DENTAL

APHTHASOL

	+	GLAXOSMITHKLINE CONS	5%	N20511 001	DEC 17, 1996	JUL	CAHN		
--	---	----------------------	----	------------	--------------	-----	------	--	--

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL

		NOVARTIS	EQ 5MG BASE;20MG	N20364 004	MAR 03, 1995	AUG	CRLD		
	+		EQ 10MG BASE;20MG	N20364 005	JUN 20, 2002	AUG	NEWA		

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB		CLAY PARK	EQ 12% BASE	N75774 001	MAY 01, 2002	MAY	NEWA		
		LAC-HYDRIN							
AB	+	WESTWOOD SQUIBB	EQ 12% BASE	N20508 001	AUG 29, 1996	MAY	CFTG		
		LOTION; TOPICAL							
		AMMONIUM LACTATE							
AB		PADDOCK	EQ 12% BASE	N75575 001	JUN 11, 2002	JUN	NEWA		
		LAC-HYDRIN							
AB	+	WESTWOOD SQUIBB	EQ 12% BASE	N19155 001	APR 24, 1985	JUN	CFTG		

AMOXICILLIN

TABLET, CHEWABLE; ORAL

AMOXICILLIN

	@	APOTHECON	125MG	N64131 001	MAY 06, 1996	JUL	DISC		
	@		250MG	N64131 002	MAY 06, 1996	JUL	DISC		

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM
GENEVA PHARMS 200MG/5ML;EQ 28.5MG BASE/5ML
400MG/5ML;EQ 57MG BASE/5ML

N65066 001 JUN 05, 2002 JUN NEWA
N65066 002 JUN 05, 2002 JUN NEWA

OCT NEWA
OCT NEWA
OCT NEWA
OCT NEWA
OCT NEWA
OCT NEWA

AB AUGMENTIN '200'
GLAXOSMITHKLINE 200MG/5ML;EQ 28.5MG BASE/5ML
AB AUGMENTIN '400'
GLAXOSMITHKLINE 400MG/5ML;EQ 57MG BASE/5ML
400MG/5ML;EQ 57MG BASE/5ML

N50725 001 MAY 31, 1996 JUN CFTG
N50725 002 MAY 31, 1996 JUN CFTG
N50725 002 MAY 31, 1996 FEB CRLD

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM
GENEVA PHARMS 500MG;EQ 125MG BASE
875MG;EQ 125MG BASE

N65064 001 MAR 15, 2002 MAR NEWA
N65063 001 MAR 14, 2002 MAR NEWA
N65102 001 SEP 17, 2002 SEP NEWA
N65101 001 OCT 30, 2002 OCT NEWA
N65096 001 OCT 29, 2002 OCT NEWA

OCT CFTG
OCT CFTG

OCT CRLD
OCT CRLD

OCT CRLD
OCT CRLD

AB RANBAXY
TEVA 500MG;EQ 125MG BASE
875MG;EQ 125MG BASE

N50564 002 AUG 06, 1984 MAR CFTG
N50720 001 FEB 13, 1996 MAR CFTG

AB AUGMENTIN '500'
GLAXOSMITHKLINE 500MG;EQ 125MG BASE
AB AUGMENTIN '875'
GLAXOSMITHKLINE 875MG;EQ 125MG BASE

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM
GENEVA PHARMS 200MG;EQ 28.5MG BASE
400MG;EQ 57MG BASE

N65065 001 APR 18, 2002 APR NEWA
N65065 002 APR 18, 2002 APR NEWA

JUL CAHN

AUG CRLD
AUG NEWA

AB AUGMENTIN '200'
GLAXOSMITHKLINE 200MG;EQ 28.5MG BASE
AB AUGMENTIN '400'
GLAXOSMITHKLINE 400MG;EQ 57MG BASE
AB + GLAXOSMITHKLINE
TABLET, EXTENDED RELEASE; ORAL

N50726 001 MAY 31, 1996 APR CFTG
N50726 002 MAY 31, 1996 APR CFTG

AUGMENTIN XR 1GM;62.5MG
+ GLAXOSMITHKLINE

N50785 001 SEP 25, 2002 SEP NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;
DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10
SHIRE PHARM 2.5MG;2.5MG;2.5MG;2.5MG

N21303 001 OCT 11, 2001 AUG CAHN

ADDERALL XR 15
SHIRE LABS 3.75MG;3.75MG;3.75MG;3.75MG
SHIRE PHARM 3.75MG;3.75MG;3.75MG;3.75MG

N21303 006 MAY 22, 2002 JUN NEWA
N21303 006 MAY 22, 2002 AUG CAHN

ADDERALL XR 20
SHIRE PHARM 5MG;5MG;5MG;5MG

N21303 002 OCT 11, 2001 AUG CAHN

ADDERALL XR 25
SHIRE LABS 6.25MG;6.25MG;6.25MG;6.25MG
SHIRE PHARM 6.25MG;6.25MG;6.25MG;6.25MG

N21303 004 MAY 22, 2002 JUN NEWA
N21303 004 MAY 22, 2002 AUG CAHN

ADDERALL XR 30
+ SHIRE PHARM 7.5MG;7.5MG;7.5MG;7.5MG

N21303 003 OCT 11, 2001 AUG CAHN

ADDERALL XR 5
SHIRE LABS 1.25MG;1.25MG;1.25MG;1.25MG
SHIRE PHARM 1.25MG;1.25MG;1.25MG;1.25MG

N21303 005 MAY 22, 2002 JUN NEWA
N21303 005 MAY 22, 2002 AUG CAHN

MAY NEWA
MAY CFTG

JUN NEWA
JUN CFTG

JUL DISC
JUL DISC

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;
DEXTROAMPHETAMINE SULFATE

TABLET; ORAL						
ADDERALL 10						
AB	SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N11522 007	FEB 13, 1996	FEB	CFTG
ADDERALL 20						
AB	SHIRE LABS	5MG;5MG;5MG;5MG	N11522 008	FEB 13, 1996	FEB	CFTG
ADDERALL 30						
AB +	SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N11522 010	MAY 12, 1997	FEB	CFTG
ADDERALL 5						
AB	SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG	N11522 009	MAY 12, 1997	FEB	CFTG
DEXTROAMP SACCHARATE, AMP		ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE				
AB	BARR	1.25MG;1.25MG;1.25MG;1.25MG	N40422 001	FEB 11, 2002	FEB	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	N40422 002	FEB 11, 2002	FEB	NEWA
AB		5MG;5MG;5MG;5MG	N40422 003	FEB 11, 2002	FEB	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40422 004	FEB 11, 2002	FEB	NEWA
AB	COREPHARMA	1.25MG;1.25MG;1.25MG;1.25MG	N40444 001	JUN 19, 2002	JUN	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	N40444 002	JUN 19, 2002	JUN	NEWA
AB		5MG;5MG;5MG;5MG	N40444 003	JUN 19, 2002	JUN	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40444 004	JUN 19, 2002	JUN	NEWA
AB	EON	1.25MG;1.25MG;1.25MG;1.25MG	N40470 001	SEP 27, 2002	SEP	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	N40439 001	JUN 14, 2002	JUN	NEWA
AB		5MG;5MG;5MG;5MG	N40439 002	JUN 14, 2002	JUN	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40439 003	JUN 14, 2002	JUN	NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

+ ELAN PHARMS 5MG/ML

N50724 001 NOV 20, 1995 JAN CAHN

SUSPENSION; ORAL

FUNGIZONE

@ BRISTOL MYERS SQUIBB 100MG/ML

N50341 003 JUN DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	ESI LEDERLE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N65074 001	MAR 19, 2002	MAR	NEWA
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N65074 002	MAR 19, 2002	MAR	NEWA
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N65076 001	MAR 19, 2002	MAR	NEWA
UNASYN						
AP +	PFIZER	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N50608 002	DEC 31, 1986	MAR	CFTG
AP +		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N50608 001	DEC 31, 1986	MAR	CFTG
AP +		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N50608 005	DEC 10, 1993	MAR	CFTG

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

@ GLAXOSMITHKLINE 50MG

N21007 001 APR 15, 1999 MAY DISC

@ 150MG

N21007 002 APR 15, 1999 MAY DISC

SOLUTION; ORAL

@ GLAXOSMITHKLINE 15MG/ML

N21039 001 APR 15, 1999 MAY DISC

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)
INFUVITE PEDIATRIC
+ SABEX 2002

80MG/VIAL;0.02MG/VIAL;400
IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14M
G/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIA
L;1.2MG/VIAL;7 IU/VIAL;2,300
IU/VIAL;0.2MG/VIAL

N21265 001 FEB 21, 2001 APR CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)
M.V.I. PEDIATRIC
+ AAIPHARMA

80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;
5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17
MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/V
IAL;EQ 1.2MG
BASE/VIAL;0.7MG/VIAL;7MG/VIAL

N18920 001 SEP 21, 2000 JUL CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M.V.I.-12
AP + AAIPHARMA

10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/
ML;20
IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.3
6MG/ML;0.3MG/ML;330 UNITS/ML;1
IU/ML

N08809 004 AUG 08, 1985 JUL CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON COMPOUND

+ AAIPHARMA LLC

389MG;32.4MG;32MG

DARVON COMPOUND-65

AA + AAIPHARMA LLC

389MG;32.4MG;65MG

N10996 006 MAR 08, 1983 JUN CAHN

N10996 007 MAR 08, 1983 JUN CAHN

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

@ SANOFI SYNTHELABO

325MG;EQ 12.5MG BASE

N16891 001

JUN DISC

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

+ AAIPHARMA LLC

325MG;65MG

N10996 005

JUN CAHN

<u>ASPIRIN; PROPOXYPHENE NAPSYLATE</u> CAPSULE; ORAL DARVON-N W/ ASA @ AAIPHARMA LLC	325MG;100MG	N16829 001		
TABLET; ORAL @ AAIPHARMA LLC	325MG;100MG			JUN CAHN
<u>ATROPINE; PRALIDOXIME CHLORIDE</u> INJECTABLE; INTRAMUSCULAR ATNAA + @ US ARMY @	2.1MG/0.7ML;600MG/2ML 2.1MG/0.7ML;600MG/2ML	N16863 001		JUN CAHN
<u>AZELASTINE HYDROCHLORIDE</u> SOLUTION/DROPS; OPHTHALMIC OPTIVAR + MURO	0.05%	N21175 001	JAN 17, 2002	JAN NEWA
		N21175 001	JAN 17, 2002	FEB NEWA
<u>AZITHROMYCIN DIHYDRATE</u> TABLET; ORAL ZITHROMAX + PFIZER	EQ 500MG BASE	N21127 001	MAY 22, 2000	MAY CAHN
<u>AZTREONAM</u> INJECTABLE; INJECTION AZACTAM @ BRISTOL MYERS SQUIBB @ @	500MG/VIAL 1GM/VIAL 2GM/VIAL	N50784 001	MAY 24, 2002	MAY NEWA
<u>BACITRACIN ZINC; POLYMYXIN B SULFATE</u> OINTMENT; OPHTHALMIC BACITRACIN ZINC AND POLYMYXIN B SULFATE AT ALTANA	500 UNITS/GM;10,000 UNITS/GM	N50580 001	DEC 31, 1986	JUN DISC
		N50580 002	DEC 31, 1986	JUN DISC
		N50580 003	DEC 31, 1986	JUN DISC
<u>BECLOMETHASONE DIPROPIONATE MONOHYDRATE</u> SPRAY, METERED; NASAL VANCENASE AQ + SCHERING @	EQ 0.084MG DIPROP/SPRAY EQ 0.084MG DIPROP/SPRAY	N65022 001	FEB 27, 2002	FEB NEWA
>D> >A>		N20469 001	JUN 26, 1996	OCT DISC
<u>BENDROFLUMETHIAZIDE</u> TABLET; ORAL NATURETIN-10 @ APOTHECON NATURETIN-5 + APOTHECON	10MG 5MG	N20469 001	JUN 26, 1996	OCT DISC
<u>BENZONATATE</u> CAPSULE; ORAL TESSALON + FOREST LABS	200MG	N12164 003		JUN DISC
		N12164 002		JUN CRLD
		N11210 003	JUN 25, 1999	MAR NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

DUAC

	+ STIEFEL	5%;EQ 1% BASE	N50741 001	AUG 26, 2002	AUG	NEWA
--	-----------	---------------	------------	--------------	-----	------

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA	COREPHARMA	0.5MG	N72264 001	FEB 27, 1989	MAY	CAHN
AA		1MG	N72265 001	FEB 27, 1989	MAY	CAHN
AA		2MG	N72266 001	FEB 27, 1989	MAY	CAHN
AA	+ PAR PHARM	0.5MG	N88877 001	APR 11, 1985	AUG	CRLD
AA	+	1MG	N88894 001	APR 11, 1985	AUG	CRLD
AA	+	2MG	N88895 001	APR 11, 1985	AUG	CRLD
	COGENTIN					
	@ MERCK	0.5MG	N09193 004		AUG	DISC
	@	1MG	N09193 003		AUG	DISC
	@	2MG	N09193 002		AUG	DISC

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

	+ SCHWARZ PHARMA	60UMOLAR	N50114 001		JUL	CAHN
--	------------------	----------	------------	--	-----	------

BETAMETHASONE DIPROPIONATE

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+ FOUGERA	EQ 0.05% BASE	N19141 001	SEP 04, 1984	AUG	CRLD
	DIPROSONE					
	@ SCHERING	EQ 0.05% BASE	N17691 001		AUG	DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	ALPHARMA US PHARM	EQ 0.05% BASE;1%	N76002 001	AUG 02, 2002	AUG	NEWA
----	-------------------	------------------	------------	--------------	-----	------

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

KERLEDEX

	@ LOREX	5MG;12.5MG	N19807 001	OCT 30, 1992	JUN	DISC
	@	10MG;12.5MG	N19807 002	OCT 30, 1992	JUN	DISC

BETAXOLOL HYDROCHLORIDE; Pilocarpine Hydrochloride

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC PILO

	@ ALCON	EQ 0.25% BASE;1.75%	N20619 001	APR 17, 1997	JUN	DISC
--	---------	---------------------	------------	--------------	-----	------

BIPERIDEN LACTATE

INJECTABLE; INJECTION

AKINETON

	@ ABBOTT	5MG/ML	N12418 002		JUN	DISC
--	----------	--------	------------	--	-----	------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

>A>	AB	MUTUAL PHARM	5MG	N75474 001	OCT 25, 2002	OCT	NEWA
>A>	AB		10MG	N75474 002	OCT 25, 2002	OCT	NEWA

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

	@	SANOFI SYNTHELABO	0.37MG/INH	N18770 001	DEC 28, 1984	JUN	DISC
		SOLUTION; INHALATION					
	@	SANOFI SYNTHELABO	0.2%	N19548 001	FEB 19, 1992	JUN	DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

	@	ALLERGAN	0.2%	N20613 001	SEP 06, 1996	AUG	DISC
--	---	----------	------	------------	--------------	-----	------

BROMOCRIPTINE MESYLATE

TABLET; ORAL

BROMOCRIPTINE MESYLATE

AB		LEK SVCS	EQ 2.5MG BASE	N74631 001	JAN 13, 1998	JAN	CMFD
		PARLODEL					
AB +		NOVARTIS	EQ 2.5MG BASE	N17962 001		JAN	CFTG

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

BROMANYL

	@	ALPHARMA	12.5MG/5ML; 10MG/5ML	N88343 001	AUG 15, 1984	MAY	DISC
--	---	----------	----------------------	------------	--------------	-----	------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DM

>D>	AA	ALPHARMA	2MG/5ML; 10MG/5ML; 30MG/5ML	N88722 001	MAR 07, 1985	OCT	DISC
>D>		@	2MG/5ML; 10MG/5ML; 30MG/5ML	N88722 001	MAR 07, 1985	OCT	DISC

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HCL KIT

	@	ABBOTT	0.075%	N19978 001	SEP 03, 1992	JUN	DISC
	@		0.114%	N19978 002	SEP 03, 1992	JUN	DISC
	@		0.23%	N19978 003	SEP 03, 1992	JUN	DISC
		BUPIVACINE HCL PRESERVATIVE FREE					
AP		INTL MEDICATED	0.25%	N76012 001	JAN 09, 2002	JAN	NEWA
AP			0.5%	N76012 002	JAN 09, 2002	JAN	NEWA
AP			0.75%	N76012 003	JAN 09, 2002	JAN	NEWA

BUPRENORPHINE HYDROCHLORIDE

>A>		TABLET; SUBLINGUAL					
>A>		SUBUTEX					
>A>		RECKITT BENCKISER	EQ 2MG BASE	N20732 002	OCT 08, 2002	OCT	NEWA
>A>	+		EQ 8MG BASE	N20732 003	OCT 08, 2002	OCT	NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL
SUBOXONE
RECKITT BENCKISER 2MG;0.5MG
8MG;2MG

N20733 001 OCT 08, 2002 OCT NEWA
N20733 002 OCT 08, 2002 OCT NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN SR
GLAXOSMITHKLINE 150MG
200MG

N20358 003 OCT 04, 1996 JUL CRLD
N20358 004 JUN 14, 2002 JUL NEWA

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL
BUSPAR
@ BRISTOL MYERS SQUIBB 5MG
@ 7.5MG
@ 10MG
@ 15MG

N21190 001 DEC 20, 2000 JUN DISC
N21190 002 DEC 20, 2000 JUN DISC
N21190 003 DEC 20, 2000 JUN DISC
N21190 004 DEC 20, 2000 JUN DISC

TABLET; ORAL

BUSPIRONE HCL
AB EGIS 5MG
10MG
AB GENEVA PHARMS 5MG
10MG
15MG
AB KV PHARM 5MG
10MG
15MG
AB MYLAN 5MG
10MG
30MG
5MG
AB PAR PHARM 10MG
15MG
5MG
AB PHARMEX PRODS 10MG
15MG
5MG
AB TEVA 10MG
15MG
5MG
AB TORPHARM 10MG
15MG
5MG
AB ZENITH GOLDLINE 10MG
15MG
AB

N75119 001 MAR 14, 2002 MAR NEWA
N75119 002 MAR 14, 2002 MAR NEWA
N75413 001 MAR 19, 2002 MAR NEWA
N75413 002 MAR 19, 2002 MAR NEWA
N75413 003 MAR 19, 2002 MAR NEWA
N75572 001 FEB 27, 2002 FEB NEWA
N75572 002 FEB 27, 2002 FEB NEWA
N75572 003 FEB 27, 2002 FEB NEWA
N75272 001 MAR 01, 2002 MAR NEWA
N75272 002 MAR 01, 2002 MAR NEWA
N76008 001 JUN 28, 2001 MAY CAHN
N75467 001 FEB 28, 2002 FEB NEWA
N75467 003 FEB 28, 2002 FEB NEWA
N75467 004 FEB 28, 2002 FEB NEWA
N75388 001 MAY 09, 2002 MAY NEWA
N75388 002 MAY 09, 2002 MAY NEWA
N75388 003 MAY 09, 2002 MAY NEWA
N75022 001 FEB 28, 2002 FEB NEWA
N75022 002 FEB 28, 2002 FEB NEWA
N75022 003 FEB 28, 2002 FEB NEWA
N75521 001 APR 05, 2002 APR NEWA
N75521 002 APR 05, 2002 APR NEWA
N75521 003 APR 05, 2002 APR NEWA
N75385 001 MAR 01, 2002 MAR NEWA
N75385 002 MAR 01, 2002 MAR NEWA
N75385 003 MAR 01, 2002 MAR NEWA

BUTABARBITAL SODIUM

TABLET; ORAL
BUTISOL SODIUM
+ WALLACE LABS 15MG

N00793 002

OCT DISC

>D>

>A>	@	15MG	N00793 002	OCT	DISC
>D>	+	100MG	N00793 005	OCT	DISC
>A>	@	100MG	N00793 005	OCT	DISC

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

>A>		MENTAX-TC			
>A>	+	BERTEK	1%	N21408 001	OCT 17, 2002 OCT NEWA

BUTORPHANOL TARTRATE

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

AB		ROXANE	1MG/SPRAY	N75824 001	MAR 12, 2002 MAR NEWA
----	--	--------	-----------	------------	-----------------------

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

ERCATAB

+		GENEVA PHARMS	100MG;1MG	N84294 001	JUN CTEC
---	--	---------------	-----------	------------	----------

WIGRAINE

@		ORGANON	100MG;1MG	N86562 001	JUN DISC
---	--	---------	-----------	------------	----------

CALCIFEDIOL

CAPSULE; ORAL

CALDEROL

@		ORGANON	0.02MG	N18312 001	JUN DISC
---	--	---------	--------	------------	----------

@			0.05MG	N18312 002	JUN DISC
---	--	--	--------	------------	----------

CALCIPOTRIENE

OINTMENT; TOPICAL

DOVONEX

+		BRISTOL MYERS SQUIBB	0.005%	N20273 001	DEC 29, 1993 FEB CAHN
---	--	----------------------	--------	------------	-----------------------

SOLUTION; TOPICAL

+		BRISTOL MYERS SQUIBB	0.005%	N20611 001	MAR 03, 1997 FEB CAHN
---	--	----------------------	--------	------------	-----------------------

CAPTOPRIL

TABLET; ORAL

CAPOTEN

AB		PAR PHARM	12.5MG	N18343 005	JAN 17, 1985 MAY CAHN
----	--	-----------	--------	------------	-----------------------

AB			25MG	N18343 002	MAY CAHN
----	--	--	------	------------	----------

@			37.5MG	N18343 006	SEP 17, 1986 MAY CAHN
---	--	--	--------	------------	-----------------------

AB			50MG	N18343 001	MAY CAHN
----	--	--	------	------------	----------

@			75MG	N18343 007	JUN 13, 1995 MAY CAHN
---	--	--	------	------------	-----------------------

AB	+		100MG	N18343 003	MAY CAHN
----	---	--	-------	------------	----------

@			150MG	N18343 004	JUN 13, 1995 MAY CAHN
---	--	--	-------	------------	-----------------------

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

@		SHIRE LABS	100MG	N20712 003	DEC 22, 1999 JUL DISC
---	--	------------	-------	------------	-----------------------

@			200MG	N20712 001	SEP 30, 1997 JUL DISC
---	--	--	-------	------------	-----------------------

@			300MG	N20712 002	SEP 30, 1997 JUL DISC
---	--	--	-------	------------	-----------------------

+		SHIRE PHARM	100MG	N20712 003	SEP 30, 1997 SEP CMFD
---	--	-------------	-------	------------	-----------------------

+			200MG	N20712 001	SEP 30, 1997 SEP CMFD
---	--	--	-------	------------	-----------------------

OCT DISC
OCT DISC
OCT DISC

300MG
+ SUSPENSION; ORAL
CARBAMAZEPINE
MORTON GROVE
AB TABLET; ORAL 100MG/5ML
APOTEX 200MG
AB TABLET, CHEWABLE; ORAL 200MG
+ TARO PHARM INDS

N20712 002 SEP 30, 1997 SEP CMFD

N75714 001 JUN 05, 2002 JUN NEWA

N75948 001 FEB 27, 2002 FEB NEWA

N75687 002 JUL 29, 2002 JUL NEWA

2002 OCT NEWA

CARTEOLOL HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
CARTEOLOL HCL 1%
AT NOVEX

N76097 001 FEB 06, 2002 FEB NEWA

2002 MAR NEWA

CEFACTOR
TABLET, EXTENDED RELEASE; ORAL
CECLOR CD EQ 375MG BASE
@ LILLY
CEFACTOR EQ 375MG BASE
TEVA EQ 500MG BASE

N50673 001 JUN 28, 1996 JUN DISC

JUN CTEC

N65058 001 SEP 04, 2002 SEP NEWA
N65058 002 SEP 04, 2002 SEP NEWA

JUN DISC

AB
CEFADROXIL/CEFADROXIL HEMIHYDRATE
CAPSULE; ORAL
DURICEF EQ 250MG BASE
@ GALEN CHEM EQ 250MG BASE
@ WARNER CHILCOTT EQ 500MG BASE
AB +
FOR SUSPENSION; ORAL
GALEN CHEM EQ 125MG BASE/5ML
EQ 250MG BASE/5ML
EQ 500MG BASE/5ML
+ WARNER CHILCOTT EQ 125MG BASE/5ML
EQ 250MG BASE/5ML
EQ 500MG BASE/5ML

N50512 002
N50512 002
N50512 001

MAY CAHN
JUL CAHN
JUL CAHN

JUN DISC

N50527 002
N50527 003
N50527 001
N50527 002
N50527 003
N50527 001

MAY CAHN
MAY CAHN
MAY CAHN
JUL CAHN
JUL CAHN
JUL CAHN

JUN DISC

N50528 001
N50528 001

MAY CAHN
JUL CAHN

1993 FEB CAHN

AB + TABLET; ORAL EQ 1GM BASE
+ GALEN CHEM EQ 1GM BASE
AB + WARNER CHILCOTT

N50504 004

JUN DISC

1997 FEB CAHN

CEFAMANDOLE NAFATE
INJECTABLE; INJECTION
MANDOL EQ 10GM BASE/VIAL
@ LILLY

N50554 001 MAY 24, 1984 JUN DISC
N50554 002 MAY 24, 1984 JUN DISC
N50554 003 MAY 24, 1984 JUN DISC
N50554 004 MAY 24, 1984 JUN DISC
N50554 005 MAY 24, 1984 JUN DISC

1985 MAY CAHN

CEFORANIDE
INJECTABLE; INJECTION
PRECEF 500MG/VIAL
@ BRISTOL 1GM/VIAL
@ 2GM/VIAL
@ 10GM/VIAL
@ 20GM/VIAL

MAY CAHN

1986 MAY CAHN

MAY CAHN

1995 MAY CAHN

MAY CAHN

1995 MAY CAHN

1999 JUL DISC

1997 JUL DISC

1997 JUL DISC

1997 SEP CMFD

1997 SEP CMFD

Drug Name	Strength	Code	Effective Date	Category
<u>CEFPODOXIME PROXETIL</u> FOR SUSPENSION; ORAL CEFPODOXIME PROXETIL RANBAXY	EQ 50MG BASE/5ML EQ 100MG BASE/5ML	N65082 001 N65082 002	MAY 31, 2002 MAY 31, 2002	MAY NEWA MAY NEWA
VANTIN PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML EQ 100MG BASE/5ML	N50675 001 N50675 002	AUG 07, 1992 AUG 07, 1992	MAY CFTG MAY CFTG
<u>CEFTIZOXIME SODIUM</u> INJECTABLE; INJECTION CEFIZOX @ FUJISAWA HLTHCARE	EQ 500MG BASE/VIAL	N50560 001	SEP 15, 1983	JUL DISC
<u>CEFTRIAZONE SODIUM; LIDOCAINE</u> INJECTABLE; INJECTION ROCEPHIN KIT @ HLR @	EQ 500MG BASE/VIAL;1% EQ 1GM BASE/VIAL;1%	N50585 007 N50585 006	MAY 08, 1996 MAY 08, 1996	JUN DISC JUN DISC
<u>CEFUROXIME AXETIL</u> TABLET; ORAL CEFTIN GLAXOSMITHKLINE	EQ 125MG BASE EQ 250MG BASE EQ 500MG BASE	N50605 001 N50605 002 N50605 003	DEC 28, 1987 DEC 28, 1987 DEC 28, 1987	FEB CFTG FEB CFTG FEB CFTG
<u>CEFUROXIME AXETIL</u> APOTEX	EQ 250MG BASE EQ 500MG BASE	N65069 001 N65069 002	OCT 02, 2002 OCT 02, 2002	OCT NEWA OCT NEWA
RANBAXY	EQ 125MG BASE EQ 250MG BASE EQ 500MG BASE	N65043 003 N65043 002 N65043 001	FEB 15, 2002 FEB 15, 2002 FEB 15, 2002	FEB NEWA FEB NEWA FEB NEWA
<u>CELECOXIB</u> CAPSULE; ORAL CELEBREX GD SEARLE LLC +	200MG 400MG	N20998 002 N20998 003	DEC 31, 1998 AUG 29, 2002	AUG CRLD AUG NEWA
<u>CEPHALEXIN</u> FOR SUSPENSION; ORAL CEPHALEXIN @ TEVA @	EQ 125MG BASE/5ML EQ 250MG BASE/5ML	N62873 001 N62867 001	MAY 23, 1988 APR 15, 1988	APR DISC APR DISC
TABLET; ORAL TEVA KEFLET @ LILLY @	EQ 500MG BASE EQ 500MG BASE EQ 1GM BASE	N63024 001 N50440 001 N50440 002	JAN 12, 1989	JUN CTEC JUN DISC JUL DISC

CEPHALOGLYCIN

CAPSULE; ORAL

KAFOCIN

@ LILLY

250MG

N50219 001

MAY DISC

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

KEFLIN

@ LILLY

EQ 20GM BASE/VIAL

N50482 007

JUN DISC

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

APOTHECON

@

@

@

@

EQ 500MG BASE/VIAL

EQ 1GM BASE/VIAL

EQ 2GM BASE/VIAL

EQ 4GM BASE/VIAL

N62961 001 SEP 20, 1988 JUN DISC

N62961 002 SEP 20, 1988 JUN DISC

N62961 003 SEP 20, 1988 JUN DISC

N62961 004 SEP 20, 1988 JUN DISC

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

@ BAYER

@

@

@

0.2MG

0.3MG

0.4MG

0.8MG

N20740 003 JUN 26, 1997 JAN DISC

N20740 004 JUN 26, 1997 JAN DISC

N20740 005 MAY 24, 1999 JAN DISC

N20740 006 JUL 24, 2000 JAN DISC

CHLORAMPHENICOL

FOR SOLUTION; OPHTHALMIC

CHLOROMYCETIN

@ PARKEDALE

25MG/VIAL

N50143 001

JUL DISC

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL

CHLOROMYCETIN PALMITATE

@ PARKE DAVIS

EQ 150MG BASE/5ML

N50152 001

JUN DISC

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

@ PARKEDALE

12.5MG/VIAL;25MG/VIAL

N50202 001

JUL DISC

CHLORMEZANONE

TABLET; ORAL

TRANCOPAL

@ SANOFI SYNTHELABO

@

100MG

200MG

N11467 003

JUN DISC

N11467 005

JUN DISC

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE AND RESERPINE

@ WEST WARD

@

250MG;0.125MG

500MG;0.125MG

N88557 001 DEC 22, 1983 AUG DISC

N88365 001 DEC 22, 1983 AUG DISC

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE-RESERPINE

@ MYLAN	250MG;0.125MG	N87744 001	MAY 06, 1982	AUG	DISC
@	500MG;0.125MG	N87745 001	MAY 06, 1982	AUG	DISC

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

@ PHARMACIA AND UPJOHN	400MG	N14217 002		JUN	DISC
------------------------	-------	------------	--	-----	------

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

THORAZINE

@ GLAXOSMITHKLINE	30MG	N11120 016		JUN	DISC
@	75MG	N11120 017		JUN	DISC
@	150MG	N11120 018		JUN	DISC

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ LEDERLE	100MG	N89561 001	SEP 04, 1987	MAY	DISC
@	250MG	N89562 001	SEP 04, 1987	MAY	DISC

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

@ LEDERLE	1%	N50404 001		JUN	DISC
-----------	----	------------	--	-----	------

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

>D> TABLET; ORAL

>D> CLONIDINE HCL AND CHLORTHALIDONE

>D> AB PAR PHARM 15MG;0.3MG

N71142 001 DEC 16, 1987 OCT DISC

>A> @ 15MG;0.3MG

N71142 001 DEC 16, 1987 OCT DISC

>D> AB 15MG;0.2MG

N71178 001 DEC 16, 1987 OCT DISC

>A> @ 15MG;0.2MG

N71178 001 DEC 16, 1987 OCT DISC

>D> AB 15MG;0.1MG

N71179 001 DEC 16, 1987 OCT DISC

>A> @ 15MG;0.1MG

N71179 001 DEC 16, 1987 OCT DISC

CLORPRES

>D> AB MYLAN 15MG;0.3MG

N71325 001 FEB 09, 1987 OCT CRLD

>A> + 15MG;0.3MG

N71325 001 FEB 09, 1987 OCT CRLD

>D> COMBIPRES

>D> AB BOEHRINGER INGELHEIM 15MG;0.1MG

N17503 001 OCT DISC

>D> AB 15MG;0.2MG

N17503 002 OCT DISC

>D> AB + 15MG;0.3MG

N17503 003 APR 10, 1984 OCT DISC

>A> @ 15MG;0.1MG

N17503 001 OCT DISC

>A> @ 15MG;0.3MG

N17503 003 APR 10, 1984 OCT DISC

>A> @ 15MG;0.2MG

N17503 002 OCT DISC

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

1-17

CHLORTHALIDONE; RESERPINE

TABLET; ORAL
 DEMI-REGROTON 25MG;0.125MG
 @ AVENTIS PHARMS
 REGROTON 50MG;0.25MG
 @ AVENTIS PHARMS

N15103 002 JUL DISC
 N15103 001 JUL DISC

CHOLESTYRAMINE

TABLET; ORAL
 QUESTRAN EQ 800MG RESIN
 @ APOTHECON

N73403 002 DEC 27, 1999 JUN DISC

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION
 OVIDREL 0.25MG/VIAL
 + SERONO INC

N21149 001 SEP 20, 2000 FEB CAHN

CHYMOPAPAIN

INJECTABLE; INJECTION
 CHYMODIACTIN 4,000 UNITS/VIAL
 @ ABBOTT

N18663 002 AUG 21, 1984 JUN DISC

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC
 ZOLYSE 750 UNITS/VIAL
 @ ALCON

N11903 001 JUN DISC

CICLOPIROX

SOLUTION; TOPICAL
 PENLAC 8%
 + DERMIK LABS

N21022 001 DEC 17, 1999 JUN CAHN

CIMETIDINE

TABLET; ORAL
 CIMETIDINE 300MG
 AB LEK LJUBLJANA 400MG
 AR 800MG
 AB

N74250 002 JUN 29, 1995 FEB CMFD
 N74250 003 JUN 29, 1995 FEB CMFD
 N74250 004 JUN 29, 1995 FEB CMFD

CINOXACIN

CAPSULE; ORAL
 CINOBAC 250MG
 @ LILLY 500MG
 @

N18067 001 JUN DISC
 N18067 002 JUN DISC

CLADRIBINE

INJECTABLE; INJECTION
 LEUSTATIN 1MG/ML
 + ORTHO BIOTECH

N20229 001 FEB 26, 1993 MAR CAHN

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

1-19

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL
TRANXENE SD 11.25MG
OVATION PHARMS 22.5MG

N17105 005
N17105 004

SEP CAHN
SEP CAHN

CLOZAPINE

TABLET; ORAL
CLOZARIL 25MG
NOVARTIS 100MG

N19758 001 SEP 26, 1989 MAY CRLD
N19758 002 SEP 26, 1989 MAY CRLD

COLCHICINE; PROBENECID

TABLET; ORAL
COL-PROBENECID 0.5MG;500MG
WATSON LABS
COLBENEMID 0.5MG;500MG
@ MERCK

N84279 001

JUN CRLD

N12383 001

JUN DISC

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL
WELCHOL 375MG
@ SANKYO

N21141 001 MAY 26, 2000 JUN DISC

CORTICOTROPIN

INJECTABLE; INJECTION
CORTICOTROPIN 40 UNITS/ML
+ ORGANICS LAGRANGE
H.P. ACTHAR GEL 40 UNITS/ML
@ QUESTCOR PHARMS

N10831 001

AUG CRLD

N08372 006

JUL DISC

CORTISONE ACETATE

INJECTABLE; INJECTION
CORTONE 25MG/ML
@ MERCK 50MG/ML
@

N07110 002
N07110 003

JUN DISC
JUN DISC

CROMOLYN SODIUM

SOLUTION; INHALATION
CROMOLYN SODIUM 10MG/ML
NOVEX

N75333 001 APR 30, 2002 APR NEWA

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A
DICOPAC KIT N/A;N/A;N/A
@ AMERSHAM HLTH

N17406 001

FEB DISC

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A; N/A
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT
@ MALLINCKRODT 0.1MG;0.5uCi;60MG

N16635 001

JUN DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
 FLEXERIL
 @ MCNEIL CONS SPECLT
 AB + 5MG
 10MG

N17821 001
 N17821 002

JUN CAHN
 JUN CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
 CYCLOPHOSPHAMIDE
 BAXTER HLTHCARE
 AP 100MG/VIAL
 AP 200MG/VIAL
 AP 500MG/VIAL
 AP 1GM/VIAL

N88371 001 JUL 03, 1986 JUN CAHN
 N88372 001 JUL 03, 1986 JUN CAHN
 N88373 001 JUL 03, 1986 JUN CAHN
 N88374 001 SEP 24, 1986 JUN CAHN

CYCLOSPORINE

CAPSULE; ORAL
 CYCLOSPORINE
 ABBOTT
 AB1 25MG
 BX 50MG
 AB1 100MG
 AB1 25MG
 AB1 100MG
 AB1 SIDMAK LABS 25MG
 AB1 TORPHARM 100MG
 AB2 25MG
 AB2 100MG
 NEORAL
 AB1 NOVARTIS 25MG
 AB1 + 100MG
 SANDIMMUNE
 AB2 NOVARTIS 25MG
 AB2 + 100MG
 SOLUTION; ORAL
 CYCLOSPORINE
 ABBOTT
 AB 100MG/ML

N65003 001 MAY 12, 2000 MAY CTEC
 N65003 002 MAY 12, 2000 MAY CTEC
 N65003 003 MAY 12, 2000 MAY CTEC
 N65017 002 JAN 13, 2000 MAY CTEC
 N65017 001 JAN 13, 2000 MAY CTEC
 N65044 002 DEC 20, 2000 MAY CTEC
 N65044 001 DEC 20, 2000 MAY CTEC
 N65040 001 MAY 09, 2002 MAY CTEC
 N65040 002 MAY 09, 2002 MAY NEWA
 N50715 001 JUL 14, 1995 MAY CTEC
 N50715 002 JUL 14, 1995 MAY CTEC
 N50625 001 MAR 02, 1990 MAY CTEC
 N50625 002 MAR 02, 1990 MAY CTEC
 N65025 001 MAR 03, 2000 JAN CMFD

CYTARABINE

INJECTABLE; INJECTION
 CYTARABINE
 + FAULDING
 100MG/ML

N75383 001 NOV 22, 1999 AUG CPOT

DACARBAZINE

INJECTABLE; INJECTION
 DACARBAZINE
 GENZIA SICOR PHARMS
 >D> AP 500MG/VIAL
 >A> AP + 500MG/VIAL

N75259 001 SEP 22, 2000 OCT CRLD
 N75259 001 SEP 22, 2000 OCT CRLD

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)
 SYNERCID
 + AVENTIS
 @
 350MG/VIAL; 150MG/VIAL
 420MG/VIAL; 180MG/VIAL

N50748 001 SEP 21, 1999 JUN CRLD
 N50748 002 AUG 24, 2000 JUN DISC

DANAPAROID SODIUM

INJECTABLE; INJECTION

ORGARAN

© ORGANON

750 UNITS/0.6ML

N20430 001 DEC 24, 1996 JUN DISC

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DESFERAL

+ NOVARTIS

2GM/VIAL

N16267 002 MAY 25, 2000 FEB CPOT

DEMECARIUM BROMIDE

SOLUTION/DROPS; OPHTHALMIC

HUMORSOL

© MERCK

0.125%

N11860 002

JUN DISC

©

0.25%

N11860 001

JUN DISC

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

© LEDERLE

75MG

N50261 001

JUN DISC

DESLORATADINE

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

+ SCHERING

5MG

N21312 001 JUN 26, 2002 JUN NEWA

DESMOPRESSIN ACETATE

SOLUTION; NASAL

CONCENTRAID

© FERRING

0.01%

N19776 001 DEC 26, 1990 JUN DISC

DDAVP

+ AVENTIS

0.01%

N17922 001

SEP CTEC

SPRAY; NASAL

DESMOPRESSIN ACETATE

+ FERRING

0.1MG/SPRAY

N21333 001 SEP 16, 2002 SEP NEWA

SPRAY, METERED; NASAL

DDAVP

© AVENTIS

0.01MG/SPRAY

N17922 002 FEB 06, 1989 MAY DISC

DESMOPRESSIN ACETATE

AB + BAUSCH AND LOMB

0.01MG/SPRAY

N74830 001 JAN 25, 1999 MAY CRLD

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

KARIVA

AB BARR

0.15MG;0.02MG;0.01MG

N75863 001 APR 05, 2002 APR NEWA

MIRCETTE

AB + ORGANON

0.15MG;0.02MG;0.01MG

N20713 001 APR 22, 1998 APR CFTG

DESONIDE

LOTION; TOPICAL

DESONIDE

AB ALTANA

0.05%

N75860 001 MAR 19, 2002 MAR NEWA

DESONIDE

LOTION; TOPICAL
 DESOWEN
 AB + GALDERMA LABS LP 0.05% N72354 001 JAN 24, 1992 MAR CFTG

DESOXIMETASONE

OINTMENT; TOPICAL
 DESOXIMETASONE
 @ ALTANA 0.25% N73440 001 APR 01, 1998 MAY DISC

DEXAMETHASONE

AEROSOL; TOPICAL
 DECASPRAY
 @ MERCK 0.04% N12731 002 JUN DISC
 TABLET; ORAL
 DEXAMETHASONE
 @ WATSON LABS 0.25MG N85455 001 AUG DISC
 @ 0.5MG N85458 001 AUG DISC
 @ 1.5MG N85456 001 AUG DISC

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION
 DECADRON-LA
 @ MERCK EQ 8MG BASE/ML N16675 001 APR DISC
 DEXAMETHASONE ACETATE
 @ STERIS EQ 8MG BASE/ML N84315 001 APR DISC
 @ EQ 16MG BASE/ML N87711 001 MAY 24, 1982 APR DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
 >D> DECADRON N12071 002 OCT DISC
 >D> AP + MERCK EQ 4MG PHOSPHATE/ML N12071 002 OCT DISC
 >A> @ EQ 4MG PHOSPHATE/ML N12071 004 OCT DISC
 >D> + EQ 24MG PHOSPHATE/ML N12071 004 OCT DISC
 >A> @ EQ 24MG PHOSPHATE/ML
 DEXAMETHASONE
 >D> AP AM PHARM PARTNERS EQ 10MG PHOSPHATE/ML N88469 001 JAN 25, 1984 OCT DISC
 >A> @ EQ 10MG PHOSPHATE/ML N88469 001 JAN 25, 1984 OCT DISC
 DEXAMETHASONE SODIUM PHOSPHATE
 >D> AP GENZIA SICOR PHARMS EQ 10MG PHOSPHATE/ML N81126 001 AUG 31, 1990 OCT CRLD
 >A> AP + EQ 10MG PHOSPHATE/ML N81126 001 AUG 31, 1990 OCT CRLD
 >D> AP LUITPOLD EQ 4MG PHOSPHATE/ML N87440 001 JUL 21, 1982 OCT CRLD
 >A> AP + EQ 4MG PHOSPHATE/ML N87440 001 JUL 21, 1982 OCT CRLD
 >D> AP STERIS EQ 4MG PHOSPHATE/ML N89169 001 APR 09, 1986 OCT DISC
 >A> @ EQ 4MG PHOSPHATE/ML N89169 001 APR 09, 1986 OCT DISC
 >D> AP EQ 10MG PHOSPHATE/ML N87668 001 JUL 01, 1982 OCT DISC
 >A> @ EQ 10MG PHOSPHATE/ML N87668 001 JUL 01, 1982 OCT DISC
 >D> HEXADROL
 >D> AP + ORGANON EQ 4MG PHOSPHATE/ML N14694 002 OCT DISC
 >A> @ EQ 4MG PHOSPHATE/ML N14694 002 OCT DISC
 >D> AP + EQ 10MG PHOSPHATE/ML N14694 003 OCT DISC

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

1-23

1-22

92 MAR CFTG

98 MAY DISC

JUN DISC

AUG DISC

AUG DISC

AUG DISC

APR DISC

APR DISC

982 APR DISC

OCT DISC

OCT DISC

OCT DISC

OCT DISC

1984 OCT DISC

1984 OCT DISC

1990 OCT CRLD

1990 OCT CRLD

1982 OCT CRLD

1982 OCT CRLD

1986 OCT DISC

1986 OCT DISC

1982 OCT DISC

1982 OCT DISC

OCT DISC

OCT DISC

OCT DISC

Q OINTMENT; OPHTHALMIC
MAXIDEX
Q ALCON

EQ 10MG PHOSPHATE/ML

N14694 003

OCT DISC

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION

DECADRON W/ XYLOCAINE
Q MERCK

EQ 0.05% PHOSPHATE
EQ 4MG PHOSPHATE/ML; 10MG/ML

N83342 001

JUN DISC

DEXYROAMPHETAMINE SULFATE
CAPSULE, EXTENDED RELEASE; ORAL

AB + DEXEDRINE 5MG
GLAXOSMITHKLINE 10MG

AB + 15MG

AB + DEXTROAMPHETAMINE SULFATE 5MG
BARR 10MG

AB 15MG

AA TABLET; ORAL 5MG
KV PHARM 10MG

AA 5MG

AA MALLINCKRODT 10MG

AA

DIATRIZOATE MEGLUMINE
INJECTABLE; INJECTION

DIATRIZOATE MEGLUMINE
Q BRACCO

76%

N10040 017

JUN DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM
INJECTABLE; INJECTION

RENOVIST 34.3%; 35%
Q BRACCO

RENOVIST II 28.5%; 29.1%
Q BRACCO

N10040 020

JUN DISC

N10040 019

JUN DISC

DIATRIZOATE SODIUM
INJECTABLE; INJECTION

HYPAAQUE 25%
Q AMERSHAM HLTH

SOLUTION; ORAL, RECTAL 40%
Q AMERSHAM HLTH

SOLUTION; URETERAL

HYPAAQUE SODIUM 20% 20%
Q AMERSHAM HLTH

N09561 003

JUN DISC

N11386 003

JUL DISC

N09561 002

JUN DISC

DIAZEPAM
INJECTABLE; INJECTION

DIAZEPAM 5MG/ML
ABBOTT 5MG/ML

>D> AP ABBOTT

>A> AP +

N71583 001 OCT 13, 1987 OCT CRLD

N71583 002 OCT 13, 1987 OCT CRLD

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

a ABBOTT

187MG/5ML

N50698 003 SEP 30, 1998 JUN DISC

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

>D> CLINDAMYCIN PHOSPHATE

>D> BT GALDERMA LABS LP EQ 1% BASE

N50782 001 NOV 27, 2000 OCT CTNA

>A> CLINDAGEL

>A> BT GALDERMA LABS LP EQ 1% BASE

N50782 001 NOV 27, 2000 OCT CTNA

LOTION; TOPICAL

CLEOCIN T

AB + PHARMACIA AND UPJOHN EQ 1% BASE

N50600 001 MAY 31, 1989 JAN CFTG

CLINDAMYCIN PHOSPHATE

AB ALTANA EQ 1% BASE

N65067 001 JAN 31, 2002 JAN NEWA

SWAB; TOPICAL

AT CLAY PARK EQ 1% BASE

N65049 001 MAY 25, 2000 FEB CDFR

CLOBETASOL PROPIONATE

GEL; TOPICAL

EMBELINE

AB HEALTHPOINT 0.05%

N76141 001 APR 12, 2002 APR NEWA

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

a NOVARTIS

100MG

N19500 001 DEC 15, 1986 JUN DISC

CLONAZEPAM

TABLET; ORAL

KLONOPIN

a ROCHE 0.125MG

N17533 005 APR 09, 1997 JUN DISC

a 0.25MG

N17533 006 APR 09, 1997 JUN DISC

TABLET, ORALLY DISINTEGRATING; ORAL

KLONOPIN RAPIDLY DISINTEGRATING

a ROCHE 0.125MG

N20813 001 DEC 23, 1997 JUN DISC

a 0.25MG

N20813 002 DEC 23, 1997 JUN DISC

a 0.5MG

N20813 003 DEC 23, 1997 JUN DISC

a 1MG

N20813 004 DEC 23, 1997 JUN DISC

a 2MG

N20813 005 DEC 23, 1997 JUN DISC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

a OVATION PHARMS 3.75MG

N17105 001 SEP CAHN

a 7.5MG

N17105 002 SEP CAHN

a 15MG

N17105 003 SEP CAHN

TABLET; ORAL

AB OVATION PHARMS 3.75MG

N17105 006 SEP CAHN

AB 7.5MG

N17105 007 SEP CAHN

AB + 15MG

N17105 008 SEP CAHN

DIAZEPAM

	INJECTABLE; INJECTION			
>D>	VALIUM		N16087 001	OCT DISC
>D>	AP + ROCHE	5MG/ML		
>A>	@	5MG/ML	N16087 001	OCT DISC

DIAZOXIDE

	CAPSULE; ORAL			
	PROGLYCEM			
	@ BAKER NORTON	50MG	N17425 001	JUN DISC

DICLOFENAC POTASSIUM

	TABLET; ORAL			
	DICLOFENAC POTASSIUM			
AB	MUTUAL PHARM	50MG	N75470 001	FEB 21, 2002 FEB NEWA

DICLOFENAC SODIUM

	GEL; TOPICAL			
	SOLARAZE			
	+ BIOGLAN PHARMA	3%	N21005 001	OCT 16, 2000 JUL CAHN
	TABLET, DELAYED RELEASE; ORAL			
	DICLOFENAC SODIUM			
AB	ALPHAPHARM	50MG	N75281 002	FEB 12, 2002 FEB NEWA
AB		75MG	N75281 003	FEB 12, 2002 FEB NEWA
	TABLET, EXTENDED RELEASE; ORAL			
AB	PUREPAC PHARM	100MG	N75910 001	JAN 07, 2002 JAN NEWA

DICUMAROL

	TABLET; ORAL			
	DICUMAROL			
	@ ABBOTT	25MG	N05545 003	JUN DISC

DIENESTROL

	CREAM; VAGINAL			
	DIENESTROL			
	+ ORTHO MCNEIL	0.01%	N06110 005	JUN CAHN

DIGOXIN

	TABLET; ORAL			
	DIGOXIN			
AB	STEVENS J	0.125MG	N76268 001	JUL 26, 2002 JUL NEWA
AB		0.25MG	N76268 002	JUL 26, 2002 JUL NEWA

DIHYDROERGOTAMINE MESYLATE

	INJECTABLE; INJECTION			
	D.H.E. 45			
	XCEL PHARMS	1MG/ML	N05929 001	JUN CAHN
	SPRAY, METERED; NASAL			
	MIGRANAL			
	+ XCEL PHARM	0.5MG/INH	N20148 001	DEC 08, 1997 JUL CAHN

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

1-25

DILTIAZEM HYDROCHLORIDE
 INJECTABLE; INJECTION
 CARDIZEM 5MG/ML
 AP + BIOVAIL 25MG/VIAL
 +
 DILTIAZEM HCL 10MG/ML
 + GENSTA SICOR PHARMS

N20027 001 OCT 24, 1991 JUN CAHN
 N20027 003 AUG 18, 1995 JUN CAHN
 N74894 002 APR 19, 2002 APR NEWA

DILTIAZEM MALATE; ENALAPRIL MALEATE
 TABLET, EXTENDED RELEASE; ORAL
 TECZEM EQ 180MG HCL;5MG
 + BIOVAIL

N20507 001 OCT 04, 1996 JUN CAHN

DIMYRISTOYL LECITHIN; PERFLEXANE
 INJECTABLE; INTRAVENOUS
 IMAGENT 0.92MG/VIAL;0.092MG/VIAL
 + ALLIANCE PHARM

N21191 001 MAY 31, 2002 MAY NEWA

DIPHENHYDRAMINE HYDROCHLORIDE
 INJECTABLE; INJECTION
 DIPHENHYDRAMINE HCL 50MG/ML
 AP AM PHARM PARTNERS

N40466 001 MAY 28, 2002 MAY NEWA

DIPHENIDOL HYDROCHLORIDE
 TABLET; ORAL
 VONTROL EQ 25MG BASE
 @ GLAXOSMITHKLINE

N16033 001 JUN DISC

DIVALPROEX SODIUM
 TABLET, EXTENDED RELEASE; ORAL
 DEPAKOTE ER EQ 250MG VALPROIC ACID
 ABBOTT

N21168 002 MAY 31, 2002 JUL NEWA

DONEPEZIL HYDROCHLORIDE
 TABLET; ORAL
 ARICEPT 5MG
 EISAI MEDCL RES 10MG
 +

N20690 002 NOV 25, 1996 MAY CAHN
 N20690 001 NOV 25, 1996 MAY CAHN

DOXEPIN HYDROCHLORIDE
 CAPSULE; ORAL
 DOXEPIN HCL EQ 10MG BASE
 @ LEDERLE EQ 25MG BASE
 @ EQ 50MG BASE
 @ EQ 75MG BASE
 @ EQ 100MG BASE
 @ EQ 150MG BASE
 CREAM; TOPICAL
 ZONALON 5%
 + BIOGLAN PHARMS

N71685 001 JAN 05, 1988 MAY DISC
 N71686 001 JAN 05, 1988 MAY DISC
 N71673 001 JAN 05, 1988 MAY DISC
 N71674 001 JAN 05, 1988 MAY DISC
 N71675 001 JAN 05, 1988 MAY DISC
 N71676 001 JAN 05, 1988 MAY DISC

N20126 001 APR 01, 1994 JUN CAHN

	<u>DOXYCYCLINE HYCLATE</u>				
	CAPSULE; ORAL				
	PERIOSTAT				
	@ COLLAGENEX				
			EQ 20MG BASE		
	<u>DROPERIDOL; FENTANYL CITRATE</u>				N50744 001 SEP 30, 1998 JUN DISC
	INJECTABLE; INJECTION				
	FENTANYL CITRATE AND DROPERIDOL				
	+ ABBOTT			2.5MG/ML;EQ 0.05MG BASE/ML	
	@ ASTRAZENECA			2.5MG/ML;EQ 0.05MG BASE/ML	
	<u>DUTASTERIDE</u>				N71982 001 MAY 04, 1988 JUN CTEC
	CAPSULE; ORAL				N72026 001 APR 13, 1989 JUN DISC
	AVODART				
>A>	+ GLAXOSMITHKLINE		0.5MG		
>A>	DUTASTERIDE				
>D>	+ GLAXOSMITHKLINE		0.5MG		
>D>					
	<u>ECHOTHIOPHATE IODIDE</u>				
	FOR SOLUTION; OPHTHALMIC				
	PHOSPHOLINE IODIDE				
	@ AYERST			0.03%	
	@			0.06%	
	@			0.25%	
	<u>EDETATE DISODIUM</u>				
	INJECTABLE; INJECTION				
	EDETATE DISODIUM				
AP	PHARMAFORCE			150MG/ML	
	<u>EFAVIRENZ</u>				
	TABLET; ORAL				
	SUSTIVA				
	BRISTOL MYERS SQUIBB		300MG		
	+		600MG		
	<u>EFLORNITHINE HYDROCHLORIDE</u>				
	CREAM; TOPICAL				
	VANIQA				
	+ WOMEN FIRST HLTHCARE			13.9%	
	<u>ENALAPRIL MALEATE</u>				
	TABLET; ORAL				
	VASOTEC				
AB	BIOVAIL		2.5MG		
AB			5MG		
AB			10MG		
AB +			20MG		
	<u>ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE</u>				
	TABLET; ORAL				
	VASERETIC				
AB	BIOVAIL			5MG;12.5MG	
					N18998 005 JUL 26, 1988 MAY CAHN
					N18998 001 DEC 24, 1985 MAY CAHN
					N18998 002 DEC 24, 1985 MAY CAHN
					N18998 003 DEC 24, 1985 MAY CAHN
					N21360 001 FEB 01, 2002 FEB NEWA
					N21360 002 FEB 01, 2002 FEB NEWA
					N40437 001 JUL 09, 2002 JUL NEWA
					N21145 001 JUL 27, 2000 JUL CAHN
					N19221 003 JUL 12, 1995 MAY CAHN

AB +	10MG;25MG	N19221 001	OCT 31, 1986	MAY	CAHN
<u>ENALAPRILAT</u>					
INJECTABLE; INJECTION					
VASOTEC					
AP +	BIOVAIL	1.25MG/ML	N19309 001	FEB 09, 1988	MAY CAHN
<u>ENOXACIN</u>					
TABLET; ORAL					
PENETREX					
@	AVENTIS	200MG	N19616 004	DEC 31, 1991	JUN DISC
@		400MG	N19616 005	DEC 31, 1991	JUN DISC
<u>ENOXAPARIN SODIUM</u>					
INJECTABLE; SUBCUTANEOUS					
LOVENOX					
@	AVENTIS	90MG/0.6ML	N20164 006	JUN 02, 2000	JUN DISC
<u>EPINEPHRINE</u>					
INJECTABLE; INJECTION					
SUS-PHRINE SULFITE-FREE					
@	FORREST LABS	1.5MG/AMP	N07942 003	FEB 05, 1999	JUN DISC
@		5MG/ML	N07942 001		JUN DISC
INJECTABLE; INTRAMUSCULAR					
EPI E Z PEN JR					
@	MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N19430 004	AUG 03, 1995	JUN DISC
EPIPEN E Z PEN					
@	MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N19430 003	AUG 03, 1995	JUN DISC
<u>EPLERENONE</u>					
TABLET; ORAL					
INSPIRA					
GD SEARLE LLC	25MG	N21437 001	SEP 27, 2002	SEP	NEWA
	50MG	N21437 002	SEP 27, 2002	SEP	NEWA
+	100MG	N21437 003	SEP 27, 2002	SEP	NEWA
<u>EPROSARTAN MESYLATE</u>					
TABLET; ORAL					
TEVETEN					
BIOVAIL PHARMS	EQ 300MG BASE	N20738 004	DEC 22, 1997	JUN	CAHN
	EQ 400MG BASE	N20738 005	DEC 22, 1997	JUN	CAHN
+	EQ 600MG BASE	N20738 006	MAY 27, 1999	JUN	CAHN
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE</u>					
TABLET; ORAL					
TEVETEN HCT					
BIOVAIL PHARMS	600MG;12.5MG	N21268 001	NOV 01, 2001	JUN	CAHN
+	600MG;25MG	N21268 002	NOV 01, 2001	JUN	CAHN
<u>EPTIFIBATIDE</u>					
INJECTABLE; INJECTION					
INTEGRILIN					
+	MILLENNIUM PHARMS	2MG/ML	N20718 001	MAY 18, 1998	FEB CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPRO (PREMARIN;CYCRIN)

@ WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20303 001	DEC 30, 1994	JUN	DISC
----------------	-----------------------------	------------	--------------	-----	------

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

PMB 200

@ WYETH AYERST	0.45MG;200MG	N10971 005		JUN	DISC
----------------	--------------	------------	--	-----	------

PMB 400

@ WYETH AYERST	0.45MG;400MG	N10971 003		JUN	DISC
----------------	--------------	------------	--	-----	------

ETHCHLORVYNOL

CAPSULE; ORAL

PLACIDYL

@ ABBOTT	200MG	N10021 007		JUN	DISC
----------	-------	------------	--	-----	------

@	500MG	N10021 002		JUN	DISC
---	-------	------------	--	-----	------

@	750MG	N10021 010		JUN	DISC
---	-------	------------	--	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

AB + WYETH AYERST	0.02MG;0.1MG	N20683 001	MAR 27, 1997	MAR	CTEC
-------------------	--------------	------------	--------------	-----	------

AB1 +	0.02MG;0.1MG	N20683 001	MAR 27, 1997	MAY	CTEC
-------	--------------	------------	--------------	-----	------

AVIANE-21

AB1 DURAMED PHARM BARR	0.02MG;0.1MG	N75796 002	APR 30, 2001	MAR	CTEC
------------------------	--------------	------------	--------------	-----	------

LESSINA-21

AB2 BARR	0.02MG;0.1MG	N75803 001	MAR 20, 2002	MAR	NEWA
----------	--------------	------------	--------------	-----	------

LEVLITE

AB2 + BERLEX LABS	0.02MG;0.1MG	N20860 001	JUL 13, 1998	MAR	CTEC
-------------------	--------------	------------	--------------	-----	------

PORTIA-21

AB BARR	0.03MG;0.15MG	N75866 001	MAY 23, 2002	MAY	NEWA
---------	---------------	------------	--------------	-----	------

TABLET; ORAL-28

ALESSE

AB1 WYETH AYERST	0.02MG;0.1MG	N20683 002	MAR 27, 1997	MAR	CTEC
------------------	--------------	------------	--------------	-----	------

AVIANE-28

AB1 DURAMED PHARM BARR	0.02MG;0.1MG	N75796 001	APR 30, 2001	MAR	CTEC
------------------------	--------------	------------	--------------	-----	------

LESSINA-28

AB BARR	0.02MG;0.1MG	N75803 002	MAR 20, 2002	MAR	NEWA
---------	--------------	------------	--------------	-----	------

LEVLITE

AB BERLEX LABS	0.02MG;0.1MG	N20860 002	JUL 13, 1998	MAR	CTEC
----------------	--------------	------------	--------------	-----	------

PORTIA-28

AB BARR	0.03MG;0.15MG	N75866 002	MAY 23, 2002	MAY	NEWA
---------	---------------	------------	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORTREL 0.5/35-21

AB BARR	0.035MG;0.5MG	N72692 001	FEB 28, 1992	AUG	CTNA
---------	---------------	------------	--------------	-----	------

NORTREL 1/35-21

AB BARR	0.035MG;1MG	N72693 001	FEB 28, 1992	AUG	CTNA
---------	-------------	------------	--------------	-----	------

NORTREL 7/7/7

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORTREL 7/7/7
AB BARR 0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.75MG N75478 001 AUG 30, 2002 AUG NEWA

ORTHO-NOVUM 7/7/7-21
AB + ORTHO MCNEIL PHARM 0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.75MG N18985 001 APR 04, 1984 AUG CFTG

TABLET; ORAL-28
NORTREL 0.5/35-28
AB BARR 0.035MG; 0.5MG N72695 001 FEB 28, 1992 AUG CTNA

NORTREL 1/35-28
AB BARR 0.035MG; 1MG N72696 001 FEB 28, 1992 AUG CTNA

NORTREL 7/7/7
AB BARR 0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG N75478 002 AUG 30, 2002 AUG NEWA

ORTHO-NOVUM 7/7/7-28
AB ORTHO MCNEIL PHARM 0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.75MG N18985 002 APR 04, 1984 AUG CFTG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21
ESTROSTEP 21
@ PARKE DAVIS 0.02MG; 0.03MG; 0.035MG; 1MG; 1MG; 1MG N20130 001 OCT 09, 1996 JUN DISC

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28
ORTHO CYCLEN-28
AB + ORTHO MCNEIL PHARM 0.035MG; 0.25MG N19653 002 DEC 29, 1989 SEP CFTG

ORTHO TRI-CYCLEN
+ ORTHO MCNEIL PHARM 0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG N19697 001 JUL 03, 1992 SEP CRLD

ORTHO TRI-CYCLEN LO
+ JOHNSON AND JOHNSON 0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.25MG, 0.215MG N21241 001 AUG 22, 2002 AUG NEWA

SPRINTEC
AB BARR 0.035MG; 0.25MG N75804 001 SEP 25, 2002 SEP NEWA

ETHOSUXIMIDE

CAPSULE; ORAL
ETHOSUXIMIDE
>A> AB BANNER PHARMACAPS 250MG N40430 001 OCT 28, 2002 OCT NEWA

ZARONTIN
>D> + PARKE DAVIS 250MG N12380 001 OCT CFTG

>A> AB + 250MG N12380 001 OCT CFTG

ETHOTOIN

TABLET; ORAL
PEGANONE
+ ABBOTT 250MG N10841 001 JUN CRLD

@ 500MG N10841 003 JUN DISC

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

@ ASTRAZENECA

1%

N17751 005

SEP DISC

ETODOLAC

CAPSULE; ORAL

ETODOLAC

AB NEOSAN PHARMS

300MG

N74929 001 JAN 30, 1998 JUL CAHN

TABLET; ORAL

AB NEOSAN PHARMS

400MG

N74927 001 OCT 30, 1997 JUL CAHN

TABLET, EXTENDED RELEASE; ORAL

AB EON

400MG

N75943 001 JUL 26, 2002 JUL NEWA

AB

500MG

N75943 002 JUL 26, 2002 JUL NEWA

AB

600MG

N75943 003 JUL 26, 2002 JUL NEWA

EZETIMIBE

TABLET; ORAL

ZETIA

+ MSP SINGAPORE

10MG

N21445 001 OCT 25, 2002 OCT NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP APOTEX

10MG/ML

N75942 001 AUG 02, 2002 AUG NEWA

AP BAXTER HLTHCARE

10MG/ML

N75799 001 APR 30, 2002 APR NEWA

FAMOTIDINE PRESERVATIVE FREE

@ APOTHECON

10MG/ML

N75708 001 APR 16, 2001 MAR WDAG

AP BAXTER HLTHCARE

10MG/ML

N75789 001 APR 30, 2002 APR NEWA

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

AB TEVA

67MG

N75753 001 SEP 03, 2002 SEP NEWA

AB

134MG

N75753 002 APR 09, 2002 APR NEWA

AB

200MG

N75753 003 APR 09, 2002 APR NEWA

TRICOR (MICRONIZED)

AB ABBOTT

67MG

N19304 002 FEB 09, 1998 SEP CFTG

AB

134MG

N19304 003 JUN 30, 1999 APR CFTG

AB +

200MG

N19304 004 JUN 30, 1999 APR CFTG

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

AB + RANBAXY

EQ 300MG BASE

N17604 002

JUN CAHN

NALFON 200

AB RANBAXY

EQ 200MG BASE

N17604 003

JUN CAHN

FENTANYL CITRATE

TROCHE/LOZENGE; ORAL

FENTANYL

@ ANESTA

EQ 0.1MG BASE

N20195 007 OCT 30, 1995 JUN DISC

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

		EQ 0.2MG BASE	N20195 001	OCT 04,
		EQ 0.3MG BASE	N20195 002	OCT 04,
		EQ 0.4MG BASE	N20195 003	OCT 04,

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL

FERRISELTZ

@ AMERSHAM HLTH

600MG/PACKET

N20292 001 OCT 14,

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

>A>	AB	BARR	50MG	N75882 001	OCT 28,
>A>	AB		100MG	N75882 002	OCT 28,
>A>	AB		150MG	N75882 003	OCT 28,
>A>	AB	GENEVA PHARMS TECH	50MG	N76030 001	OCT 28,
>A>	AB		100MG	N76030 002	OCT 28,
>A>	AB		150MG	N76030 003	OCT 28,

FLOXURIDINE

INJECTABLE; INJECTION

FUDR

AP + FAULDING

500MG/VIAL

N16929 001

FLUDEOXYGLUCOSE, F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F 18

@ DOWNSTATE CLINCL

4-40mCi/ML

N20306 001 AUG 19,

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF

AB + KING PHARMS

0.1MG

N10060 001

FLUDROCORTISONE ACETATE

AB + IMPAX LABS

0.1MG

N40431 001 MAR 18,

FLUNISOLIDE

SPRAY, METERED; NASAL

FLUNISOLIDE

AB + BAUSCH AND LOMB

0.025MG/SPRAY

N74805 001 FEB 20,

NASALIDE

AB + IVAX RES

0.025MG/SPRAY

N18148 001

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

SYNALAR-HP

@ MEDICIS

0.2%

N16161 002

SOLUTION; TOPICAL

FLUONID

@ ALLERGAN HERBERT

0.01%

N87158 001 MAR 17

1993 JUN DISC
1993 JUN DISC
1993 JUN DISC

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN
CREAM; TOPICAL
TRI-LUMA
+ HILL DERMAC
0.01%;4%;0.05%

N21112 001 JAN 18, 2002 JAN NEWA

1997 JUL DISC

FLUOCINONIDE
CREAM; TOPICAL
FLUOCINONIDE EMULSIFIED BASE
0.05%
AB TEVA

N72490 001 FEB 07, 1989 AUG CTNA

2002 OCT NEWA
2002 OCT NEWA
2002 OCT NEWA
2002 OCT NEWA
2002 OCT NEWA

FLUOXETINE HYDROCHLORIDE
CAPSULE; ORAL

FLUOXETINE EQ 10MG BASE
ALPHAPHARM EQ 20MG BASE
AB ALPHAPHARM EQ 10MG BASE
AB BARR EQ 10MG BASE
AB CARLSBAD EQ 20MG BASE
AB CARLSBAD EQ 10MG BASE
AB DR REDDYS LABS INC EQ 20MG BASE
AB DR REDDYS LABS INC EQ 10MG BASE
AB EON EQ 20MG BASE
AB EON EQ 10MG BASE
AB IVAX PHARMS EQ 20MG BASE
AB IVAX PHARMS EQ 10MG BASE
AB MALLINCKRODT EQ 20MG BASE
AB MALLINCKRODT EQ 10MG BASE
AB MUTUAL PHARMA EQ 20MG BASE
AB MUTUAL PHARMA EQ 10MG BASE
AB MYLAN EQ 20MG BASE
AB MYLAN EQ 10MG BASE
AB RANBAXY EQ 20MG BASE
AB RANBAXY EQ 10MG BASE
AB SIDMAK LABS EQ 20MG BASE
AB SIDMAK LABS EQ 10MG BASE
AB SIEGFRIED EQ 20MG BASE
AB SIEGFRIED EQ 10MG BASE
AB TEVA EQ 20MG BASE
AB TEVA EQ 40MG BASE
AB TEVA EQ 10MG BASE
AB WATSON LABS EQ 20MG BASE
AB WATSON LABS
AB FLUOXETINE HCL EQ 20MG BASE
AB GENEVA PHARMS EQ 40MG BASE
SOLUTION; ORAL
FLUOXETINE EQ 20MG BASE/5ML
AA ALPHARMA EQ 20MG BASE/5ML
AA MALLINCKRODT EQ 20MG BASE/5ML
AA NOVEX EQ 20MG BASE/5ML
AA PHARM ASSOC EQ 20MG BASE/5ML
AA FLUOXETINE HCL
AA HI TECH PHARMA EQ 20MG BASE/5ML

N75577 001 JAN 29, 2002 JAN NEWA
N75577 002 JAN 29, 2002 JAN NEWA
N74803 002 JAN 30, 2002 JAN NEWA
N76022 001 JAN 30, 2002 JAN NEWA
N76022 002 JAN 30, 2002 JAN NEWA
N75465 001 JAN 29, 2002 JAN NEWA
N75465 002 JAN 29, 2002 JAN NEWA
N75807 001 JAN 29, 2002 JAN NEWA
N75807 002 JAN 29, 2002 JAN NEWA
N75245 002 JAN 31, 2002 JAN NEWA
N75245 001 JAN 31, 2002 JAN NEWA
N75658 001 JAN 29, 2002 JAN NEWA
N75658 002 JAN 29, 2002 JAN NEWA
N75787 001 JAN 29, 2002 JAN NEWA
N75787 002 JAN 29, 2002 JAN NEWA
N75207 001 JAN 30, 2002 JAN NEWA
N75207 002 JAN 30, 2002 JAN NEWA
N76165 001 FEB 01, 2002 FEB NEWA
N76165 002 FEB 01, 2002 FEB NEWA
N76001 001 JAN 29, 2002 JAN NEWA
N76001 002 JAN 29, 2002 JAN NEWA
N75464 001 JAN 30, 2002 JAN NEWA
N75464 002 JAN 30, 2002 JAN NEWA
N75452 001 JAN 29, 2002 JAN NEWA
N75452 002 JAN 29, 2002 JAN NEWA
N75452 003 JAN 29, 2002 JAN NEWA
N75662 001 JAN 29, 2002 JAN NEWA
N75662 002 JAN 29, 2002 JAN NEWA
N75049 002 JAN 29, 2002 JAN NEWA
N75049 003 JAN 29, 2002 JAN NEWA

N75690 001 JAN 31, 2002 JAN NEWA
N75920 001 JAN 29, 2002 JAN NEWA
N75292 001 FEB 07, 2002 FEB NEWA
N76015 001 JAN 30, 2002 JAN NEWA
N75525 001 JUN 27, 2002 JUN NEWA

APR CAHN

1994 JUL DISC

MAR CFTG

2002 MAR NEWA

2002 FEB NEWA

FEB CTEC

JUN DISC

1983 MAY DISC

AA	MORTON GROVE	EQ 20MG BASE/5ML	N75514 001	AUG 29, 2002	AUG	NEWA
	TABLET; ORAL					
AB	BARR	EQ 10MG BASE	N75810 001	FEB 01, 2002	FEB	NEWA
AB	DR REDDYS LABS INC	EQ 10MG BASE	N76006 001	JAN 30, 2002	JAN	NEWA
AB	EON	EQ 10MG BASE	N76024 001	JAN 29, 2002	JAN	NEWA
AB	TEVA	EQ 10MG BASE	N75872 001	JAN 29, 2002	JAN	NEWA
AB	ZENITH GOLDLINE	EQ 10MG BASE	N75865 001	FEB 28, 2002	FEB	NEWA
<u>FLUPHENAZINE ENANTHATE</u>						
	INJECTABLE; INJECTION					
	PROLIXIN ENANTHATE					
	@ APOTHECON	25MG/ML	N16110 001		JUN	DISC
<u>FLUVOXAMINE MALEATE</u>						
	TABLET; ORAL					
	FLUVOXAMINE MALEATE					
AB	+ EON	100MG	N75888 003	NOV 29, 2000	MAY	CRLD
AB	MUTUAL PHARM	25MG	N76125 001	APR 29, 2002	APR	NEWA
AB		50MG	N76125 002	APR 29, 2002	APR	NEWA
AB		100MG	N76125 003	APR 29, 2002	APR	NEWA
AB	TEVA	25MG	N75893 001	SEP 10, 2002	SEP	NEWA
AB		50MG	N75893 002	SEP 10, 2002	SEP	NEWA
AB		100MG	N75893 003	SEP 10, 2002	SEP	NEWA
	LUVOX					
	@ SOLVAY	25MG	N20243 001	DEC 05, 1994	MAY	DISC
	@	50MG	N20243 002	DEC 05, 1994	MAY	DISC
	@	100MG	N20243 003	DEC 05, 1994	MAY	DISC
<u>FOLIC ACID</u>						
	TABLET; ORAL					
	FOLIC ACID					
AA	+ WATSON LABS	1MG	N80680 001		FEB	CAHN
<u>FOLLITROPIN ALFA/BETA</u>						
	INJECTABLE; INJECTION					
	GONAL-F					
	@ SERONO	37.5 IU/VIAL	N20378 003	MAY 25, 2000	JUN	DISC
<u>FULVESTRANT</u>						
	INJECTABLE; INTRAMUSCULAR					
	FASLODEX					
	+ ASTRAZENECA	50MG/ML	N21344 001	APR 25, 2002	APR	NEWA
<u>FURAZOLIDONE</u>						
	SUSPENSION; ORAL					
	FUROXONE					
	@ SHIRE LABS	50MG/15ML	N11323 002		JUL	DISC
	TABLET; ORAL					
	@ SHIRE LABS	100MG	N11270 002		JUL	DISC

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

1-35

GALLIUM CITRATE, GA-67
INJECTABLE; INJECTION
NEOSCAN
@ AMERSHAM HLTH

2mCi/ML

N17655 001

JUN DISC

GALLIUM NITRATE
INJECTABLE; INJECTION
GANITE
@ GENTA

25MG/ML

N19961 002 JAN 17, 1991 JUL CAHN

GLATIRAMER ACETATE
FOR SOLUTION; SUBCUTANEOUS
COPAXONE

20MG/VIAL

+ TEVA
INJECTABLE; SUBCUTANEOUS
+ TEVA

20MG/ML

N20622 001 DEC 20, 1996 JUN CDFR

N20622 002 FEB 12, 2002 JUN NEWA

GLIPIZIDE
TABLET, EXTENDED RELEASE; ORAL

GLUCOTROL XL 2.5MG
PFIZER 5MG

N20329 003 AUG 10, 1999 FEB CRLD
N20329 001 APR 26, 1994 FEB CRLD

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
METAGLIP 2.5MG;250MG
BRISTOL MYERS SQUIBB 2.5MG;500MG
5MG;500MG

N21460 001 OCT 21, 2002 OCT NEWA
N21460 002 OCT 21, 2002 OCT NEWA
N21460 003 OCT 21, 2002 OCT NEWA

>A>
>A>
>A>
>A>
>A>
>A>

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION
GLUCAGON EQ 1MG BASE/VIAL
@ LILLY

N12122 001 JUN DISC

GLYBURIDE

TABLET; ORAL
GLYBURIDE 1.25MG
AB COREPHARMA 2.5MG
AB 5MG
AB

N76257 001 JUN 27, 2002 JUN NEWA
N76257 002 JUN 27, 2002 JUN NEWA
N76257 003 JUN 27, 2002 JUN NEWA

GONADORELIN ACETATE

INJECTABLE; INJECTION
LUTREPULSE KIT 0.8MG/VIAL
@ FERRING 3.2MG/VIAL
@

N19687 001 OCT 10, 1989 JUL DISC
N19687 002 OCT 10, 1989 JUN DISC

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION
FACTREL EQ 0.5MG BASE/VIAL
@ WYETH AYERST

N18123 003 SEP 30, 1982 JUN DISC

<u>GONADOTROPIN, CHORIONIC</u>					
INJECTABLE; INJECTION					
A.P.L.					
	@ WYETH AYERST	20,000 UNITS/VIAL	N17055 003		JUN
CHORIONIC GONADOTROPIN					
	@ STERIS	2,000 UNITS/VIAL	N17016 011	FEB 16, 1990	JUN
<u>GRANISETRON HYDROCHLORIDE</u>					
SOLUTION; ORAL					
KYTRIL					
	@ ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUN
<u>GRISEOFULVIN, MICROCRYSTALLINE</u>					
TABLET; ORAL					
GRISACTIN					
	@ WYETH AYERST	500MG	N60212 001		MAY
<u>GRISEOFULVIN, ULTRAMICROCRYSTALLINE</u>					
TABLET; ORAL					
GRISACTIN ULTRA					
	@ WYETH AYERST	165MG	N62438 001	NOV 17, 1983	MAY
	@	330MG	N62438 002	NOV 17, 1983	MAY
<u>GUANADREL SULFATE</u>					
TABLET; ORAL					
HYLOREL					
	@ PHARMACIA AND UPJOHN	10MG	N18104 001	DEC 29, 1982	JUN
	@	25MG	N18104 002	DEC 29, 1982	JUN
<u>GUANETHIDINE MONOSULFATE</u>					
TABLET; ORAL					
ISMELIN					
	@ NOVARTIS	EQ 10MG SULFATE	N12329 001		JUN
	@	EQ 25MG SULFATE	N12329 002		JUN
<u>GUANFACINE HYDROCHLORIDE</u>					
TABLET; ORAL					
TENEX					
AB	ESP PHARMA	EQ 1MG BASE	N19032 001	OCT 27, 1986	APR
AB +		EQ 2MG BASE	N19032 002	NOV 07, 1988	APR
	@	EQ 3MG BASE	N19032 003	NOV 07, 1988	APR
<u>HALOPERIDOL</u>					
TABLET; ORAL					
HALDOL					
	@ ORTHO MCNEIL	0.5MG	N15921 001		AUG
	@	1MG	N15921 002		AUG
	@	2MG	N15921 003		AUG
	@	5MG	N15921 004		AUG
	@	10MG	N15921 005		AUG
	@	20MG	N15921 006	FEB 02, 1982	AUG
HALOPERIDOL					

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL 20MG
+ GENEVA PHARMS

JUN DISC

N71211 001 MAR 11, 1988 AUG CRLD

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
HALDOL EQ 2MG BASE/ML

@ ORTHO MCNEIL

HALOPERIDOL EQ 2MG BASE/ML

@ ALPHARMA EQ 2MG BASE/ML

AA + TEVA

1990 JUN DISC

2001 JUN DISC

N15922 001

AUG DISC

N70318 001 APR 11, 1986 MAY DISC

N71015 001 AUG 25, 1987 AUG CRLD

HALOTHANE

LIQUID; INHALATION
FLUOTHANE 99.99%

@ WYETH AYERST

HALOTHANE 99.99%

AN + ABBOTT

MAY DISC

N11338 001

APR DISC

N83254 001

APR CTEC

HEPARIN SODIUM

INJECTABLE; INJECTION
HEP-LOCK 10 UNITS/ML
100 UNITS/ML

AP + ELKINS SINN

AP +

HEPARIN LOCK FLUSH 10 UNITS/ML
100 UNITS/ML

@ WYETH AYERST

@

HEPARIN SODIUM

AP + ABBOTT 2,500 UNITS/ML

AP + AM PHARM PARTNERS 20,000 UNITS/ML

@ WYETH AYERST 1,000 UNITS/ML

@ 2,500 UNITS/ML

@ 5,000 UNITS/ML

@ 5,000 UNITS/0.5ML

@ 7,500 UNITS/ML

@ 10,000 UNITS/ML

@ 20,000 UNITS/ML

1982 JUN DISC

1982 JUN DISC

JUN DISC

JUN DISC

N17037 007

JUN CRLD

N17037 006

JUN CRLD

N17007 008

JUN DISC

N17007 009

JUN DISC

N88099 001 APR 28, 1983

JUN CRLD

N17029 004

JUN CRLD

N17007 001

JUN DISC

N17007 007

JUN DISC

N17007 002

JUN DISC

N17007 010

JUN DISC

N17007 003

JUN DISC

N17007 004

JUN DISC

N17007 006

JUN DISC

HEXACHLOROPHENE

SOAP; TOPICAL
GAMOPHEN 2%

@ ARBROOK

SPONGE; TOPICAL

E-2 SCRUB 450MG

@ BECTON DICKINSON

N06270 003

JUN DISC

N17452 001

JUN DISC

HISTRELIN ACETATE

INJECTABLE; INJECTION
SUPPRELIN EQ 0.2MG BASE/ML

@ SHIRE LABS

N19836 001 DEC 24, 1991 JUL DISC

AUG DISC

AUG DISC

AUG DISC

AUG DISC

AUG DISC

1982 AUG DISC

	ⓐ	EQ 0.5MG BASE/ML	N19836 002	DEC 24, 1991	JUL	DISC
	ⓐ	EQ 1MG BASE/ML	N19836 003	DEC 24, 1991	JUL	DISC
<u>HYDROCHLOROTHIAZIDE</u>						
CAPSULE; ORAL						
HYDROCHLOROTHIAZIDE						
AB	VINTAGE PHARMS	12.5MG	N75907 001	SEP 17, 2002	SEP	NEWA
TABLET; ORAL						
ESIDRIX						
AB	+ NOVARTIS	100MG	N11793 009		MAR	CRLD
	ⓐ	100MG	N11793 009		SEP	DISC
HYDROCHLOROTHIAZIDE						
AB	+ IVAX PHARMS	100MG	N85022 001		SEP	CRLD
	ⓐ LEDERLE	100MG	N87060 001		SEP	DISC
AB	VINTAGE PHARMS	25MG	N40412 001	MAR 29, 2002	MAR	NEWA
AB		50MG	N40412 002	MAR 29, 2002	MAR	NEWA
	ⓐ WATSON LABS	100MG	N81190 001	JAN 24, 1992	SEP	DISC
HYDRODIURIL						
	ⓐ MERCK	25MG	N11835 003		MAR	DISC
	ⓐ	50MG	N11835 006		MAR	DISC
	ⓐ	100MG	N11835 007		MAR	DISC
ORETIC						
	ⓐ ABBOTT	25MG	N11971 001		SEP	DISC
<u>HYDROCHLOROTHIAZIDE; LISINOPRIL</u>						
TABLET; ORAL						
LISINOPRIL AND HYDROCHLOROTHIAZIDE						
AB	EON	12.5MG;10MG	N76262 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76262 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76262 003	JUL 01, 2002	JUL	NEWA
AB	GENEVA PHARMS TECH	12.5MG;10MG	N75926 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N75926 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N75926 003	JUL 01, 2002	JUL	NEWA
AB	IVAX PHARMS	12.5MG;10MG	N75776 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N75776 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N75776 003	JUL 01, 2002	JUL	NEWA
AB	MYLAN	12.5MG;10MG	N76113 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76113 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76113 003	JUL 01, 2002	JUL	NEWA
AB	PUREPAC PHARM	12.5MG;10MG	N76230 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76230 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76230 003	JUL 01, 2002	JUL	NEWA
AB	RANBAXY	12.5MG;10MG	N76007 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76007 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76007 003	JUL 01, 2002	JUL	NEWA
AB	TEVA	12.5MG;10MG	N75869 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N75869 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N75869 003	JUL 01, 2002	JUL	NEWA
AB	WATSON LABS	12.5MG;20MG	N76194 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;10MG	N76194 003	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76194 002	JUL 01, 2002	JUL	NEWA
AB	WEST WARD	12.5MG;10MG	N76265 001	JUL 08, 2002	JUL	NEWA
AB		12.5MG;20MG	N76265 002	JUL 08, 2002	JUL	NEWA

25MG;20MG

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
UNIRETIC
SCHWARZ PHARMA

12.5MG;15MG

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50

50MG;120MG

@ WYETH AYERST

INDERIDE LA 160/50

50MG;160MG

@ WYETH AYERST

INDERIDE LA 80/50

50MG;80MG

@ WYETH AYERST

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDOPRES 25

25MG;0.125MG

@ MERCK

HYDOPRES 50

50MG;0.125MG

@ MERCK

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

CODAMINE

5MG/5ML;25MG/5ML

@ ALPHARMA

HYCOMINE

5MG/5ML;25MG/5ML

@ ENDO PHARMS

HYCOMINE PEDIATRIC

2.5MG/5ML;12.5MG/5ML

@ ENDO PHARMS

HYDROCORTISONE

TABLET; ORAL

CORTEF

5MG

>D> + PHARMACIA AND UPJOHN

5MG

>A> +

5MG

+

10MG

>D> BP +

10MG

>A> BP

10MG

BP +

20MG

BP +

HYDROCORTISONE ACETATE

CREAM; TOPICAL

MICORT-HC

2%

+ FERNDAL LABS

INJECTABLE; INJECTION

HYDROCORTISONE ACETATE

25MG/ML

>D>

>D>

>D>

>A>

+ STERIS

25MG/ML

@

25MG/ML

+

N76265 003 JUL 08, 2002 JUL NEWA

N20729 003 FEB 14, 2002 JUN NEWA

N19059 002 JUL 03, 1985 JUN DISC

N19059 003 JUL 03, 1985 JUN DISC

N19059 001 JUL 03, 1985 JUN DISC

N11958 002 JUN DISC

N11958 003 JUN DISC

N75103 001 SEP 29, 2000 SEP DISC

N19410 001 AUG 17, 1990 SEP DISC

N19411 001 AUG 17, 1990 SEP DISC

N08697 003 OCT CRLD

N08697 003 OCT CRLD

N08697 003 MAY CRLD

N08697 001 OCT CRLD

N08697 001 MAY CRLD

N08697 002 MAY CRLD

N40398 001 MAR 29, 2002 MAR NEWA

N83128 001 OCT DISC

N83128 001 OCT DISC

N83128 001 JUN CRLD

<u>HYDROCORTISONE ACETATE</u> INJECTABLE; INJECTION HYDROCORTONE @ MERCK @	25MG/ML 50MG/ML	N08228 001 N08228 004	JUN DISC JUN DISC
<u>HYDROCORTISONE BUTYRATE</u> CREAM; TOPICAL LOCOID + FERNDAL LABS LOCOID LIPOCREAM + FERNDAL LABS OINTMENT; TOPICAL LOCOID + FERNDAL LABS	0.1% 0.1% 0.1%	N18514 001 N20769 001 N18652 001	MAR 31, 1982 MAR CAHN SEP 08, 1997 MAR CAHN OCT 29, 1982 MAR CAHN
<u>HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE</u> OINTMENT; OPHTHALMIC ACHROMYCIN @ LEDERLE	1.5%;1%	N50272 001	JUN DISC
<u>HYDROFLUMETHIAZIDE; RESERPINE</u> TABLET; ORAL RESERPINE AND HYDROFLUMETHIAZIDE @ PAR PHARM SALUTENSIN-DEMI @ SHIRE LABS	50MG;0.125MG 25MG;0.125MG	N88907 001 N12359 004	SEP 20, 1985 AUG DISC JUL DISC
<u>HYDROXYAMPHETAMINE HYDROBROMIDE</u> SOLUTION/DROPS; OPHTHALMIC PAREDRIINE @ AKORN	1%	N00004 004	JUN DISC
<u>HYDROXYPROGESTERONE CAPROATE</u> INJECTABLE; INJECTION HYDROXYPROGESTERONE CAPROATE @ STERIS	250MG/ML	N17439 002	JUN DISC
<u>HYDROXYZINE HYDROCHLORIDE</u> SYRUP; ORAL HYDROXYZINE HCL VINTAGE PHARMS	10MG/5ML	N40391 001	APR 10, 2002 APR NEWA
<u>IBUPROFEN</u> SUSPENSION/DROPS; ORAL MOTRIN @ MCNEIL TABLET; ORAL @ MCNEIL CONS SPECLT TABLET, CHEWABLE; ORAL @ MCNEIL CONS SPECLT	40MG/ML 100MG 50MG	N20476 001 N20418 001 N20135 001	MAY 25, 1995 JUN DISC NOV 16, 1994 JUN DISC NOV 16, 1994 JUN DISC

	@	100MG	N20135 002	NOV 16, 1994	JUN	DISC
<u>IDARUBICIN HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
IDAMYCIN						
AP	+	PHARMACIA AND UPJOHN	5MG/VIAL	N50661 002	SEP 27, 1990	MAY CFTG
		@	5MG/VIAL	N50661 002	SEP 27, 1990	JUN DISC
AP	+		10MG/VIAL	N50661 001	SEP 27, 1990	MAY CFTG
		@	10MG/VIAL	N50661 001	SEP 27, 1990	JUN DISC
AP	+		20MG/VIAL	N50661 003	APR 25, 1995	MAY CFTG
		@	20MG/VIAL	N50661 003	APR 25, 1995	JUN DISC
IDAMYCIN PFS						
AP	+	PHARMACIA AND UPJOHN	1MG/ML	N50734 001	FEB 17, 1997	MAY CFTG
IDARUBICIN HCL						
AP		GENSIA SICOR PHARMS	5MG/VIAL	N65037 003	MAY 01, 2002	MAY NEWA
	+		10MG/VIAL	N65037 002	MAY 01, 2002	JUN CRLD
AP			10MG/VIAL	N65037 002	MAY 01, 2002	MAY NEWA
	+		20MG/VIAL	N65037 001	MAY 01, 2002	JUN CRLD
AP			20MG/VIAL	N65037 001	MAY 01, 2002	MAY NEWA
IDARUBICIN HCL PFS						
AP		GENSIA SICOR PHARMS	1MG/ML	N65036 001	MAY 01, 2002	MAY NEWA
<u>IFOSFAMIDE</u>						
INJECTABLE; INJECTION						
IFOSFAMIDE						
	+	AM PHARM PARTNERS	1GM/VIAL	N76078 001	MAY 28, 2002	AUG CRLD
			1GM/VIAL	N76078 001	MAY 28, 2002	MAY NEWA
	+		3GM/VIAL	N76078 002	MAY 28, 2002	MAY NEWA
<u>IFOSFAMIDE; MESNA</u>						
INJECTABLE; INTRAVENOUS						
IFOSFAMIDE/MESNA KIT						
	+	GENSIA SICOR PHARMS	1GM /20ML(50MG/ML);1GM			
			/10ML(100MG/ML)	N75874 001	FEB 26, 2002	FEB NEWA
	+		3GM /60ML(50MG/ML);1GM			
			/10ML(100MG/ML)	N75874 002	FEB 26, 2002	FEB NEWA
<u>INAMRINONE LACTATE</u>						
INJECTABLE; INJECTION						
AMRINONE						
AP	+	ABBOTT	EQ 5MG BASE/ML	N74616 001	AUG 03, 1998	JUN CRLD
		INOCOR				
	@	SANOFI SYNTHELABO	EQ 5MG BASE/ML	N18700 001	JUL 31, 1984	JUN DISC
<u>INDOCYANINE GREEN</u>						
INJECTABLE; INJECTION						
CARDIO-GREEN						
	@	AKORN	50MG/VIAL	N11525 002		JUN DISC
<u>INDOMETHACIN</u>						
CAPSULE; ORAL						
INDOMETHACIN						
AB		PAR PHARM	25MG	N18829 002	AUG 06, 1984	JUL CAHN

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

AB	50MG	N18829 001	AUG 06, 1984
	CAPSULE, EXTENDED RELEASE; ORAL		
AB	75MG	N76114 001	FEB 06, 2002
	ABLE		
	SUPPOSITORY; RECTAL		
	INDOCIN		
	@ MERCK	N17814 001	AUG 13, 1984
	INDOMETHEGAN		
+	G AND W LABS	N73314 001	AUG 31, 1992
	50MG		
<u>INSULIN PORK</u>			
	INJECTABLE; INJECTION		
	Iletin I		
	@ LILLY	N17931 001	
	500 UNITS/ML		
<u>IODIPAMIDE MEGLUMINE</u>			
	INJECTABLE; INJECTION		
	CHOLOGRAFIN MEGLUMINE		
	@ BRACCO	N09321 007	
	10.3%		
<u>IODIXANOL</u>			
	INJECTABLE; INJECTION		
	VISIPAQUE 270		
	@ AMERSHAM HLTH	N20808 001	AUG 29, 1997
	55%		
	VISIPAQUE 320		
	@ AMERSHAM HLTH	N20808 002	AUG 29, 1997
	65.2%		
<u>IODOHIPPURATE SODIUM, I-131</u>			
	INJECTABLE; INJECTION		
	HIPPURAN I 131		
	@ MALLINCKRODT	N16666 001	
	0.25mCi/ML		
<u>IOFETAMINE HYDROCHLORIDE I-123</u>			
	INJECTABLE; INJECTION		
	SPECTAMINE		
	@ IMP	N19432 001	DEC 24, 1987
	1mCi/ML		
<u>IOHEXOL</u>			
	INJECTABLE; INJECTION		
	OMNIPAQUE 210		
	@ AMERSHAM HLTH	N18956 006	JUN 30, 1989
	45.3%		
	SOLUTION; URETHRAL		
	OMNIPAQUE 70		
	@ AMERSHAM HLTH	N18956 007	JUN 01, 1994
	15.1%		
<u>IOPAMIDOL</u>			
	INJECTABLE; INJECTION		
	IOPAMIDOL		
	@ FAULDING	N74734 001	DEC 10, 1996
	61%	N74734 002	DEC 10, 1996
	@		
	76%		
	ISOVUE-128		
	@ BRACCO	N18735 005	OCT 21, 1986
	26%		

1984 JUL CAHN
 2002 FEB NEWA
 1984 MAY DISC
 1992 MAY CRLD
 JUN DISC
 JUN DISC
 1997 JUN DISC
 1997 JUN DISC
 JUN DISC
 1987 JUN DISC
 1989 JUN DISC
 1994 JUN DISC
 1996 JUL DISC
 1996 JUL DISC
 1986 JUN DISC

IOPROMIDE

INJECTABLE; INJECTION
 ULTRAVIST (PHARMACY BULK)
 + BERLEX LABS 300MG/ML
 + 370MG/ML

N21425 001 SEP 20, 2002 SEP NEWA
 N21425 002 SEP 20, 2002 SEP NEWA

IOTHALAMATE SODIUM

INJECTABLE; INJECTION
 CONRAY 325 54.3%
 @ MALLINCKRODT

N17685 001 JUN DISC

IOXILAN

INJECTABLE; INJECTION
 OXILAN-300 62%
 GUERBET
 OXILAN-350 73%
 GUERBET

N20316 001 DEC 21, 1995 JUN CAHN
 N20316 002 DEC 21, 1995 JUN CAHN

IPODATE SODIUM

CAPSULE; ORAL
 DRAGRAFIN SODIUM 500MG
 @ BRACCO

N12967 001 JUN DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
 IPATROPIUM BROMIDE 0.02%
 AN ROXANE

N75867 001 JUL 22, 2002 JUL NEWA

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION
 ISOPROTERENOL HCL 0.12MG/INH
 @ 3M

N10375 004 JUN DISC

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION
 MEDIHALER-ISO 0.08MG/INH
 @ 3M

N10375 003 JUN DISC

ISOSORBIDE

SOLUTION; ORAL
 ISMOTIC 100GM/220ML
 @ ALCON

N17063 001 JUN DISC

ISOSORBIDE DINITRATE

TABLET; ORAL
 SORBITRATE 5MG
 @ ASTRAZENECA 10MG
 @
 TABLET, CHEWABLE; ORAL 5MG
 @ ASTRAZENECA

N16192 001 APR 01, 1996 SEP DISC
 N16192 002 APR 01, 1996 SEP DISC
 N16776 002 APR 01, 1996 SEP DISC

LAMOTRIGINE

TABLET, CHEWABLE; ORAL

LAMICTAL CD 25MG
+ GLAXOSMITHKLINE 100MG
a

1991 JUL CAHN

N20764 002 AUG 24, 1998 MAR CRLD
N20764 003 AUG 24, 1998 MAR DISC

LANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING; ORAL

PREVACID 15MG
TAP PHARM 30MG
+

2002 OCT NEWA

N21428 001 AUG 30, 2002 AUG NEWA
N21428 002 AUG 30, 2002 AUG NEWA

LEUCOVORIN CALCIUM

TABLET; ORAL

LEUCOVORIN CALCIUM EQ 5MG BASE
XANODYNE PHARM EQ 10MG BASE
EQ 15MG BASE
BX
AB
AB

1999 JUL CAHN
2002 JAN NEWA

N18459 001 JAN 30, 1986 AUG CAHN
N71962 001 NOV 19, 1987 AUG CAHN
N71104 001 MAR 04, 1987 JUN CAHN

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS

ELIGARD 7.5MG/VIAL
+ ATRIX 22.5MG/VIAL
+

2002 FEB NEWA
2002 FEB NEWA
2002 FEB NEWA

N21343 001 JAN 23, 2002 JAN NEWA
N21379 001 JUL 24, 2002 JUL NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

XOPENEX EQ 0.0105% BASE
+ SEPRACOR

2002 JAN NEWA
2002 JAN NEWA

N20837 003 JAN 30, 2002 JUN NEWA

LEVOCARNITINE

SOLUTION; ORAL

CARNITOR 1GM/10ML
a SIGMA TAU 1GM/10ML
+
a 1GM/10ML

JUL DISC

N18948 002 APR 27, 1988 JUN DISC
N19257 001 APR 10, 1986 JUL CMFD
N19257 001 APR 10, 1986 JUN DISC

LEVODOPA

TABLET; ORAL

LARODOPA 100MG
a ROCHE 250MG
a 500MG
a

2002 JUL NEWA

N16912 005 JUN DISC
N16912 003 JUN DISC
N16912 004 JUN DISC

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVO-T 0.025MG
BX MOVA 0.05MG
BX 0.075MG
BX 0.088MG
BX 0.1MG
BX

2002 FEB NEWA
JUL DISC
1988 JUL CRLD

N21342 001 MAR 01, 2002 MAR NEWA
N21342 002 MAR 01, 2002 MAR NEWA
N21342 003 MAR 01, 2002 MAR NEWA
N21342 004 MAR 01, 2002 MAR NEWA
N21342 005 MAR 01, 2002 MAR NEWA

BX		0.112MG	N21342 006	MAR 01, 2002	MAR	NEWA	
BX		0.125MG	N21342 007	MAR 01, 2002	MAR	NEWA	>A> BX
BX		0.15MG	N21342 008	MAR 01, 2002	MAR	NEWA	>A> BX
BX		0.175MG	N21342 009	MAR 01, 2002	MAR	NEWA	>A> BX
BX		0.2MG	N21342 010	MAR 01, 2002	MAR	NEWA	
BX +		0.3MG	N21342 011	MAR 01, 2002	MAR	NEWA	AB
	LEVOTHYROXINE SODIUM						AB
AB	MYLAN	0.025MG	N76187 001	JUN 05, 2002	JUN	NEWA	AB
AB		0.05MG	N76187 002	JUN 05, 2002	JUN	NEWA	AB
AB		0.075MG	N76187 003	JUN 05, 2002	JUN	NEWA	AB
AB		0.088MG	N76187 004	JUN 05, 2002	JUN	NEWA	AB
AB		0.1MG	N76187 005	JUN 05, 2002	JUN	NEWA	AB
AB		0.112MG	N76187 006	JUN 05, 2002	JUN	NEWA	AB
AB		0.125MG	N76187 007	JUN 05, 2002	JUN	NEWA	AB
AB		0.15MG	N76187 008	JUN 05, 2002	JUN	NEWA	AB
AB		0.175MG	N76187 009	JUN 05, 2002	JUN	NEWA	AB
AB		0.2MG	N76187 010	JUN 05, 2002	JUN	NEWA	AB
AB		0.3MG	N76187 011	JUN 05, 2002	JUN	NEWA	AB
	NOVOTHYROX						
BX	GENPHARM	0.025MG	N21292 001	MAY 31, 2002	MAY	NEWA	
BX		0.05MG	N21292 002	MAY 31, 2002	MAY	NEWA	
BX		0.075MG	N21292 003	MAY 31, 2002	MAY	NEWA	
BX		0.088MG	N21292 004	MAY 31, 2002	MAY	NEWA	
BX		0.1MG	N21292 005	MAY 31, 2002	MAY	NEWA	
BX		0.112MG	N21292 006	MAY 31, 2002	MAY	NEWA	
BX		0.125MG	N21292 007	MAY 31, 2002	MAY	NEWA	
BX		0.137MG	N21292 008	MAY 31, 2002	MAY	NEWA	
BX		0.15MG	N21292 009	MAY 31, 2002	MAY	NEWA	
BX		0.175MG	N21292 010	MAY 31, 2002	MAY	NEWA	
BX		0.2MG	N21292 011	MAY 31, 2002	MAY	NEWA	
BX +		0.3MG	N21292 012	MAY 31, 2002	MAY	NEWA	
	SYNTHROID						
BX	ABBOTT	0.025MG	N21402 001	JUL 24, 2002	JUL	NEWA	
BX		0.05MG	N21402 002	JUL 24, 2002	JUL	NEWA	
BX		0.075MG	N21402 003	JUL 24, 2002	JUL	NEWA	
BX		0.088MG	N21402 004	JUL 24, 2002	JUL	NEWA	
BX		0.1MG	N21402 005	JUL 24, 2002	JUL	NEWA	
BX		0.112MG	N21402 006	JUL 24, 2002	JUL	NEWA	
BX		0.125MG	N21402 007	JUL 24, 2002	JUL	NEWA	
BX		0.137MG	N21402 008	JUL 24, 2002	JUL	NEWA	
BX		0.15MG	N21402 009	JUL 24, 2002	JUL	NEWA	
BX		0.175MG	N21402 010	JUL 24, 2002	JUL	NEWA	
BX		0.2MG	N21402 012	JUL 24, 2002	AUG	NEWA	
BX +		0.3MG	N21402 011	JUL 24, 2002	JUL	NEWA	
	THYRO-TABS						
>A>	BX	LLOYD	0.025MG	N21116 001	OCT 24, 2002	OCT	NEWA
>A>	BX		0.05MG	N21116 002	OCT 24, 2002	OCT	NEWA
>A>	BX		0.075MG	N21116 003	OCT 24, 2002	OCT	NEWA
>A>	BX		0.088MG	N21116 010	OCT 24, 2002	OCT	NEWA
>A>	BX		0.1MG	N21116 004	OCT 24, 2002	OCT	NEWA
>A>	BX		0.112MG	N21116 011	OCT 24, 2002	OCT	NEWA
>A>	BX		0.125MG	N21116 005	OCT 24, 2002	OCT	NEWA
>A>	BX		0.15MG	N21116 006	OCT 24, 2002	OCT	NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

1-48

AB		30MG	N76102 005	SEP 30, 2002	SEP	NEW
AB		40MG	N76102 006	SEP 30, 2002	SEP	NEW
AB	EON	2.5MG	N75994 001	JUL 01, 2002	JUL	NEW
AB		5MG	N75994 002	JUL 01, 2002	JUL	NEW
AB		10MG	N75994 003	JUL 01, 2002	JUL	NEW
AB		20MG	N75994 004	JUL 01, 2002	JUL	NEW
AB		30MG	N75994 005	JUL 01, 2002	JUL	NEW
AB		40MG	N75994 006	JUL 01, 2002	JUL	NEW
AB	GENEVA PHARMS TECH	2.5MG	N75903 001	JUL 01, 2002	JUL	NEW
AB		5MG	N75903 002	JUL 01, 2002	JUL	NEW
AB		10MG	N75903 003	JUL 01, 2002	JUL	NEW
AB		20MG	N75903 004	JUL 01, 2002	JUL	NEW
AB		30MG	N75903 005	JUL 01, 2002	JUL	NEW
AB		40MG	N75903 006	JUL 01, 2002	JUL	NEW
AB	IVAX PHARMS	2.5MG	N75752 001	JUL 01, 2002	JUL	NEW
AB		5MG	N75752 002	JUL 01, 2002	JUL	NEW
AB		10MG	N75752 003	JUL 01, 2002	JUL	NEW
AB		20MG	N75752 004	JUL 01, 2002	JUL	NEW
AB		30MG	N75752 005	JUL 01, 2002	JUL	NEW
AB		40MG	N75752 006	JUL 01, 2002	JUL	NEW
AB	LEK PHARM	2.5MG	N75999 001	JUL 01, 2002	AUG	NEW
AB		5MG	N75999 002	JUL 01, 2002	AUG	NEW
AB		10MG	N75999 003	JUL 01, 2002	AUG	NEW
AB		20MG	N75999 004	JUL 01, 2002	AUG	NEW
AB		30MG	N75999 005	JUL 01, 2002	AUG	NEW
AB		40MG	N75999 006	JUL 01, 2002	AUG	NEW
AB	MYLAN	2.5MG	N76071 001	JUL 01, 2002	JUL	NEW
AB		5MG	N76071 002	JUL 01, 2002	JUL	NEW
AB		10MG	N76071 003	JUL 01, 2002	JUL	NEW
AB		20MG	N76071 004	JUL 01, 2002	JUL	NEW
AB		30MG	N76071 005	JUL 01, 2002	JUL	NEW
AB		40MG	N76071 006	JUL 01, 2002	JUL	NEW
AB	PAR PHARM	2.5MG	N75743 001	JUL 01, 2002	JUL	NEW
AB		5MG	N75743 002	JUL 01, 2002	JUL	NEW
AB		10MG	N75743 003	JUL 01, 2002	JUL	NEW
AB		20MG	N75743 004	JUL 01, 2002	JUL	NEW
AB		30MG	N75743 005	JUL 01, 2002	JUL	NEW
AB		40MG	N75743 006	JUL 01, 2002	JUL	NEW
AB	PUREPAC PHARM	2.5MG	N76180 001	JUL 01, 2002	JUL	NEW
AB		5MG	N76180 002	JUL 01, 2002	JUL	NEW
AB		10MG	N76180 003	JUL 01, 2002	JUL	NEW
AB		20MG	N76164 001	JUL 01, 2002	JUL	NEW
AB		30MG	N76164 002	JUL 01, 2002	JUL	NEW
AB		40MG	N76164 003	JUL 01, 2002	JUL	NEW
AB	RANBAXY	2.5MG	N75944 001	JUL 01, 2002	JUL	NEW
AB		5MG	N75944 002	JUL 01, 2002	JUL	NEW
AB		10MG	N75944 003	JUL 01, 2002	JUL	NEW
AB		20MG	N75944 004	JUL 01, 2002	JUL	NEW
AB		40MG	N75944 005	JUL 01, 2002	JUL	NEW
AB	TEVA	2.5MG	N75783 001	JUL 01, 2002	JUL	NEW
AB		5MG	N75783 002	JUL 01, 2002	JUL	NEW
AB		10MG	N75783 003	JUL 01, 2002	JUL	NEW
AB		20MG	N75783 004	JUL 01, 2002	JUL	NEW

	30MG	N75783 005	JUL 01, 2002	JUL	NEWA	
	40MG	N75783 006	JUL 01, 2002	JUL	NEWA	
AB	2.5MG	N76059 001	JUL 01, 2002	JUL	NEWA	
AB	5MG	N76059 002	JUL 01, 2002	JUL	NEWA	
AB	10MG	N76059 003	JUL 01, 2002	JUL	NEWA	
AB	20MG	N76059 004	JUL 01, 2002	JUL	NEWA	
AB	30MG	N76059 005	JUL 01, 2002	JUL	NEWA	
AB	40MG	N76059 006	JUL 01, 2002	JUL	NEWA	
AB	2.5MG	N76063 001	JUL 01, 2002	JUL	NEWA	
AB	5MG	N76063 002	JUL 01, 2002	JUL	NEWA	
AB	10MG	N76063 003	JUL 01, 2002	JUL	NEWA	
AB	20MG	N76063 004	JUL 01, 2002	JUL	NEWA	
AB	40MG	N76063 005	JUL 01, 2002	JUL	NEWA	
AB	ZESTRIL	N19777 006	JAN 20, 1999	JUL	CFTG	
AB +	ASTRAZENECA					
<u>LITHIUM CARBONATE</u>						
CAPSULE; ORAL						
LITHIUM CARBONATE						
AB	WEST WARD	300MG	N76243 001	JUN 27, 2002	JUN	NEWA
TABLET, EXTENDED RELEASE; ORAL						
AB	BARR	300MG	N76170 001	JUN 10, 2002	JUN	NEWA
LITHOBID						
AB +	SOLVAY	300MG	N18027 001		JUN	CFTG
<u>LOMEFLOXACIN HYDROCHLORIDE</u>						
TABLET; ORAL						
MAXAQUIN						
+	PHARMACIA	EQ 400MG BASE	N20013 001	FEB 21, 1992	JUL	CAHN
<u>LORATADINE</u>						
TABLET; ORAL						
CLARITIN						
+	SCHERING	10MG	N19658 001	APR 12, 1993	JUL	CTEC
<u>LOVASTATIN</u>						
TABLET; ORAL						
LOVASTATIN						
AB	CARLSBAD	10MG	N75991 001	JUN 05, 2002	JUN	NEWA
AB		20MG	N75991 002	JUN 05, 2002	JUN	NEWA
AB		40MG	N75991 003	JUN 05, 2002	JUN	NEWA
TABLET, EXTENDED RELEASE; ORAL						
ALTOCOR						
ANDRX						
		10MG	N21316 001	JUN 26, 2002	JUL	CAHN
		20MG	N21316 002	JUN 26, 2002	JUL	CAHN
		40MG	N21316 003	JUN 26, 2002	JUL	CAHN
+		60MG	N21316 004	JUN 26, 2002	JUL	CAHN
	AURA LABS	10MG	N21316 001	JUN 26, 2002	JUN	NEWA
		20MG	N21316 002	JUN 26, 2002	JUN	NEWA
		40MG	N21316 003	JUN 26, 2002	JUN	NEWA
		60MG	N21316 004	JUN 26, 2002	JUN	NEWA

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

@ WATSON LABS

EQ 25MG BASE/ML

N17658 001

INJECTABLE; INJECTION

LOXITANE IM

@ WATSON LABS

EQ 50MG BASE/ML

N18039 001

JUL DISC

JUL DISC

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL

LUMENHANCE

@ BRACCO

3.49MG/GM

N20686 001 DEC 19, 1997

JUN DISC

MASOPROCOL

CREAM; TOPICAL

ACTINEX

@ UNIV AZ CANCER CTR

10%

N19940 001 SEP 04, 1992

JUN DISC

MAZINDOL

TABLET; ORAL

MAZANOR

@ WYETH AYERST

1MG

N17980 002

APR DISC

SANOREX

NOVARTIS

1MG

N17247 001

APR CTEC

@

1MG

N17247 001

JUN DISC

@

2MG

N17247 002

JUN DISC

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

AMEN

@ AMARIN PHARMS

10MG

N83242 001

SEP DISC

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

AB + ROCHE

250MG

N19591 001 MAY 02, 1989

FEB CFTD

MEFLOQUINE HCL

AB

GENEVA PHARMS TECH

250MG

N76175 001 FEB 20, 2002

FEB NEWA

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

AB

ROXANE

40MG/ML

N75997 001 FEB 15, 2002

FEB NEWA

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

PERGONAL

BX +

SERONO

75 IU/AMP;75 IU/AMP

N17646 001

75 IU/AMP;75 IU/AMP

N17646 001

150 IU/AMP;150 IU/AMP

N17646 002 MAY 20, 1985

AUG CMTD

JUN DISC

JUN DISC

@

REPRONEX

+

FERRING

75 IU/VIAL;75 IU/VIAL

N21047 001 AUG 27, 1999

JUN CMLD

BX + 75 IU/VIAL;75 IU/VIAL N21047 001 AUG 27, 1999 AUG CRLD
 150 IU/VIAL;150 IU/VIAL N21047 002 AUG 27, 1999 JUN CRLD

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HCL

AA

CARACO

50MG

N40446 001 AUG 08, 2002 AUG NEWA

AA

100MG

N40446 002 AUG 08, 2002 AUG NEWA

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

@ WYETH AYERST

25MG/ML;25MG/ML

N11730 001

JUN DISC

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

@ WYETH AYERST

EQ 15MG BASE/ML

N08248 002

JUN DISC

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

@ NOVARTIS

100MG

N06008 001

JUN DISC

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

+ GALDERMA LABS

2%;0.01%

N20922 001 DEC 10, 1999 APR CAHN

MESNA

INJECTABLE; INTRAVENOUS

MESNEX

AP + BAXTER HLTHCARE

100MG/ML

N19884 001 DEC 30, 1988 MAR CAHN

TABLET; ORAL

+ BAXTER HLTHCARE

400MG

N20855 001 MAR 21, 2002 JUN CAHN

+ BRISTOL MYERS SQUIBB

400MG

N20855 001 MAR 21, 2002 MAR NEWA

MESORIDAZINE BESYLATE

INJECTABLE; INJECTION

SERENTIL

@ NOVARTIS

EQ 25MG BASE/ML

N16775 001

JUN DISC

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

NORINYL 1+50 28-DAY

AB WATSON LABS

0.05MG;1MG

N16659 001

JAN CAHN

METAPROTERENOL SULFATE

SOLUTION; INHALATION

ALUPENT

@ BOEHRINGER INGELHEIM

5%

N17659 001

JUN DISC

METAPROTERENOL SULFATE

AN MORTON GROVE

0.4%

N75586 001 MAY 30, 2002 MAY NEWA

AN		0.6%		N75586 002	MAY 30, 2002	MAY	NEW
	<u>METAXALONE</u>						
	TABLET; ORAL						
	SKELAXIN						
	+	ELAN PHARMS	400MG	N13217 001			
			400MG	N13217 001		JUN	CAN
	+		800MG	N13217 003	AUG 30, 2002	AUG	CAN
						AUG	NEW
	<u>METFORMIN HYDROCHLORIDE</u>						
	TABLET; ORAL						
	GLUCOPHAGE						
AB	BRISTOL MYERS SQUIBB		500MG	N20357 001	MAR 03, 1995	JAN	CAN
AB			850MG	N20357 002	MAR 03, 1995	JAN	CAN
AB	+		1GM	N20357 005	NOV 05, 1998	JAN	CAN
	METFORMIN HCL						
AB	ALPHAPHARM		500MG	N75969 001	JAN 29, 2002	JAN	NEW
AB			850MG	N75969 002	JAN 29, 2002	JAN	NEW
AB			1GM	N75969 003	JAN 29, 2002	JAN	NEW
AB	ANDRX PHARMS		500MG	N75961 001	JAN 25, 2002	JAN	NEW
AB			850MG	N75961 002	JAN 25, 2002	JAN	NEW
AB			1GM	N75961 003	JAN 25, 2002	JAN	NEW
AB	BARR		500MG	N75971 001	JAN 25, 2002	JAN	NEW
AB			850MG	N75971 002	JAN 25, 2002	JAN	NEW
AB			1GM	N75971 003	JAN 25, 2002	JAN	NEW
AB	CARACO		500MG	N75967 001	JAN 29, 2002	JAN	NEW
AB			850MG	N75967 002	JAN 29, 2002	JAN	NEW
AB			1GM	N75967 003	JAN 29, 2002	JAN	NEW
AB	EON		500MG	N75965 001	JAN 25, 2002	JAN	NEW
AB			850MG	N75965 002	JAN 25, 2002	JAN	NEW
AB			1GM	N75965 003	JAN 25, 2002	JAN	NEW
AB	GENEVA PHARMS		500MG	N75985 001	JAN 25, 2002	MAY	CAN
AB			850MG	N75985 002	JAN 25, 2002	MAY	CAN
AB			1GM	N75985 003	JAN 25, 2002	MAY	CAN
AB	GENEVA PHARMS TECH		500MG	N75985 001	JAN 25, 2002	JAN	NEW
AB			850MG	N75985 002	JAN 25, 2002	JAN	NEW
AB			1GM	N75985 003	JAN 25, 2002	JAN	NEW
AB	GENPHARM		500MG	N75973 001	JAN 25, 2002	JAN	NEW
AB			850MG	N75973 002	JAN 25, 2002	JAN	NEW
AB			1GM	N75973 003	JAN 25, 2002	JAN	NEW
AB	GOLDLINE		500MG	N75972 001	JAN 24, 2002	JAN	NEW
AB			625MG	N75972 005	JAN 24, 2002	JAN	NEW
AB			750MG	N75972 004	JAN 24, 2002	JAN	NEW
AB			850MG	N75972 002	JAN 24, 2002	JAN	NEW
AB			1GM	N75972 003	JAN 24, 2002	JAN	NEW
AB	MUTUAL PHARMA		500MG	N76038 001	FEB 21, 2002	FEB	NEW
AB			850MG	N76038 002	FEB 21, 2002	FEB	NEW
AB			1GM	N76038 003	FEB 21, 2002	FEB	NEW
AB	MYLAN		500MG	N75976 001	JAN 24, 2002	JAN	NEW
AB			850MG	N75976 002	JAN 24, 2002	JAN	NEW
AB			1GM	N75976 003	JAN 24, 2002	JAN	NEW
AB	PUREPAC PHARM		500MG	N76033 001	JAN 24, 2002	JAN	NEW
AB			850MG	N76033 002	JAN 24, 2002	JAN	NEW

		1GM	N76033 003	JAN 24, 2001	JAN	NEWA
AB		500MG	N75978 001	JAN 25, 2002	JAN	NEWA
AB	TEVA	850MG	N75978 002	JAN 25, 2002	JAN	NEWA
AB		500MG	N75984 001	APR 23, 2002	APR	NEWA
AB	TORPHARM	850MG	N75984 002	APR 23, 2002	APR	NEWA
AB		1GM	N75984 003	APR 23, 2002	APR	NEWA
AB		500MG	N75979 001	JAN 24, 2002	JAN	NEWA
AB	WATSON LABS	850MG	N75979 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N75979 003	JAN 24, 2002	JAN	NEWA
AB		500MG	N75975 001	JAN 24, 2002	JAN	NEWA
AB	ZENITH GOLDLINE	625MG	N75975 004	JAN 24, 2002	JAN	NEWA
AB		750MG	N75975 005	JAN 24, 2002	JAN	NEWA
AB		850MG	N75975 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N75975 003	JAN 24, 2002	JAN	NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

GLAXOSMITHKLINE

500MG;EQ 1MG BASE

N21410 001 OCT 10, 2002 OCT NEWA

500MG;EQ 2MG BASE

N21410 002 OCT 10, 2002 OCT NEWA

500MG;EQ 4MG BASE

N21410 003 OCT 10, 2002 OCT NEWA

METHADONE HYDROCHLORIDE

SYRUP; ORAL

DOLOPHINE HCL

@ ROXANE

10MG/30ML

N06134 004

JUL DISC

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

+ OVATION PHARMS

5MG

N05378 002

SEP CAHN

TABLET, EXTENDED RELEASE; ORAL

@ ABBOTT

5MG

N05378 004

JUN DISC

@

10MG

N05378 003

JUN DISC

@

15MG

N05378 005

JUN DISC

@ OVATION PHARMS

5MG

N05378 004

SEP CAHN

@

10MG

N05378 003

SEP CAHN

@

15MG

N05378 005

SEP CAHN

METHANHELINE BROMIDE

TABLET; ORAL

BANTHINE

@ SHIRE LABS

50MG

N07390 001

JUL DISC

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+ KING PHARMS

500MG/VIAL

N11559 001

FEB CAHN

+

2.5GM/VIAL

N11559 002

FEB CAHN

+

5GM/VIAL

N11559 003

FEB CAHN

METHOTREXATE SODIUM

	INJECTABLE; INJECTION				
	FOLEX				
	+ PHARMACIA AND UPJOHN	EQ 50MG BASE/VIAL	N87695 002	APR 08, 1983	JUN DISC
	+	EQ 100MG BASE/VIAL	N87695 003	APR 08, 1983	JUN DISC
	METHOTREXATE SODIUM				
	@ LEDERLE	EQ 2.5MG BASE/ML	N11719 004		JUN DISC
	@	EQ 50MG BASE/VIAL	N11719 003		JUN DISC
	@	EQ 100MG BASE/VIAL	N11719 006		JUN DISC
	TABLET; ORAL				
AB	+ CLONMEL HLTHCARE	EQ 2.5MG BASE	N08085 002		JUL CAN

METHYLCLOTHIAZIDE; RESERPINE

>D>	TABLET; ORAL				
>D>	DIUTENSEN-R				
>D>	+ WALLACE LABS	2.5MG;0.1MG	N12708 005		OCT DISC
>A>	@	2.5MG;0.1MG	N12708 005		OCT DISC

METHYLDOPA

	SUSPENSION; ORAL				
	ALDOMET				
	@ MERCK	250MG/5ML	N18389 001		JUN DISC

METHYLPHENIDATE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL				
	METADATE CD				
BX	+ CELLTECH PHARMS	20MG	N21259 001	APR 03, 2001	JUN DISC
	RITALIN LA				
BX	NOVARTIS	20MG	N21284 001	JUN 05, 2002	JUN NEAR
		30MG	N21284 002	JUN 05, 2002	JUN NEAR
	+	40MG	N21284 003	JUN 05, 2002	JUN NEAR
	TABLET; ORAL				
	METHYLPHENIDATE HCL				
AB	PUREPAC PHARM	5MG	N40321 001	FEB 05, 2002	FEB NEAR
AB		10MG	N40321 002	FEB 05, 2002	FEB NEAR
AB		20MG	N40321 003	FEB 05, 2002	FEB NEAR
	TABLET, EXTENDED RELEASE; ORAL				
	CONCERTA				
	+ ALZA	27MG	N21121 004	APR 01, 2002	JUN NEAR

METHYLPREDNISOLONE

	TABLET; ORAL				
	METHYLPREDNISOLONE				
AB	GENEVA PHARMS	4MG	N40194 001	OCT 31, 1997	MAY CAN

METHYLPREDNISOLONE ACETATE

	INJECTABLE; INJECTION				
	DEPO-MEDROL				
	+ PHARMACIA AND UPJOHN	80MG/ML	N11757 004		SEP DISC
	METHYLPREDNISOLONE ACETATE				
	@ STERIS	20MG/ML	N85597 001		SEP DISC
	@	80MG/ML	N85595 001		SEP DISC

METHYLTESTOSTERONE

TABLET; ORAL

METHYLTESTOSTERONE

Q LANNETT

Q

10MG

25MG

N87092 001 NOV 05, 1982 SEP DISC

N87111 001 JAN 27, 1983 SEP DISC

METRONIDAZOLE

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP + GD SEARLE LLC

500MG/100ML

N18353 002

JUL CAHN

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

+ GD SEARLE LLC

EQ 500MG BASE/VIAL

N18353 001

JUL CAHN

MICONAZOLE NITRATE

CREAM, INSERT; TOPICAL, VAGINAL

MONISTAT DUAL- PAK

Q PERSONAL PRODS

1.2GM;2%

N20968 001 JUN 30, 1999 JUN DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HCL

>> AP ABBOTT

EQ 1MG BASE/ML

N75293 001 JUN 20, 2000 OCT CRLD

>> AP +

EQ 1MG BASE/ML

N75293 001 JUN 20, 2000 OCT CRLD

AP

EQ 1MG BASE/ML

N75857 001 JUL 22, 2002 JUL NEWA

>> AP

EQ 5MG BASE/ML

N75293 002 JUN 20, 2000 OCT CRLD

>> AP +

EQ 5MG BASE/ML

N75293 002 JUN 20, 2000 OCT CRLD

AP

EQ 5MG BASE/ML

N75857 002 JUL 22, 2002 JUL NEWA

AP

EQ 1MG BASE/ML

N75856 001 JUN 13, 2002 JUN NEWA

AP

EQ 5MG BASE/ML

N75856 002 JUN 13, 2002 JUN NEWA

>> AP +

VERSED

EQ 1MG BASE/ML

N18654 002 MAY 26, 1987 OCT DISC

>> AP +

HLR

EQ 1MG BASE/ML

N18654 002 MAY 26, 1987 OCT DISC

>> AP +

Q

EQ 5MG BASE/ML

N18654 001 DEC 20, 1985 OCT DISC

>> AP +

Q

EQ 5MG BASE/ML

N18654 001 DEC 20, 1985 OCT DISC

STYRUP; ORAL

MIDAZOLAM HCL

AA

RANBAXY

EQ 2MG BASE/ML

N76058 001 MAR 15, 2002 MAR NEWA

AA +

ROXANE

EQ 2MG BASE/ML

N75873 001 APR 30, 2002 SEP CRLD

AA

VERSED

EQ 2MG BASE/ML

N75873 001 APR 30, 2002 APR NEWA

AA +

ROCHE

EQ 2MG BASE/ML

N20942 001 OCT 15, 1998 MAR CFTG

AA

Q

EQ 2MG BASE/ML

N20942 001 OCT 15, 1998 AUG DISC

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

SHIRE LABS

10MG

10MG

10MG

N19815 003 MAR 20, 2002 OCT CRLD

N19815 003 MAR 20, 2002 JUL CRLD

N19815 003 MAR 20, 2002 JUN NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

1-56

	SHIRE PHARM	2.5MG	N19815 001	SEP 06, 1996	SEP	ORAL
>D>		5MG	N19815 002	SEP 06, 1996	OCT	ORAL
>A>	+	5MG	N19815 002	SEP 06, 1996	OCT	ORAL
		5MG	N19815 002	SEP 06, 1996	JUN	ORAL
>A>		10MG	N19815 003	MAR 20, 2002	OCT	ORAL

MIFEPRISTONE

TABLET; ORAL

MIFEPREX

>A>	+	DANCO LABS LLC	200MG	N20687 001	SEP 28, 2000	OCT	CANAL
>D>	+	POPULATION COUNCIL	200MG	N20687 001	SEP 28, 2000	OCT	CANAL

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP		ABBOTT	EQ 1MG BASE/ML	N75884 001	MAY 28, 2002	MAY	NEAR
AP		AM PHARM PARTNERS	EQ 1MG BASE/ML	N75936 001	MAY 28, 2002	MAY	NEAR
AP		BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	N75852 001	MAY 28, 2002	MAY	NEAR
AP		BEDFORD	EQ 10MG 10/ML (10MG/ML)	N75660 001	MAY 28, 2002	MAY	NEAR
AP			EQ 20MG /20ML (1MG/ML)	N75660 002	MAY 28, 2002	MAY	NEAR
AP			EQ 50MG /50ML (1MG/ML)	N75660 003	MAY 28, 2002	MAY	NEAR
AP		ESI LEDERLE	EQ 1MG BASE/ML	N75530 001	MAY 28, 2002	MAY	NEAR
AP		FAULDING	EQ 1MG BASE/ML	N75830 001	MAY 28, 2002	MAY	NEAR
AP		INTL MEDICATED	EQ 1MG BASE/ML	N76013 001	AUG 02, 2002	AUG	NEAR
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP		ABBOTT	EQ 20MG BASE/100ML	N75885 001	MAY 28, 2002	MAY	NEAR
AP	+		EQ 40MG BASE/200ML	N75885 002	MAY 28, 2002	MAY	NEAR
AP		BAXTER HLTHCARE	EQ 20MG BASE/100ML	N75834 001	MAY 28, 2002	MAY	NEAR
AP			EQ 40MG BASE/100ML	N75834 002	MAY 28, 2002	MAY	NEAR
AP			EQ 40MG BASE/200ML	N75834 002	MAY 28, 2002	JUN	NEAR
AP		ESI LEDERLE	EQ 20MG BASE/100ML	N75510 001	MAY 28, 2002	MAY	NEAR
		MILRINONE LACTOSE IN 5% DEXTROSE					
AP		ESI LEDERLE	EQ 20MG BASE/100ML	N76259 001	AUG 08, 2002	AUG	NEAR
		PRIMACOR					
AP	+	SANOFI SYNTHELABO	EQ 1MG BASE/ML	N19436 001	DEC 31, 1987	MAY	CFTG
		PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP		SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994	MAY	CFTG
AP	+		EQ 40MG BASE/100ML	N20343 004	AUG 09, 1994	MAY	CFTG
AP	+		EQ 40MG BASE/200ML	N20343 004	AUG 09, 1994	JUN	CFTG

MINOCYCLINE HYDROCHLORIDE

SUSPENSION; ORAL

MINOCIN

@ LEDERLE

EQ 50MG BASE/5ML

N50445 001

JUN 018G

MISOPROSTOL

TABLET; ORAL

CYTOTEC

AB		GD SEARLE LLC	0.1MG	N19268 003	SEP 21, 1990	JUL	CFTG
AB	+		0.2MG	N19268 001	DEC 27, 1988	JUL	CFTG
		MISOPROSTOL					
AB		IVAX PHARMS	0.1MG	N76095 001	JUL 10, 2002	JUL	NEAR
AB			0.2MG	N76095 002	JUL 10, 2002	JUL	NEAR

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
EQ 0.5MG BASE/ML
@ ABBOTT

N20098 002 JAN 22, 1992 JUN DISC

MOMETASONE FUROATE
OINTMENT; TOPICAL

ELOCON
AB + SCHERING 0.1%
MOMETASONE FUROATE
AB CLAY PARK 0.1%

N19543 001 APR 30, 1987 MAR CFTG

N76067 001 MAR 18, 2002 MAR NEWA

MONOCTANOIN

LIQUID; PERFUSION, BILIARY
MOCTANIN
@ ETHITEK 100%

N19368 001 OCT 29, 1985 JUN DISC

MONTELUKAST SODIUM

GRANULE; ORAL
SINGULAIR
+ MERCK EQ 4MG BASE/PACKET

N21409 001 JUL 26, 2002 JUL NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
AVINZA

BX + ELAN PHARM 30MG
30MG
BX + 60MG
60MG
+ 90MG
90MG
+ 120MG

N21260 001 MAR 20, 2002 SEP CTEC
N21260 001 MAR 20, 2002 MAR NEWA
N21260 002 MAR 20, 2002 SEP CTEC
N21260 002 MAR 20, 2002 MAR NEWA
N21260 003 MAR 20, 2002 SEP CRLD
N21260 003 MAR 20, 2002 MAR NEWA
N21260 004 MAR 20, 2002 MAR NEWA

KADIAN

BX + FAULDING PHARMS 30MG
BX + 60MG

N20616 004 MAR 09, 2001 SEP CTEC
N20616 005 MAR 09, 2001 SEP CTEC

TABLET, EXTENDED RELEASE; ORAL

MS CONTIN

>> AB + PURDUE FREDERICK 15MG
>> AB 15MG
>> AB + 30MG
>> AB 30MG
>> AB + 100MG
>> AB 100MG
>> AB + 200MG
>> AB 200MG

N19516 003 SEP 12, 1989 OCT CRLD
N19516 003 SEP 12, 1989 OCT CRLD
N19516 001 MAY 29, 1987 OCT CRLD
N19516 001 MAY 29, 1987 OCT CRLD
N19516 004 JAN 16, 1990 OCT CRLD
N19516 004 JAN 16, 1990 OCT CRLD
N19516 005 NOV 08, 1993 OCT CRLD
N19516 005 NOV 08, 1993 OCT CRLD

NABUMETONE

TABLET; ORAL
NABUMETONE

AB EDN 500MG
AB 750MG
AB INVAMED 500MG

N75280 001 FEB 25, 2002 FEB NEWA
N75280 002 FEB 25, 2002 FEB NEWA
N75590 001 FEB 25, 2002 FEB NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

1-58

AB		750MG		N75590 002	FEB 25, 2002	FEB	NEW
	<u>NAFCILLIN SODIUM</u>						
	CAPSULE; ORAL						
	UNIPEN						
	@ WYETH AYERST	EQ 250MG BASE		N50111 001		JUN	DISC
	<u>NALBUPHINE HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION						
	NALBUPHINE HCL						
	@ ABBOTT	1.5MG/ML		N20200 001	MAR 12, 1993	JUL	DISC
	<u>NALIDIXIC ACID</u>						
	SUSPENSION; ORAL						
	NEGRAM						
	@ SANOFI SYNTHELABO	250MG/5ML		N17430 001		JUN	DISC
	<u>NALTREXONE HYDROCHLORIDE</u>						
	TABLET; ORAL						
	NALTREXONE HCL						
	MALLINCKRODT	25MG		N76264 001	MAR 22, 2002	MAR	NEW
AB		50MG		N76264 002	MAR 22, 2002	MAR	NEW
	+	100MG		N76264 003	MAR 22, 2002	MAR	NEW
	<u>NAPROXEN SODIUM</u>						
	TABLET, EXTENDED RELEASE; ORAL						
	NAPRELAN						
	@ ELAN PHARM	EQ 750MG BASE		N20353 003	JAN 05, 1996	JUN	DISC
	<u>NEOMYCIN SULFATE</u>						
	SOLUTION; ORAL						
	MYCIFRADIN						
AA	+	PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N50285 001		MAY	DISC
		@	EQ 87.5MG BASE/5ML	N50285 001		JUN	DISC
	NEO-FRADIN						
	+	PHARMATEK	EQ 87.5MG BASE/5ML	N65010 001	MAY 23, 2002	JUN	DISC
AA			EQ 87.5MG BASE/5ML	N65010 001	MAY 23, 2002	MAY	NEW
	<u>NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>						
	OINTMENT; OPHTHALMIC						
	STATROL						
	@ ALCON	EQ 3.5MG BASE/GM;10,000 UNITS/GM		N50344 002		JUN	DISC
	SOLUTION/DROPS; OPHTHALMIC						
	@ ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML		N50456 001		JUN	DISC
	<u>NIACIN</u>						
	TABLET, EXTENDED RELEASE; ORAL						
	NIASPAN						
	@ KOS	375MG		N20381 001	JUL 28, 1997	AUG	DISC
	+	500MG		N20381 002	JUL 28, 1997	AUG	DISC
	@	500MG		N20381 002	JUL 28, 1997	JUN	DISC
	NIASPAN TITRATION STARTER PACK						
	@ KOS	375MG;500MG;750MG		N20381 005	JUL 28, 1997	JUN	DISC

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC	90MG	N20198 003	APR 21, 1993	AUG	CTEC
AB1 + BAYER					
NIFEDIPINE	90MG	N76070 001	AUG 16, 2002	AUG	NEWA
AB1 BIOVAIL					

NILUTAMIDE

TABLET; ORAL

NILANDRON	50MG	N20169 001	SEP 19, 1996	JUN	DISC
@ AVENTIS PHARMS					
	150MG	N20169 002	APR 30, 1999	JUL	CMFD

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR					
+ FIRST HORIZON	10MG	N20356 001	FEB 02, 1995	MAR	CAHN
	20MG	N20356 002	FEB 02, 1995	MAR	CAHN
	30MG	N20356 003	FEB 02, 1995	MAR	CAHN
	40MG	N20356 004	FEB 02, 1995	MAR	CAHN
+ WHITEHALL ROBINS	10MG	N20356 001	FEB 02, 1995	FEB	CAHN
	20MG	N20356 002	FEB 02, 1995	FEB	CAHN
	40MG	N20356 004	FEB 02, 1995	FEB	CAHN

NITISINONE

CAPSULE; ORAL

ORFADIN					
R R REGISTRATIONS	2MG	N21232 001	JAN 18, 2002	JAN	NEWA
	5MG	N21232 002	JAN 18, 2002	JAN	NEWA
	10MG	N21232 003	JAN 18, 2002	JAN	NEWA
+ SWEDISH ORPHAN	2MG	N21232 001	JAN 18, 2002	MAY	CAHN
	5MG	N21232 002	JAN 18, 2002	MAY	CAHN
	10MG	N21232 003	JAN 18, 2002	MAY	CAHN

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN					
+ FIRST HORIZON	25MG/5ML	N09175 001		JAN	CAHN

NITROFURAZONE

CREAM; TOPICAL

FURACIN					
@ SHIRE LABS	0.2%	N83789 001		JUL	DISC
ointment; TOPICAL					
@ SHIRE LABS	0.2%	N05795 001		JUL	DISC
+ SHIRE PHARM	0.2%	N05795 001		SEP	CMFD

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL					
@ FIRST HORIZON	0.4MG/SPRAY	N18705 001	OCT 31, 1985	APR	CAHN
@ POHL BOSKAMP	0.4MG/SPRAY	N18705 001	OCT 31, 1985	JUN	CAHN

NITROGLYCERIN

SPRAY, METERED; SUBLINGUAL

NITROLINGUAL PUMPSPRAY

+ FIRST HORIZON 0.4MG/SPRAY

N18705 002 JAN 10, 1997 APR CARR
N18705 002 JAN 10, 1997 JUN CARR

TABLET; SUBLINGUAL

NITROSTAT

PFIZER PHARMS 0.4MG

N21134 002 MAY 01, 2000 JUN CARR

NIZATIDINE

CAPSULE; ORAL

AXID

AB LILLY 150MG
AB + 300MG
AB RELIANT PHARMS 150MG
AB + 300MG

N19508 001 APR 12, 1988 JUL CFTG
N19508 002 APR 12, 1988 JUL CFTG
N19508 001 APR 12, 1988 AUG CARR
N19508 002 APR 12, 1988 AUG CARR

NIZATIDINE

AB EON 150MG
AB 300MG
AB GENPHARM 150MG
AB 300MG
AB MYLAN 150MG
AB 300MG
AB TEVA 150MG
AB 300MG
AB WATSON LABS 150MG
AB 300MG
AB ZENITH GOLDLINE 150MG
AB 300MG

N76178 001 JUL 05, 2002 JUL NEWA
N76178 002 JUL 05, 2002 JUL NEWA
N75934 001 JUL 09, 2002 JUL NEWA
N75934 002 JUL 09, 2002 JUL NEWA
N75806 001 JUL 05, 2002 JUL NEWA
N75806 002 JUL 05, 2002 JUL NEWA
N75668 001 SEP 12, 2002 SEP NEWA
N75668 002 SEP 12, 2002 SEP NEWA
N75616 001 JUL 09, 2002 JUL NEWA
N75616 002 JUL 09, 2002 JUL NEWA
N75461 001 JUL 08, 2002 JUL NEWA
N75461 002 JUL 08, 2002 JUL NEWA

NORETHINDRONE

TABLET; ORAL

NOR-QD

+ WATSON LABS (UTAH) 0.35MG

N17060 001 MAY CARR

TABLET; ORAL-28

>A> CAMILA
>A> AB1 BARR 0.35MG
>A> ERRIN
>A> AB2 BARR 0.35MG

N76177 001 OCT 21, 2002 OCT NEWA
N76225 001 OCT 21, 2002 OCT NEWA

MICRONOR

>D> + ORTHO MCNEIL PHARM 0.35MG
>A> AB2 + 0.35MG

N16954 001 JAN 02, 2073 OCT CFTG
N16954 001 JAN 02, 2073 OCT CFTG

NOR-QD

>D> + WATSON LABS (UTAH) 0.35MG
>A> AB1 + 0.35MG

N17060 001 JAN 02, 2073 OCT CFTG
N17060 001 JAN 02, 2073 OCT CFTG

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION; ORAL
 AVENTYL HCL
 AA + RANBAXY EQ 10MG BASE/5ML N14685 001 JUN CAHN

NOVOBIOCIN SODIUM

CAPSULE; ORAL
 A' BAMYCIN
 @ PHARMACIA AND UPJOHN EQ 250MG BASE N50339 001 JUN DISC

NYSTATIN

TABLET; ORAL
 NILSTAT
 @ LEDERLE 500,000 UNITS N61151 001 JUN DISC
 TABLET; VAGINAL
 @ LEDERLE 100,000 UNITS N61325 001 JUL DISC

OFLOXACIN

INJECTABLE; INJECTION
 FLOXIN
 AP + JOHNSON RW 40MG/ML N20087 003 MAR 31, 1992 JAN CFTG
 @ ORTHO MCNEIL PHARM 20MG/ML N20087 002 MAR 31, 1992 JUL DISC
 OFLOXACIN
 AP BEDFORD 40MG/ML N75762 001 JAN 16, 2002 JAN NEWA

OLANZAPINE

TABLET; ORAL
 ZYPREXA
 + LILLY 2.5MG N20592 001 SEP 30, 1996 OCT CRLD
 2.5MG N20592 001 SEP 30, 1996 OCT CRLD

OLMESARTAN MEDOXOMIL

TABLET; ORAL
 BENICAR
 SANKYO 5MG N21286 001 APR 25, 2002 APR NEWA
 20MG N21286 003 APR 25, 2002 APR NEWA
 40MG N21286 004 APR 25, 2002 APR NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)
 ELOXATIN
 SANOFI 50MG/VIAL N21492 001 AUG 09, 2002 AUG NEWA
 100MG/VIAL N21492 002 AUG 09, 2002 AUG NEWA

OXANDROLONE

TABLET; ORAL
 OXANDRIN
 BIO TECH GEN 2.5MG N13718 001 JUN CRLD
 10MG N13718 002 NOV 05, 2001 JUN NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

1-62

OXAPROZIN

TABLET; ORAL

OXAPROZIN

AB	CARACO	600MG	N75844 001	JAN 03, 2002	JAN	NEAR
AB	IVAX PHARMS	600MG	N75846 001	MAY 13, 2002	MAY	NEAR
AB	TEVA	600MG	N75849 001	JUL 03, 2002	JUL	NEAR

>A> OXAPROZIN POTASSIUM

>A> TABLET; ORAL

>A> DAYRO ALTA

>A> + PHARMACIA 600MG N20776 001 OCT 17, 2002 OCT NEAR

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

AP	ABBOTT	6MG/ML	N76131 001	MAY 08, 2002	MAY	NEAR
AP	NAPRO	6MG/ML	N76233 001	AUG 01, 2002	AUG	NEAR

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	AESGEN	30MG/VIAL	N75594 001	MAY 06, 2002	MAY	NEAR
AP		90MG/VIAL	N75594 002	MAY 06, 2002	MAY	NEAR
AP	AM PHARM PARTNERS	30MG/VIAL	N75773 001	MAY 06, 2002	MAY	NEAR
AP		30MG /10ML(3MG/ML)	N76207 001	MAY 17, 2002	MAY	NEAR
AP		90MG/VIAL	N75773 002	MAY 06, 2002	MAY	NEAR
AP		90MG /10ML(9MG/ML)	N76207 002	MAY 17, 2002	MAY	NEAR
AP	BEDFORD	30MG /10ML(3MG/ML)	N21113 001	MAR 04, 2002	MAY	CDIFR
AP	+	90MG /10ML(9MG/ML)	N21113 002	MAR 04, 2002	MAY	CDIFR
AP	FAULDING	30MG /10ML(3MG/ML)	N75841 001	JUN 27, 2002	JUN	NEAR
AP		60MG /10ML(6MG/ML)	N75841 002	JUN 27, 2002	JUN	NEAR
AP		90MG /10ML(9MG/ML)	N75841 003	JUN 27, 2002	JUN	NEAR
AP	GENSIA SICOR PHARMS	30MG /10ML(3MG/ML)	N76153 001	MAR 27, 2002	MAY	CDIFR
AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002	MAY	CDIFR
AP		30MG /10ML(3MG/ML)	N21113 001	MAR 04, 2002	MAR	NEAR
AP	+	90MG /10ML(9MG/ML)	N21113 002	MAR 04, 2002	MAR	NEAR
AP	GENSIA SICOR PHARMS	30MG /10ML(3MG/ML)	N76153 001	MAR 27, 2002	MAR	NEAR
AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002	MAR	NEAR

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE; ORAL

COTAZYM

@ ORGANON

30,000USP UNITS;8,000USP UNITS;30,000USP UNITS

N20580 001 DEC 09, 1996 JUN DISC

PARAMETHADIONE

CAPSULE; ORAL

PARADIONE

@ ABBOTT

@

150MG
300MG

N06800 003
N06800 001

JUN DISC
JUN DISC

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PAXIL CR EQ 12.5MG BASE
 + GLAXOSMITHKLINE EQ 12.5MG BASE
 + EQ 25MG BASE
 + EQ 25MG BASE

N20936 001 FEB 16, 1999 OCT CRLD
 N20936 001 FEB 16, 1999 OCT CRLD
 N20936 002 FEB 16, 1999 OCT CRLD
 N20936 002 FEB 16, 1999 OCT CRLD

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

AP PENICILLIN G POTASSIUM 1,000,000 UNITS/VIAL
 AP GENEVA PHARMS 5,000,000 UNITS/VIAL
 AP 20,000,000 UNITS/VIAL

N65079 001 AUG 30, 2002 AUG NEWA
 N65079 002 AUG 30, 2002 AUG NEWA
 N65079 003 AUG 30, 2002 AUG NEWA

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PEN-VEE K EQ 125MG BASE/5ML
 @ WYETH AYERST EQ 250MG BASE/5ML
 @

N60007 001 MAY DISC
 N60007 002 MAY DISC

PENTAGASTRIN

INJECTABLE; INJECTION

PEPTAVLON 0.25MG/ML
 @ WYETH AYERST

N17048 001 APR DISC

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON
 + JOHNSON AND JOHNSON 100MG

N20193 001 SEP 26, 1996 JUL CAHN

PHENACEMIDE

TABLET; ORAL

PHENURONE
 @ ABBOTT 500MG

N07707 001 JUN DISC

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL
 @ ABLE 200MG;800MG;160MG

N21105 001 JUN 26, 2001 JUN DISC

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE
 AA MIKART 35MG

N89452 001 OCT 30, 1991 MAR CMFD

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HCL
 AA VINTAGE PHARMS 37.5MG

N40377 001 JAN 04, 2002 JAN NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

1-66

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

PREFRIN-A

@ ALLERGAN 0.12%;0.1%

N07953 001

JUN DISC

PHENYTOIN

SUSPENSION; ORAL

PHENTYTOIN

AB MORTON GROVE 125MG/5ML

N40420 001 APR 19, 2002

APR NEW

PILOCARPINE

DRUG DELIVERY SYSTEM; OPHTHALMIC

OCUSERT PILO-40

@ AKORN 11MG

N17548 001

JUN DISC

INSERT, EXTENDED RELEASE; OPHTHALMIC

OCUSERT PILO-20

@ AKORN 5MG

N17431 001

JUN DISC

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION

ARDUAN

@ ORGANON 10MG/VIAL

N19638 001 JUN 26, 1990

JUN DISC

PODOFILOX

SOLUTION; TOPICAL

CONDYLOX

AT + PADDOCK 0.5%

N19795 001 DEC 13, 1990

JAN CFTG

PODOFILOX

AT PADDOCK 0.5%

N75600 001 JAN 29, 2002

JAN NEW

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB ANDRX PHARMS 10MEQ

N75604 001 APR 10, 2002

APR NEW

AB 20MEQ

N75604 002 APR 10, 2002

APR NEW

AB KV PHARM 20MEQ

N76044 001 APR 05, 2002

APR NEW

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

BRISTOL MYERS SQUIBB 40MG

N19898 004 MAR 22, 1993

MAR COLD

+ 80MG

N19898 008 DEC 18, 2001

MAR NEW

PREDNICARBATE

CREAM; TOPICAL

DERMATOP

+ DERMIK LABS 0.1%

N20279 001 OCT 29, 1993

JUN CASH

OINTMENT; TOPICAL

+ DERMIK LABS 0.1%

N19568 001 SEP 23, 1991

JUN CASH

PREDNISOLONE
 SYRUP; ORAL
 PREDNISOLONE
 KV PHARM

15MG/5ML

N40364 001 APR 10, 2002 APR NEWA

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
 OINTMENT; OPHTHALMIC

METIMYD
 @ SCHERING 0.5%;10%

N10210 002 SEP 09, 1984 JUL DISC

VASOCIDIN
 + NOVARTIS 0.5%;10%

N88791 001 OCT 05, 1984 AUG CRLD

SUSPENSION; OPHTHALMIC

ISOPTO CETAPRED
 @ ALCON 0.25%;10%

N87547 001 JUN DISC

SUSPENSION/DROPS; OPHTHALMIC

METIMYD
 @ SCHERING 0.5%;10%

N10210 001 JUL DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

AA + ASCENT PEDS EQ 15MG BASE/5ML

N75117 001 DEC 14, 2000 JUL CFTG

PEDIAPRED

AA + CELLTECH PHARMS EQ 5MG BASE/5ML

N19157 001 MAY 28, 1986 JUN CFTG

PREDNISOLONE SODIUM PHOSPHATE

AA MORTON GROVE EQ 5MG BASE/5ML

N75099 001 JUN 28, 2002 JUN NEWA

AA WE PHARMS EQ 15MG BASE/5ML

N75250 001 JUL 12, 2002 JUL NEWA

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION

HYDELTRA-TBA

@ MERCK

20MG/ML

N10562 001 JUN DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

@ LANNETT

5MG

N80514 001 SEP DISC

AB VINTAGE PHARMS

5MG

N40256 001 JUL 12, 2002 JUL NEWA

AB

10MG

N40256 002 JUL 12, 2002 JUL NEWA

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

@ XCEL PHARMS

250MG/5ML

N10401 001 JUL DISC

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

@ GLAXOSMITHKLINE

EQ 10MG BASE

N11000 001 JUN DISC

EQ 10MG BASE

N21019 001 OCT 06, 1999 JUN CRLD

EQ 15MG BASE

N11000 002 JUN DISC

EQ 15MG BASE

N21019 002 OCT 06, 1999 JUN CRLD

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

1-66

	@	EQ 30MG BASE	N11000 003				
<u>PROGESTERONE</u>							
		INSERT, EXTENDED RELEASE; INTRAUTERINE PROGESTASERT					
	@	ALZA	38MG	N17553 001			JUN DISC
<u>PROMAZINE HYDROCHLORIDE</u>							
		INJECTABLE; INJECTION SPARINE					
	@	WYETH AYERST	50MG/ML	N10349 006			JUN DISC
		TABLET; ORAL					
	@	WYETH AYERST	25MG	N10348 001			JUN DISC
	@		50MG	N10348 002			JUN DISC
<u>PROMETHAZINE HYDROCHLORIDE</u>							
		INJECTABLE; INJECTION PROMETHAZINE HCL					
AP		GENSIA SICOR PHARMS	25MG/ML	N40454 001	AUG 22, 2002	AUG	NEWR
AP			50MG/ML	N40454 002	AUG 22, 2002	AUG	NEWR
		SUPPOSITORY; RECTAL PHENERGAN					
AB	+	WYETH AYERST	25MG	N10926 001			FEB CTEC
		PROMETHAZINE HCL					
AB		G AND W LABS	25MG	N40428 001	FEB 05, 2002	FEB	NEWR
		SYRUP; ORAL PHENERGAN FORTIS					
	@	WYETH AYERST	25MG/5ML	N08381 003			JUN DISC
<u>PROPAFENONE HYDROCHLORIDE</u>							
		TABLET; ORAL PROPAFENONE HCL					
AB		KV PHARM	150MG	N76193 001	FEB 07, 2002	FEB	NEWR
AB			225MG	N76193 002	FEB 07, 2002	FEB	NEWR
AB			300MG	N76193 003	FEB 07, 2002	FEB	NEWR
>A>	AB	VINTAGE PHARMS	150MG	N75938 001	OCT 17, 2002	OCT	NEWR
>A>	AB		225MG	N75938 002	OCT 17, 2002	OCT	NEWR
>A>	AB		300MG	N75938 003	OCT 17, 2002	OCT	NEWR
<u>PROPOXYPHENE HYDROCHLORIDE</u>							
		CAPSULE; ORAL DARVON					
AA	+	AAI PHARMA	32MG	N10997 001			JUN CARH
AA	+		65MG	N10997 003			JUN CARH
<u>PROPOXYPHENE NAPSYLATE</u>							
		SUSPENSION; ORAL DARVON-N					
	+	NEOSAN PHARMS	50MG/5ML	N16861 001			JUN CARH
		TABLET; ORAL					
	+	AAIPHARMA LLC	100MG	N16862 002			JUN CARH

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL

Ⓢ LEDERLE	60MG
Ⓢ	80MG
Ⓢ	90MG
Ⓢ	10MG
Ⓢ PUREPAC PHARM	20MG
Ⓢ	40MG
Ⓢ	60MG
Ⓢ	80MG

N71495 001	DEC 31, 1987	FEB	DISC
N70128 001	JUL 30, 1985	MAY	CAHN
N71496 001	DEC 31, 1987	FEB	DISC
N70814 001	NOV 03, 1986	MAY	DISC
N70815 001	NOV 03, 1986	MAY	DISC
N70816 001	NOV 03, 1986	MAY	DISC
N70817 001	NOV 03, 1986	MAY	DISC
N70757 001	NOV 03, 1986	MAY	DISC

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

AB + CLOMEL 500MG

N80157 001 JUL CAHN

QUINETHAZONE

TABLET; ORAL

HYDROMOX

Ⓢ LEDERLE 50MG

N13264 001 APR DISC

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

ACIPHEX

Ⓢ EISAI MEDCL RES	10MG
+	20MG
+	20MG
Ⓢ	20MG

N20973 001	MAY 29, 2002	JUL	DISC
N20973 002	AUG 19, 1999	MAY	CAHN
N20973 002	AUG 19, 1999	JUL	CMFD
N20973 002	AUG 19, 1999	JUN	DISC

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HCL

AB + GENEVA PHARMS EQ 300MG BASE

N74655 002 OCT 22, 1997 AUG CRLD

ZANTAC 300

Ⓢ GLAXOSMITHKLINE EQ 300MG BASE

N20095 002 MAR 08, 1994 AUG DISC

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION

RAPLON

Ⓢ ORGANON	100MG/VIAL
Ⓢ	200MG/VIAL

N20984 001	AUG 18, 1999	JUN	DISC
N20984 002	AUG 18, 1999	JUN	DISC

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HCL

AB IMPAX LABS 100MG

N76132 001 AUG 30, 2002 AUG NEWA

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

PROCTER AND GAMBLE 30MG

N20835 001 MAR 27, 1998 JUL CRLD

	+		35MG		N20835 003	MAY 25, 2002	JUL	NEW
<u>RITONAVIR</u>								
		CAPSULE; ORAL						
		NORVIR						
		@	ABBOTT	100MG	N20680 001	MAR 01, 1996	JUN	DISC
	+			100MG	N20945 001	JUN 29, 1999	JUN	CRLS
<u>ROCURONIUM BROMIDE</u>								
		INJECTABLE; INJECTION						
		ZEMURON						
		@	ORGANON	10MG/ML	N20214 002	MAR 17, 1994	JUN	DISC
<u>SECOBARBITAL SODIUM</u>								
		CAPSULE; ORAL						
		SECONAL SODIUM						
	+		RANBAXY	50MG	N86101 001	OCT 03, 1983	JUN	CARR
AA	+			100MG	N86101 002	OCT 03, 1983	JUN	CARR
<u>SECRETIN</u>								
		FOR SOLUTION; INTRAVENOUS						
		SECREFOLO						
	+		CHIRHOCLIN	16UGM/VIAL	N21209 001	APR 04, 2002	APR	NEW
<u>SELEGILINE HYDROCHLORIDE</u>								
		CAPSULE; ORAL						
		SELEGILINE HCL						
AB			CLONMEL HLHCARE	5MG	N75352 001	NOV 30, 1998	JUN	CARR
		TABLET; ORAL						
AB			CLONMEL HLHCARE	5MG	N74641 001	AUG 02, 1996	APR	CARR
AB			SIEGFRIED	5MG	N74672 001	APR 01, 1997	AUG	CARR
<u>SELENIUM SULFIDE</u>								
		LOTION/SHAMPOO; TOPICAL						
		SELSUN						
AT	+		CHATTEM	2.5%	N07936 001		AUG	CARR
<u>SELENOMETHIONINE, SE-75</u>								
		INJECTABLE; INJECTION						
		SELENOMETHIONINE SE 75						
		@	CIS	500uCi/ML	N17322 001		JUN	DISC
<u>SEVOFLURANE</u>								
		LIQUID; INHALATION						
		SEVOFLURANE						
AN			BAXTER HLHCARE	100%	N75895 001	JUL 02, 2002	SEP	NEW
		ULTANE						
AN	+		ABBOTT	100%	N20478 001	JUN 07, 1995	SEP	CFTC
<u>SIMETHICONE-CELLULOSE</u>								
		SUSPENSION; ORAL						
		SONORX						
		@	BRACCO	7.5MG/ML	N20773 001	OCT 29, 1998	JUN	DISC

SIROLIMUS

TABLET; ORAL

RAPAMUNE

+ WYETH AYERST

1MG

N21110 001 AUG 25, 2000 JUN NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL

UCEPHAN

@ B BRAUN

100MG/ML; 100MG/ML

N19530 001 DEC 23, 1987 JUN DISC

SODIUM IODIDE, I-131

CAPSULE; ORAL

IODOIPE

@ BRACCO

1-150mCi

N10929 003 JUN DISC

SOLUTION; ORAL

@ BRACCO

7-106mCi/BOT

N10929 002 JUN DISC

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+ ORPHAN MEDCL

500MG/ML

N21196 001 JUL 17, 2002 JUL NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN

@ NOVO NORDISK

4MG/VIAL

N19721 001 MAY 08, 1995 JUN DISC

@

8MG/VIAL

N19721 002 MAY 08, 1995 JUN DISC

NUTROPIN AQ PEN

BX + GENENTECH

5MG/ML

N20522 002 APR 22, 2002 JUN NEWA

SAIZEN

BX + SERONO

8.8MG/VIAL

N19764 003 AUG 29, 2000 SEP CDFR

SEROSTIM

BX + SERONO

4MG/VIAL

N20604 003 JUL 25, 1997 JUN CRLD

BX

6MG/VIAL

N20604 001 AUG 23, 1996 JUN CRLD

BX +

8.8MG/VIAL

N20604 004 SEP 06, 2001 SEP CTNA

SEROSTIM IN PLASTIC CONTAINER

BX + SERONO

8.8MG/VIAL

N20604 004 SEP 06, 2001 JUN NEWA

TEV-TROVIN

BX + BIO TECH GEN

5MG/ML

N19774 002 JAN 04, 2002 JUN NEWA

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HCL

AB APOTEX

80MG

N76140 001 SEP 26, 2002 SEP NEWA

AB

120MG

N76140 002 SEP 26, 2002 SEP NEWA

AB

160MG

N76140 003 SEP 26, 2002 SEP NEWA

AB

240MG

N76140 004 SEP 26, 2002 SEP NEWA

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

@ PHARMACIA AND UPJOHN

EQ 4GM BASE/VIAL

N50347 002

JUN DISC

<u>SUCCINYLCOLINE CHLORIDE</u>				
INJECTABLE; INJECTION				
QUELICIN PRESERVATIVE FREE				
@ ABBOTT	50MG/ML	N08845 002		JUN DISC
<u>SULFAMETHIZOLE</u>				
TABLET; ORAL				
THIOSULFIL				
@ WYETH AYERST	500MG	N08565 004		JUN DISC
<u>SULFAMETHOXAZOLE</u>				
TABLET; ORAL				
GANTANOL				
@ ROCHE	500MG	N12715 002		MAY CTEC
<u>SULFAMETHOXAZOLE; TRIMETHOPRIM</u>				
SUSPENSION; ORAL				
BACTRIM PEDIATRIC				
@ WOMEN FIRST HLTHCARE	200MG/5ML;40MG/5ML	N17560 002		APR DISC
SEPTRA				
AB + MONARCH PHARMS	200MG/5ML;40MG/5ML	N17598 001		APR CRLD
<u>SULFAPYRIDINE</u>				
TABLET; ORAL				
SULFAPYRIDINE				
@ LILLY	500MG	N00159 001		JUN DISC
<u>SULFASALAZINE</u>				
TABLET; ORAL				
SULFASALAZINE				
AB VINTAGE PHARMS	500MG	N40349 001	JAN 11, 2002	JAN NEAR
TABLET, DELAYED RELEASE; ORAL				
AZULFIDINE EN-TABS				
AB + PHARMACIA AND UPJOHN	500MG	N07073 002	APR 06, 1983	JAN CFTG
SULFASALAZINE				
AB VINTAGE PHARMS	500MG	N75339 001	JAN 11, 2002	JAN NEAR
<u>SULFISOXAZOLE ACETYL</u>				
SYRUP; ORAL				
GANTRISIN				
@ ROCHE	EQ 500MG BASE/5ML	N09182 002		JUN DISC
<u>SUMATRIPTAN SUCCINATE</u>				
TABLET; ORAL				
IMITREX				
GLAXOSMITHKLINE	EQ 50MG BASE	N20132 003	JUN 01, 1995	JUN CRLD
+	EQ 100MG BASE	N20132 001	JUN 01, 1995	JUN CRFD
<u>SUPROFEN</u>				
SOLUTION/DROPS; OPHTHALMIC				
PROFENAL				
@ ALCON	1%	N19387 001	DEC 23, 1988	JUN DISC

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
+ ASTRAZENECA EQ 20MG BASE

N17970 002 MAR 21, 1994 AUG CTEC

TAZAROTENE

CREAM; TOPICAL
AVAGE
+ ALLERGAN 0.1%

N21184 003 SEP 30, 2002 OCT NEWA

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION
MICROLITE
@ CIS N/A

N18263 001 MAR 25, 1983 JUN DISC

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION
TECHNETIUM TC 99M HSA
@ AMERSHAM HLTH N/A

N17775 001 JUL DISC

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION
RBC-SCAN
@ CADEMA N/A

N20063 001 JUN 11, 1992 JUN DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL
SODIUM PERTECHNETATE TC 99M
@ MALLINCKRODT 10-60mCi/ML

N17725 001 JUN DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
TECHNETIUM TC 99M GENERATOR
@ AMERSHAM HLTH 830-16600mCi/GENERATOR

N17693 001 JUN DISC

TEGASEROD MALEATE

TABLET; ORAL
ZELNORM
NOVARTIS EQ 2MG BASE
+ 2MG
+ EQ 6MG BASE
6MG

N21200 001 JUL 24, 2002 AUG CPOT
N21200 001 JUL 24, 2002 JUL NEWA
N21200 002 JUL 24, 2002 AUG CPOT
N21200 002 JUL 24, 2002 JUL NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HCL
RANBAXY EQ 1MG BASE
EQ 2MG BASE
EQ 5MG BASE
EQ 10MG BASE

N76021 001 AUG 22, 2002 AUG NEWA
N76021 002 AUG 22, 2002 AUG NEWA
N76021 003 AUG 22, 2002 AUG NEWA
N76021 004 AUG 22, 2002 AUG NEWA

TERBINAFINE

GEL; TOPICAL
LAMISIL
@ NOVARTIS

1%

N20846 001 APR 29, 1998 JUN DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION
BRETHINE

+ AAIPHARMA 1MG/ML
+ NEOSAN PHARMS 1MG/ML

N18571 001 JUL CARR
N18571 001 FEB CARR

TABLET; ORAL

AB AAIPHARMA 2.5MG
AB + 5MG
AB NEOSAN PHARMS 2.5MG
AB + 5MG

N17849 001 JUL CARR
N17849 002 JUL CARR
N17849 001 FEB CARR
N17849 002 FEB CARR

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
TESTODERM TTS

BX + ALZA 5MG/24HR

N20791 001 DEC 18, 1997 JAN CTM

GEL; TOPICAL

>A> TESTIM

>A> + AUXILIUM A2 1%

N21454 001 OCT 31, 2002 OCT NEW

TETRACYCLINE HYDROCHLORIDE

FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE

+ ALZA 12.7MG/FIBER

N50653 001 MAR 25, 1994 FEB CARR

FOR SOLUTION; TOPICAL

TOPICYCLINE
@ SHIRE LABS 2.2MG/ML

N50493 001 JUL DISC

INJECTABLE; INJECTION

ACHROMYCIN
@ LEDERLE 250MG/VIAL
+ 500MG/VIAL
@ 500MG/VIAL

N50273 002 JUN DISC
N50273 003 JUN CRD
N50273 003 JUL DISC

SUSPENSION; ORAL

ACHROMYCIN V
@ LEDERLE 125MG/5ML

N50263 002 APR DISC

SUMYCIN
+ APOTHECON 125MG/5ML

N60400 001 APR CTEC

TABLET; ORAL

@ PAR PHARM 50MG
@ 100MG
250MG
+ 500MG

N61147 003 MAY CARR
N61147 002 MAY CARR
N61147 001 MAY CARR
N61147 004 MAY CARR

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
THEO-DUR

>D> AB + KEY PHARMS 100MG
>D> AB + 200MG

N85328 001 OCT CRD
N86998 001 OCT CRD

		300MG		N85328 002		OCT	CRLD
>> AB +		450MG		N89131 001	JUN 25, 1986	OCT	CRLD
>> AB +	SCHERING	100MG		N85328 001		OCT	CRLD
>> AB		200MG		N86998 001		OCT	CRLD
>> AB		300MG		N85328 002		OCT	CRLD
>> AB		450MG		N89131 001	JUN 25, 1986	OCT	CRLD
>> AB	THEOPHYLLINE						
	SIDMAK LABS NJ	100MG		N89807 001	APR 30, 1990	OCT	CRLD
>> AB		100MG		N89807 001	APR 30, 1990	OCT	CRLD
>> AB +		200MG		N89808 001	APR 30, 1990	OCT	CRLD
>> AB		200MG		N89808 001	APR 30, 1990	OCT	CRLD
>> AB +		300MG		N89763 001	APR 30, 1990	OCT	CRLD
>> AB		300MG		N89763 001	APR 30, 1990	OCT	CRLD
>> AB +		450MG		N81236 001	NOV 09, 1992	OCT	CRLD
>> AB		450MG		N81236 001	NOV 09, 1992	OCT	CRLD
	UNI-DUR						
>> BC +	SCHERING	400MG		N89822 001	JAN 04, 1995	OCT	CRLD
>> BC		400MG		N89822 001	JAN 04, 1995	OCT	CRLD
>> BC +		600MG		N89823 001	JAN 04, 1995	OCT	CRLD
>> BC		600MG		N89823 001	JAN 04, 1995	OCT	CRLD
	UNIPHYL						
>> BC	PURDUE FREDERICK	400MG		N87571 001	SEP 01, 1982	OCT	CRLD
>> BC +		400MG		N87571 001	SEP 01, 1982	OCT	CRLD
>> BC		600MG		N40086 001	APR 15, 1996	OCT	CRLD
>> BC +		600MG		N40086 001	APR 15, 1996	OCT	CRLD
<u>THIETHYLPERAZINE MALATE</u>							
INJECTABLE; INJECTION							
TORECAN							
	NOVARTIS	5MG/ML		N12754 002		JUN	DISC
<u>THIORIDAZINE</u>							
SUSPENSION; ORAL							
MELLARIL-S							
	NOVARTIS	EQ 25MG HCL/5ML		N17923 001		JUN	DISC
		EQ 100MG HCL/5ML		N17923 002		JUN	DISC
<u>THIORIDAZINE HYDROCHLORIDE</u>							
CONCENTRATE; ORAL							
MELLARIL							
	NOVARTIS	30MG/ML		N11808 012		AUG	DISC
		100MG/ML		N11808 018		AUG	DISC
THIORIDAZINE HCL							
AA +	COPLY PHARM	30MG/ML		N89602 001	NOV 09, 1987	AUG	CRLD
AA +		100MG/ML		N89603 001	NOV 09, 1987	AUG	CRLD
TABLET; ORAL							
MELLARIL							
	NOVARTIS	10MG		N11808 003		AUG	DISC
		15MG		N11808 016		AUG	DISC
		25MG		N11808 006		AUG	DISC
		50MG		N11808 011		AUG	DISC
		100MG		N11808 009		AUG	DISC
		150MG		N11808 017		AUG	DISC

	@	200MG	N11808 015			
	THIORIDAZINE HCL				AUG DISC	
AB +	GENEVA PHARMS	25MG	N88133 001	AUG 30, 1983	AUG CRJ3	
AB +		100MG	N88135 001	NOV 20, 1984	AUG CRJ3	
AB +		200MG	N88137 001	SEP 17, 1986	AUG CRJ3	
<u>THIOTEPA</u>						
INJECTABLE; INJECTION						
THIOTEPA						
AP	AM PHARM PARTNERS	15MG/VIAL	N75698 001	SEP 20, 2001	FEB CAN	
<u>THIOTHIXENE HYDROCHLORIDE</u>						
CONCENTRATE; ORAL						
THIOTHIXENE HCL INTENSOL						
	@ ROXANE	EQ 5MG BASE/ML	N73494 001	JUN 30, 1992	JAN DISC	
<u>TIAGABINE HYDROCHLORIDE</u>						
TABLET; ORAL						
GABITRIL						
+	CEPHALON	16MG	N20646 003	SEP 30, 1997	JUN CRJ3	
	@	20MG	N20646 004	SEP 30, 1997	JUN DISC	
<u>TICLOPIDINE HYDROCHLORIDE</u>						
TABLET; ORAL						
TICLOPIDINE HCL						
AB	CARACO	250MG	N75526 001	SEP 26, 2002	SEP NEW	
<u>TIMOLOL MALEATE</u>						
SOLUTION; OPHTHALMIC						
TIMOLOL MALEATE						
AT	HI TECH PHARMA	EQ 0.5% BASE	N75163 001	SEP 10, 2002	SEP NEW	
<u>TINZAPARIN SODIUM</u>						
INJECTABLE; INJECTION						
INNOHEP						
+	LEO PHARM	20,000 IU/ML	N20484 001	JUL 14, 2000	APR CAN	
+	PHARMION	20,000 IU/ML	N20484 001	JUL 14, 2000	JUL CAN	
<u>TIZANIDINE HYDROCHLORIDE</u>						
CAPSULE; ORAL						
ZANAFLEX						
	ELAN PHARMS	EQ 2MG BASE	N21447 001	AUG 29, 2002	AUG NEW	
		EQ 4MG BASE	N21447 002	AUG 29, 2002	AUG NEW	
+		EQ 6MG BASE	N21447 003	AUG 29, 2002	AUG NEW	
TABLET; ORAL						
TIZANIDINE HCL						
>A>	AB	COREPHARMA	EQ 2MG BASE	N76347 001	OCT 11, 2002	OCT NEW
>A>	AB		EQ 4MG BASE	N76347 002	OCT 11, 2002	OCT NEW
	AB	DR REDDYS LABS INC	EQ 2MG BASE	N76286 001	JUL 03, 2002	JUL NEW
	AB		EQ 4MG BASE	N76286 002	JUL 03, 2002	JUL NEW
	AB	EON	EQ 4MG BASE	N76280 002	JUN 27, 2002	JUN NEW
	AB	PUREPAC PHARM	EQ 2MG BASE	N76283 001	JUL 12, 2002	JUL NEW
	AB		EQ 4MG BASE	N76283 002	JUL 12, 2002	JUL NEW

1-74
 AUG DISC
 AUG CRUI
 AUG CRUI
 AUG CRUI
 FEB CAH
 JUN CRUI
 JUN DISC
 SEP NEW
 APR CAH
 JUL CAH
 AUG NEW
 AUG NEW
 AUG NEW
 OCT NEW
 OCT NEW
 JUL NEW
 JUL NEW
 JUN NEW
 JUL NEW
 JUL NEW

AB	TEVA	EQ 2MG BASE	N76284 001	JUL 03, 2002	JUL	NEWA
AB		EQ 4MG BASE	N76284 002	JUL 03, 2002	JUL	NEWA
AB	ZANAFLEX	EQ 2MG BASE	N20397 002	FEB 04, 2000	AUG	CFTG
AB	ELAN PHARMS	EQ 4MG BASE	N20397 001	NOV 27, 1996	JUN	CFTG
AB	+					
<u>TOBRAMYCIN</u>						
SOLUTION/DROPS; OPHTHALMIC						
AT	NOVEX	0.3%	N65087 001	FEB 25, 2002	FEB	NEWA
<u>TOBRAMYCIN SULFATE</u>						
INJECTABLE; INJECTION						
	TOBRAMYCIN SULFATE	EQ 40MG BASE/ML	N63120 001	OCT 31, 1994	FEB	DISC
	@ ASTRAZENECA	EQ 40MG BASE/ML	N63122 001	OCT 31, 1994	JAN	DISC
	@					
<u>TOLAZOLINE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
	PRISCOLINE	25MG/ML	N06403 005	FEB 22, 1985	JUN	DISC
	@ NOVARTIS					
<u>TOPIRAMATE</u>						
TABLET; ORAL						
	TOPAMAX					
	+ JOHNSON AND JOHNSON	25MG	N20505 004	DEC 24, 1996	JAN	CAHN
	@	50MG	N20505 005	DEC 24, 1996	JAN	CAHN
		100MG	N20505 001	DEC 24, 1996	JAN	CAHN
		200MG	N20505 002	DEC 24, 1996	JAN	CAHN
	@	300MG	N20505 003	DEC 24, 1996	JAN	CAHN
	@	400MG	N20505 006	DEC 24, 1996	JAN	CAHN
<u>TORSEMIDE</u>						
TABLET; ORAL						
	DEMADEX					
AB	ROCHE	5MG	N20136 001	AUG 23, 1993	MAY	CFTG
AB		10MG	N20136 002	AUG 23, 1993	MAY	CFTG
AB	+	20MG	N20136 003	AUG 23, 1993	MAY	CFTG
AB		100MG	N20136 004	AUG 23, 1993	MAY	CFTG
	TORSEMIDE					
AB	TEVA	5MG	N76110 001	MAY 14, 2002	MAY	NEWA
AB		10MG	N76110 002	MAY 14, 2002	MAY	NEWA
AB		20MG	N76110 003	MAY 14, 2002	MAY	NEWA
AB		100MG	N76110 004	MAY 14, 2002	MAY	NEWA
<u>TRAMADOL HYDROCHLORIDE</u>						
TABLET; ORAL						
	TRAMADOL HCL					
AB	ABLE	50MG*	N75963 001	JUL 03, 2002	JUL	NEWA
AB	ASTA	50MG*	N75974 001	JUL 12, 2002	JUL	NEWA
AB	CARACO	50MG*	N75964 001	JUN 19, 2002	JUN	NEWA
AB	COREPHARMA	50MG*	N76003 001	JUN 20, 2002	JUN	NEWA
AB	EON	50MG*	N75968 001	JUN 25, 2002	JUN	NEWA

* SEE SECTION 1.4 OF INTRODUCTION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

1-76

AB	MALLINCKRODT	50MG*	N75983 001	JUN 25, 2002	JUN	NEW
AB	MUTUAL PHARM	50MG*	N76100 001	JUN 20, 2002	JUN	NEW
AB	MYLAN	50MG*	N75986 001	JUN 21, 2002	JUN	NEW
AB	PUREPAC PHARM	50MG*	N75960 001	JUN 19, 2002	JUN	NEW
AB	SIDMAK LABS	50MG*	N75982 001	JUL 01, 2002	JUL	NEW
AB	TEVA	50MG*	N75977 001	JUN 19, 2002	JUN	NEW
AB	TORPHARM	50MG*	N75981 001	JUL 10, 2002	JUL	NEW
AB	WATSON LABS	50MG*	N75962 001	JUN 24, 2002	JUN	NEW
	ULTRAM					
+	JOHNSON AND JOHNSON	50MG	N20281 002	MAR 03, 1995	FEB	CAN
	@	100MG	N20281 001	MAR 03, 1995	FEB	CAN
AB +	ORTHO MCNEIL PHARM	50MG	N20281 002	MAR 03, 1995	JUN	CTE

TREPROSTINIL SODIUM

INJECTABLE; SUBCUTANEOUS

REMODULIN

UNITED THERAP

		1MG/ML	N21272 001	MAY 21, 2002	MAY	NEW
		2.5MG/ML	N21272 002	MAY 21, 2002	MAY	NEW
		5MG/ML	N21272 003	MAY 21, 2002	MAY	NEW
+		10MG/ML	N21272 004	MAY 21, 2002	MAY	NEW

TRETINOIN

GEL; TOPICAL

RETIN-A

AB +	JOHNSON AND JOHNSON	0.01%	N17955 001		JUN	CFTS
	RETIN-A MICRO					
+	JOHNSON AND JOHNSON	0.04%	N20475 002	MAY 10, 2002	SEP	NEW
	TRETINOIN					
AB	SPEAR PHARMS	0.01%	N75589 001	JUN 11, 2002	JUN	NEW

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

@	FUJISAWA HLTHCARE	1MG	N11161 009		JUL	DISC
@		2MG	N11161 004		JUL	DISC
@		8MG	N11161 011		JUL	DISC

KENACORT

+	BRISTOL MYERS SQUIBB	8MG	N11283 010		AUG	CTEC
---	----------------------	-----	------------	--	-----	------

TRIAMCINOLONE ACETONIDE

INJECTABLE; INJECTION

KENALOG-10

	APOTHECON	10MG/ML	N12041 001		JUN	CRLD
--	-----------	---------	------------	--	-----	------

KENALOG-40

BP +	APOTHECON	40MG/ML	N14901 001		JUN	CRLD
+		40MG/ML	N14901 001		SEP	CTEC

TRIAMCINOLONE ACETONIDE

@	PARNELL	3MG/ML	N19503 001	OCT 16, 1987	JUN	DISC
@	STERIS	40MG/ML	N85825 001		SEP	DISC

SPRAY, METERED; NASAL

TRI-NASAL

@	MURO	0.05MG/SPRAY	N20120 001	FEB 04, 2000	JUN	DISC
---	------	--------------	------------	--------------	-----	------

* SEE SECTION 1.4 OF INTRODUCTION

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT	25MG/ML	N11685 003		OCT	CAHN
+ FUJISAWA HLTHCARE	40MG/ML	N12802 001		OCT	CAHN
+ LEDERLE	25MG/ML	N11685 003		OCT	CAHN
+ LEDERLE	40MG/ML	N12802 001		OCT	CAHN
+ LEDERLE	40MG/ML	N12802 001		SEP	CTEC
TRIAMCINOLONE DIACETATE					
@ STERIS	40MG/ML	N84072 001		SEP	DISC
SYRUP; ORAL					
ARISTOCORT					
@ FUJISAWA HLTHCARE	2MG/5ML	N11960 004		JUL	DISC

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN					
+ FUJISAWA HLTHCARE	5MG/ML	N16466 001		OCT	CAHN
+ FUJISAWA HLTHCARE	20MG/ML	N16466 002		OCT	CAHN
+ LEDERLE	5MG/ML	N16466 001		OCT	CAHN
+ LEDERLE	20MG/ML	N16466 002		OCT	CAHN

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN					
@ APOTHECON	10MG/ML	N11325 004		JUN	DISC
@ APOTHECON	20MG/ML	N11325 001		JUN	DISC

TRILOSTANE

CAPSULE; ORAL

MODRASTANE					
@ BIOENVISION	30MG	N18719 002	DEC 31, 1984	JUN	CAHN
@ BIOENVISION	60MG	N18719 001	DEC 31, 1984	JUN	CAHN

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE					
@ ABBOTT	300MG	N05856 005		JUN	DISC
SOLUTION; ORAL					
@ ABBOTT	200MG/5ML	N05856 002		JUN	DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN					
+ KING PHARMS	300MG	N17531 006	DEC 13, 2001	JAN	NEWA
INJECTABLE; INJECTION					
TRIMETHOBENZAMIDE HCL					
@ STERIS	100MG/ML	N87939 001	DEC 28, 1982	FEB	DISC

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

1-78

TRIMETHOPRIM

TABLET; ORAL

TRIMPEX

@ ROCHE

100MG

N17952 001

AUG DISC

TRIOXSALEN

TABLET; ORAL

TRISORALEN

@ ICN

5MG

N12697 001

JUN DISC

TRIPLENNAMINE CITRATE

ELIXIR; ORAL

PBZ

@ NOVARTIS

EQ 25MG HCL/5ML

N05914 004

JUN DISC

TRIPLENNAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

@ NOVARTIS

100MG

N10533 001

JUN DISC

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

TABLET; VAGINAL

SULTRIN

@ ORTHO MCNEIL PHARM

184MG;143.75MG;172.5MG

N05794 002

JUN DISC

UREA, C-13

FOR SOLUTION; ORAL

PYLORI-CHEK BREATH TEST

@ ALIMENTERICS

100MG/VIAL

N20900 001 FEB 04, 1999 JUL DISC

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

BRAVELLE

BX + FERRING

75 IU/VIAL

N21289 001 MAY 06, 2002 MAY NEW

INJECTABLE; SUBCUTANEOUS

FERTINEX

BX + SERONO

75 IU/AMP

N19415 005 AUG 23, 1996 MAY CTEC

@

150 IU/AMP

N19415 004 AUG 23, 1996 JUN DISC

URSODIOL

CAPSULE; ORAL

ACTIGALL

@ WATSON PHARMS

150MG

N19594 001 DEC 31, 1987 FEB CARB

AB +

300MG

N19594 002 DEC 31, 1987 FEB CARB

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALTREX

@ GLAXOSMITHKLINE

EQ 500MG BASE

N20487 001 JUN 23, 1995 MAR DISC

@

EQ 1GM BASE

N20487 002 JUN 23, 1995 MAR DISC

VALSARTAN

CAPSULE; ORAL

DIOVAN

80MG

N20665 001 DEC 23, 1996 JUN DISC

@ NOVARTIS

160MG

N20665 002 DEC 23, 1996 JUN DISC

@

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

20MG/VIAL

N18776 003 JAN 03, 1992 JUN DISC

@ ORGANON

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

EQ 37.5MG BASE

N20699 001 OCT 20, 1997 MAY CRLD

WYETH AYERST

EQ 150MG BASE

N20699 004 OCT 20, 1997 MAY CRLD

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERELAN

AB + ELAN DRUG

120MG

N19614 001 MAY 29, 1990 APR CAHN

AB +

180MG

N19614 003 JAN 09, 1992 APR CAHN

AB +

240MG

N19614 002 MAY 29, 1990 APR CAHN

+

360MG

N19614 004 MAY 10, 1996 APR CAHN

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+ AAIPHARMA

EQ 50,000 UNITS BASE/ML

N06823 001

JUL CAHN

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

+ PFIZER

200MG/VIAL

N21267 001 MAY 24, 2002 MAY NEWA

TABLET; ORAL

PFIZER

50MG

N21266 001 MAY 24, 2002 MAY NEWA

+

200MG

N21266 002 MAY 24, 2002 MAY NEWA

XENON, XE-127

GAS; INHALATION

XENON XE 127

@ MALLINCKRODT

5mCi/VIAL

N18536 001 OCT 01, 1982 JUN DISC

@

10mCi/VIAL

N18536 002 OCT 01, 1982 JUN DISC

XYLOSE

POWDER; ORAL

XYLOSE

@ LYNE

25GM/BOT

N18856 001 MAR 26, 1987 JUL DISC

ZILEUTON

TABLET; ORAL

ZYFLO

+ ABBOTT 300MG
 @ 300MG

N20471 001 DEC 09, 1996 JUN ORG
 N20471 001 DEC 09, 1996 JUL DUC

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON

+ PFIZER EQ 20MG BASE/ML

N20919 001 JUN 21, 2002 JUN NEW

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING; ORAL

ZOMIG-ZMT

+ ASTRAZENECA 5MG

N21231 002 SEP 17, 2001 JUN NEW

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN 650MG N76200 001 MAR 19, 2002 MAR NEWA
 COREPHARMA

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

CHLORAPREP ONE-STEP SEPP N21555 001 OCT 07, 2002 OCT NEWA
 * BECKLOFF 2%

SPONGE; TOPICAL

E-Z SCRUB N73416 001 MAR 14, 2000 SEP DISC
 @ BECTON DICKINSON 4%

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONTAC 12 HOUR N18099 001 JAN DISC
 @ GLAXOSMITHKLINE 8MG;75MG

PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE N18809 001 MAY 07, 1984 FEB DISC
 @ CENT PHARMS 8MG;75MG

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200 N20951 001 JUL 09, 1999 SEP DISC
 @ GLAXOSMITHKLINE 200MG/20ML

TABLET; ORAL

CIMETIDINE N74948 002 JUL 26, 2002 JUL NEWA
 TORPHARM 200MG

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE N76101 001 OCT 21, 2002 OCT NEWA
 EON 10MG

TORPHARM 10MG N75610 001 MAR 12, 2002 MAR NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX N21282 001 JUL 12, 2002 JUL NEWA
 ADAMS LABS 600MG

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN N21472 001 OCT 18, 2002 OCT NEWA
 BANNER PHARMACAPS 200MG

TABLET; ORAL

PERRIGO 200MG N75995 001 MAR 14, 2002 MAR NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS N21374 001 MAY 30, 2002 MAY NEWA
 WYETH CONS 200MG;30MG

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - OCT 2002

2-2

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL COLD

WYETH CONS

100MG/5ML; 15MG/5ML

N21373 001 APR 18, 2002 APR NEW

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HCL

PHARM FORM

200MG; 30MG

N75588 001 APR 08, 2002 APR NEW

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

REGULAR PURIFIED PORK INSULIN

@ NOVO NORDISK

100 UNITS/ML

N18381 001 FEB DISC

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

VELOSULIN BR

+ NOVO NORDISK

100 UNITS/ML

N21028 001 JUL 19, 1999 JUN DISC

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

NPH PURIFIED PORK ISOPHANE INSULIN

@ NOVO NORDISK

100 UNITS/ML

N18623 001 FEB DISC

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION

LENTE

@ NOVO NORDISK

100 UNITS/ML

N18383 001 FEB DISC

KETOPROFEN

TABLET; ORAL

KETOPROFEN

PERRIGO

12.5MG

N75364 001 FEB 07, 2002 FEB NEW

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL

LOPERAMIDE HCL AND SIMETHICONE

PERRIGO

2MG; 125MG

N76029 001 AUG 30, 2002 AUG NEW

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

CLAY PARK

5%

NOVEX

5%

N75737 001 MAR 15, 2002 MAR NEW

N75839 001 OCT 01, 2001 MAR CTM

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

DR REDDYS LABS INC

EQ 200MG BASE

N75168 001 JUL 28, 1998 AUG DISC

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL

HEP	COMMIT		N21330 001	OCT 31, 2002	OCT	NEWA
HEP	GLAXOSMITHKLINE CONS	2MG	N21330 002	OCT 31, 2002	OCT	NEWA
HEP		4MG				
HEP	+					

POTASSIUM IODIDE

TABLET; ORAL

HEP	THYROSAFE		N76350 001	SEP 10, 2002	SEP	NEWA
HEP	R R REGISTRATIONS	65MG				

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

HEP	SUDAFED 12 HOUR		N73585 001	OCT 31, 1991	MAY	CAHN
HEP	WARNER LAMBERT	120MG				

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

HEP	RANITIDINE		N75519 001	SEP 26, 2002	SEP	NEWA
HEP	GENEVA PHARMS	EQ 75MG BASE	N76195 001	AUG 30, 2002	AUG	NEWA
HEP	PERRIGO	EQ 75MG BASE				

DRUG PRO

NO OCTOBER 2002 APP

Office of
**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

3-1

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER '02

NO OCTOBER 2002 APPROVALS

WOOD PRODUCTS WITH ANIMAL
CENTRE FOR THE
GENERAL

PLEASE USE APPROVAL

THE UNIVERSITY OF THE WEST INDIES
TRINIDAD AND TOBAGO
SCHOOL OF DISTANCE EDUCATION
TRINIDAD CAMPUS
TRINIDAD

This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
October 2002

albuterol	DD: 3/12/2002	Prevention of paralysis due to spinal cord injury	MotoGen, Inc. 3 Pine View Road Mount Kisco NY 10549
	MA:		
alantoin	DD: 11/21/2002	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Alwyn Company, Inc. 2301 Highway 60 East Lake Crystal MN 56055
Alwetin	MA:		
angiogenic components extracted from marine cartilage Iervastat (AE-941)	DD: 10/16/2002	Treatment of renal cell carcinoma	AEterna Laboratories, Inc. Dr. Claude Hariton, Chief Medical Officer, VP, Clinical & Regulatory Affairs 1405 boul. Du Parc - Technologique Quebec G1P 4P5 CANADA
	MA:		
antigenic tumor presenting cells pulsed with autologous tumor Ig idiotype Mylovenge	DD: 4/18/2002	Treatment of multiple myeloma	Dendreon Corporation 3005 First Avenue Seattle WA 98121
	MA:		
antigenic tumor-derived gp96 heat shock protein-peptide complex OncoPhase	DD: 7/11/2002	Treatment of metastatic melanoma	Antigenics, Inc. 34 Commerce Way Woburn MA 01702
	MA:		
antigenic tumor-derived gp96 heat shock protein-peptide complex OncoPhase	DD: 5/10/2002	Treatment of renal cell carcinoma	Antigenics, Inc. 34 Commerce Way Woburn MA 01702
	MA:		
antimicrobial	DD: 3/12/2002	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Corus Pharma 2025 First Ave., Suite 800 Seattle WA 98121
	MA:		
bioartificial liver system utilizing allogeneic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	DD: 2/11/2002	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Excorp Medical, Inc. Suite 235 7200 Hudson Blvd. Oakdale MN 55128
	MA:		

Orphan Products Designations and Approvals List October 2002

capsaicin	DD: 10/23/2002	Treatment of erythromelalgia	NeurogesX, Inc. 981F Industrial Road San Carlos CA 94070
	MA:		
carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy)methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester	DD: 1/15/2002	Management of cystic fibrosis	Boehringer Ingelheim Pharmaceuticals, Inc 900 Ridgebury Road
	MA:		P.O. Box 368 Ridgefield CT 06877
cells produced using the AastromReplicelle System and SC-I Therapy Kit	DD: 7/10/2002	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Aastrom Biosciences Incorporated P.O. Box 376 Ann Arbor MI 48106
	MA:		
clofarabine	DD: 2/7/2002	Treatment of acute lymphoblastic leukemia	Ilex Products, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
Clofarex	MA:		
clofarabine	DD: 3/14/2002	Treatment of acute myelogenous leukemia	Ilex Products, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
Clofarex	MA:		
creatine	DD: 2/12/2002	Treatment of amyotrophic lateral sclerosis	Avicena Group, Inc. 580 California St. Suite 1600 San Francisco CA 94104
Creapure	MA:		
D-peptide of the sequence AKRHHGYKRKFH - NH2 PulmaDex	DD: 10/23/2002	Treatment of cystic fibrosis	Demegen, Inc. 1051 Brinton Road Pittsburgh PA 15221
	MA:		
decitabine	DD: 9/9/2002	Treatment of sickle cell anemia	SuperGen, Inc. 4140 Dublin Blvd., Suite 200 Dublin CA 94568
	MA:		
Deferasirox	DD: 11/21/2002	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover NJ 07936-1000
	MA:		
DHA-paclitaxel	DD: 10/10/2002	Treatment of metastatic malignant melanoma	Protarga, Inc. 2200 Renaissance Boulevard Suite 450 King of Prussia PA 19406
Taxoprexin	MA:		

Orphan Products Designations and Approvals List

October 2002

DD: 7/18/2002	Treatment of gastric cancer	Apton Corporation 26 Harter Avenue Suite 14 Woodland CA 95776
MA:		
DD: 7/10/2002	Treatment of adenocarcinoma of the pancreas	Apton Corporation 26 Harter Avenue Suite 14 Woodland CA 95776
MA:		
DD: 4/29/2002	Treatment of malignant glioma	MediGene, Inc. 9880 Campus Point Drive, Suite A San Diego CA 92121
MA:		
DD: 11/21/2002	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	CPL, Inc. 16020 Swingley Ridge Road Suite 145 Chesterfield MO 63017
MA:		
DD: 11/14/2002	Prophylaxis of hepatitis C infection in liver transplant recipients.	NABI 5800 Park of Commerce Blvd., N.W. Boca Raton FL 33487
MA:		
DD: 2/8/2002	Treatment for chronic myelogenous leukemia	American BioScience, Inc. 2730 Wilshire Blvd. #110 Santa Monica CA 90403
MA:		
DD: 1/11/2002	Treatment of systemic sclerosis	Genzyme Corporation One Kendall Square Cambridge MA 02139
MA:		
DD: 9/16/2002	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.	Protein Therapeutics, Inc. 9040 S. Rita Road Suite 1100 Tucson AZ 85747
MA:		
DD: 3/19/2002	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	Exhale Therapeutics, Inc. 1301 Shoreway Road Suite 320 Belmont CA 94002
MA:		
DD: 2/14/2002	treatment of malignant glioma	TransMolecular, Inc. 3800 Colonnade Parkway Suite 240 Birmingham AL 35243
MA:		
DD: 10/23/2002	Treatment of juvenile rheumatoid arthritis	Centocor, Inc. 200 Great Valley Parkway Malvern PA 19355-1307
MA:		

Orphan Products Designations and Approvals List October 2002

inolimomab	DD: 10/23/2002	Treatment of graft versus host disease	Opi 6, Chemin de l'Industrie 69570 DARDILLY - France
Leukotac	MA:		
interferon gamma-1b	DD: 9/12/2002	Treatment of idiopathic pulmonary fibrosis	InterMune, Inc. 3280 Bayshore Boulevard Brisbane CA 94005
Actimmune	MA:		
lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococci)	DD: 1/15/2002	Treatment of active chronic pouchitis	VSL Pharmaceuticals, Inc. 800 S. Frederick Avenue Gaithersburg MD 20877
	MA:		
lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	DD: 1/15/2002	Prevention of disease relapse in patients with chronic pouchitis	VSL Pharmaceuticals, Inc. 800 S. Frederick Ave. Gaithersburg MD 20877
	MA:		
lintuzumab	DD: 9/9/2002	Treatment of acute myelogenous leukemia	Protein Design Labs, Inc. 34801 Campus Drive Fremont CA 94555
Zamyl	MA:		
lipase, amylase, and protease	DD: 1/23/2002	Treatment of pancreatic insufficiency	Altus Biologics Inc. 625 Putnam Avenue Cambridge MA 02139
TheraCLEC-Total	MA:		
meloxicam	DD: 11/22/2002	Treatment of juvenile rheumatoid arthritis	Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road P. O. Box 368 Ridgefield CT 06877-0368
Mobic	MA:		
methylbicyclone	DD: 11/14/2002	Treatment of cystic fibrosis	Sucampo Pharmaceuticals, Inc. 4733 Bethesda Ave. Suite 450 Bethesda MD 20814
	MA:		
N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea	DD: 5/13/2002	Treatment of sickle cell disease	NeuroSearch A/S 93 Pederstrupvej DK-2750 Ballerup Denmark
	MA:		
N-acetylcysteine	DD: 9/9/2002	Treatment of acute liver failure	William M. Lee, MD, FACP University of Texas Southwestern Medical Center at Dallas 5323 Harry Hines Blvd Dallas TX 75390-9151
	MA:		
Natural human lymphoblastoid interferon-alpha	DD: 11/18/2002	Treatment of polycythemia vera	Amarillo Biosciences, Inc.

Orphan Products Designations and Approvals List October 2002

	MA:		800 West 9th Avenue Amarillo TX 79101
	DD: 2/14/2002	Treatment of intestinal giardiasis	Romark Laboratories, L.C. 6200 Courtney Campbell Causeway Suite 880 Tampa FL 33607
	MA:		
	DD: 5/16/2002	Prevention of <i>Pseudomonas aeruginosa</i> infections in patients with cystic fibrosis	Orphan Europe Immeuble "Le Wilson"
	MA:		70 avenue du General de Gaulle, 92046 Paris La Defense France
	DD: 2/14/2002	Treatment of ileal pouch anal anastomosis related fecal incontinence	S.L.A. Pharma Unit 3, Hill Farm Industrial Estate Leavesden, Watford United Kingdom WD25 7SA
	MA:		
	DD: 11/19/2002	Treatment for orthopox virus infections	Ribopharm, Inc. 3203 Cleveland Ave., NW Washington DC 20008-3450
	MA:		
	DD: 8/2/2002	As an adjuvant to smallpox vaccination	Ribopharm, Inc. 3203 Cleveland Ave., NW Washington DC 20008-3450
	MA:		
	DD: 2/21/2002	Treatment of metastatic melanoma	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850
	MA:		
	DD: 5/17/2002	Treatment of growth hormone insensitivity syndrome	Celtrix Pharmaceuticals, Inc. a subsidiary of Inmed, Inc. 4851 Lake Brook Drive Glen Allen VA 23060
	MA:		
	DD: 9/16/2002	Treatment of invasive candidiasis	NeuTec Pharma plc 2dn floor, Clinical Sciences Bldg. Central Manchester Healthcare Trust, Oxford Rd., Manchester M139WL, UK
	MA:		
	DD: 9/9/2002	Treatment of acute intermittent porphyria attacks	HemeBiotech A/S Roskildevej 12C 3400 Hillerod Denmark
	MA:		
	DD: 4/29/2002	Treatment of X linked severe combined immune deficiency disease	AVAX technologies, Inc. 9200 Indian Creek Parkway Building 9, Suite 200 Overland Park KS 66210
	MA:		
	DD: 3/12/2002	Treatment of immune thrombocytopenic purpura	Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990

Orphan Products Designations and Approvals List October 2002

	MA:		
rubitecan	DD: 7/17/2002	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
	MA:		
S(-)-3-[3-amino-phthalimido]-glutar amide	DD: 3/14/2002	Treatment of multiple myeloma	EntreMed Incorporated 9640 Medical Center Dr. Rockville MD 20850
	MA:		
SS1(dsFv)-PE38	DD: 2/11/2002	Treatment of epithelial ovarian cancer	NeoPharm, Inc. 150 Field Drive Suite 195 Lake Forest IL 60045
	MA:		
SS1(dsFv)-PE38	DD: 2/11/2002	Treatment of malignant mesothelioma	NeoPharm Incorporated 150 Field Drive Suite 195 Lake Forest IL 60045
	MA:		
TGF(beta)2-specific phosphorothioate antisense oligodeoxynucleotide Oncomun	DD: 6/5/2002	Treatment of malignant glioma	Antisense Pharma GmbH Josef-Engert-Str. 9 93053 Regensburg Germany
	MA:		
tinidazole	DD: 4/18/2002	Treatment of giardiasis	Presutti Laboratories, Inc. 1607 N. Douglas Ave. Arlington Heights IL 60004
	MA:		
tirapazamine	DD: 10/23/2002	For the treatment of head and neck cancer	Sanofi-Synthelabo Research 9 Great Valley Parkway Malvern PA 19355
	MA:		
toralizumab	DD: 3/14/2002	Treatment of immune thrombocytopenic purpura	IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego CA 92121
	MA:		

DRUG PROD

NO OCTOBER 2002 ADDI

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2002 ADDITIONS

THE PROJECTS WHICH ARE
THE MOST IMPORTANT

THE MOST IMPORTANT PROJECTS

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLAYS EXPIRES
021205 001	ABACAVIR SULFATE; TRIZIVIR	6417191	MAR 28, 2016	U-248		
>ADD>		6417191*PED	SEP 28, 2016	U-248		
>ADD>		6451340	JUL 23, 2018	U-470	NCE	SEP 20, 2007
>ADD>		4808716	APR 25, 2006			
>ADD>		5663159	SEP 02, 2014	U-470		
020503 001	ALBUTEROL SULFATE; PROVENTIL-HFA	4724233	APR 21, 2006	U-470		
021001 001	ALMOTRIPTAN MALATE; AXERT	6352684	NOV 28, 2009		NP	JUN 11, 2005
021001 002	ALMOTRIPTAN MALATE; AXERT	5565447	OCT 15, 2013		NP	JUN 11, 2005
021212 001	ALPROSTADIL; CAVERJECT	4410520	AUG 11, 2003		NS	JUN 20, 2005
021212 002	ALPROSTADIL; CAVERJECT	4572909	JUL 31, 2006			
020364 005	AMLODIPINE BESYLATE; LOTREL	4879303	MAR 25, 2007			
		6162802	DEC 19, 2017	U-367		
021303 001	AMPHETAMINE ASPARTATE; ADDERALL XR 10	6322819	NOV 27, 2018		NDF	OCT 11, 2004
>ADD>		6322819	NOV 27, 2018		NDF	OCT 11, 2004
>ADD>		6322819	NOV 27, 2018		NDF	OCT 11, 2004
>ADD>		6322819	NOV 27, 2018		NDF	OCT 11, 2004
020541 001	ANASTROZOLE; ARIMIDEX	5925760	AUG 04, 2017			
020883 001	ARGATROBAN; ARGATROBAN					
020702 001	ATORVASTATIN CALCIUM; LIPITOR					
>ADD>						
>ADD>						
020702 002	ATORVASTATIN CALCIUM; LIPITOR					
>ADD>						
>ADD>						
020702 003	ATORVASTATIN CALCIUM; LIPITOR					
>ADD>						
>ADD>						
020702 004	ATORVASTATIN CALCIUM; LIPITOR					
>ADD>						
>ADD>						
020911 002	BECLMETHASONE DIPROPIONATE; QVAR 40	6352684	NOV 28, 2009			
020911 001	BECLMETHASONE DIPROPIONATE; QVAR 80	6352684	NOV 28, 2009			
>ADD>		5962731	OCT 05, 2016	U-475		
>ADD>		6403649	SEP 21, 2012	U-446		
021055 001	BEXAROTENE; TARGRETIN					
021275 001	BIMATOPROST; LUMIGAN					
020490 001	BRIMONIDINE TARTRATE; ALPHAGAN					
020613 001	BRIMONIDINE TARTRATE; ALPHAGAN	6465464	JUN 28, 2015	U-394	NPP	DEC 20, 2004
>ADD>		6465464*PED	DEC 28, 2015	U-394	PED	JUN 20, 2005
>ADD>						

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>					
021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6465464	U-395 NPP		DEC 20, 2004
>ADD>		6465464*PED	U-395 PED		JUN 20, 2005
021324 001	BUDESONIDE;ENTOCORT EC	5643602		NP	OCT 02, 2004
>ADD>		5643602*PED		PED	APR 02, 2005
020441 002	BUDESONIDE; PULMICORT	4668218			
>ADD>		4907583			
>ADD>		4668218*PED			
020441 003	BUDESONIDE; PULMICORT	4907583			
>ADD>		4668218			
>ADD>		4668218*PED			
020929 001	BUDESONIDE; PULMICORT RESPULES	4907583			
>ADD>		4668218			
>ADD>		4668218*PED			
020929 002	BUDESONIDE; PULMICORT RESPULES	4787536			
>ADD>		4787536*PED			
020929 003	BUDESONIDE; PULMICORT RESPULES	4787536			
>ADD>		4787536*PED			
020746 001	BUDESONIDE; RHINOCORT	6291445			
>ADD>		6291445*PED			
020746 002	BUDESONIDE; RHINOCORT	6291445			
>ADD>		6291445*PED			
020733 001	BUPRENORPHINE HYDROCHLORIDE; SUBOXONE				
>ADD>					
020733 002	BUPRENORPHINE HYDROCHLORIDE; SUBOXONE				
>ADD>					
020732 003	BUPRENORPHINE HYDROCHLORIDE; SUBUTEX				
>ADD>					
020358 004	BUPROPION HYDROCHLORIDE; WELLBUTRIN SR				
>ADD>					
018731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR				
>ADD>					
018731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR				
>ADD>					
018731 003	BUSPIRONE HYDROCHLORIDE; BUSPAR				
>ADD>					

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE CODE	EXCLUS EXCLUS CODE	EXPIRES
018731 004	BUSPIRONE HYDROCHLORIDE; BUSPAR			M-12 PED	JUL 19, 2004
				W	JAN 19, 2005
				W	JAN 19, 2005
020954 001	BUSULFAN; BUSULFEX	5430057	U-263 ODE		FEB 04, 2006
		5559148	U-264 NDF		FEB 04, 2002
		5430057*	U-263 PED		AUG 04, 2002
		5559148*	U-264 PED		AUG 04, 2006
				NP	OCT 17, 2005
>ADD>	BUTENAFINE HYDROCHLORIDE; MENTAX-TC	5266329	U-457		
	BUTOCONAZOLE NITRATE; GYNAZOLE-1	4551148			
		5196444	U-3	M-21	SEP 13, 2005
>ADD>	CANDESARTAN CILEXETIL; ATACAND	5196444	U-3	M-21	SEP 13, 2005
>ADD>	CANDESARTAN CILEXETIL; ATACAND	5196444	U-3	M-21	SEP 13, 2005
>ADD>	CANDESARTAN CILEXETIL; ATACAND	5196444	U-3	M-21	SEP 13, 2005
>ADD>	CANDESARTAN CILEXETIL; ATACAND	5196444	U-3	M-21	SEP 13, 2005
	CANDESARTAN CILEXETIL; ATACAND HCT	5196444	U-3		
	CANDESARTAN CILEXETIL; ATACAND HCT	5196444	U-3		
021093 001	CANDESARTAN CILEXETIL; ATACAND HCT	5196444	U-3		
021093 002	CANDESARTAN CILEXETIL; ATACAND HCT	4839350			
021222 001	CEFDITOREN PIVOXIL; SPECTRACEF	4918068		I-364	AUG 21, 2005
		5958915			
		5466823		I-284	DEC 23, 2002
020998 003	CELECOXIB; CELEBREX	5563165		NCE	DEC 31, 2003
		5760068		I-338	OCT 17, 2004
		5760068		U-19	
		5972986		U-299	
		5065530		U-299	
>ADD>	CERIVASTATIN SODIUM; BAYCOL	5065530			
>ADD>	CERIVASTATIN SODIUM; BAYCOL	5065530			
>ADD>	CERIVASTATIN SODIUM; BAYCOL	5065530			
>ADD>	CERIVASTATIN SODIUM; BAYCOL	5065530			
>ADD>	CERIVASTATIN SODIUM; BAYCOL	5065530			
>ADD>	CERIVASTATIN SODIUM; BAYCOL	5065530			
>ADD>	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358		NPP	OCT 21, 2005
>ADD>	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358*		PED	APR 21, 2006
>ADD>	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358		NPP	OCT 21, 2005
>ADD>	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358*		PED	APR 21, 2006
>ADD>	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358		NPP	OCT 21, 2005
>ADD>	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358*		PED	APR 21, 2006
020346 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358*		NP	OCT 07, 2005
		4670444		U-223	
021555 001	CHLORHEXIDINE GLUCONATE; CHLORAPREP ONE-STEP			NCE	JUL 17, 2003
020369 001	CIPROFLOXACIN HYDROCHLORIDE; CILOXAN			PED	JAN 17, 2004
020822 001	CITALOPRAM HYDROBROMIDE; CELEXA			NCE	JUL 17, 2003
				PED	JAN 17, 2004
020822 002	CITALOPRAM HYDROBROMIDE; CELEXA			NCE	JUL 17, 2003
020822 003	CITALOPRAM HYDROBROMIDE; CELEXA			PED	JAN 17, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL. USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES
020796 001	ENTACAPONE; COMTAN	5446194	AUG 29, 2012		
		5135950	OCT 31, 2010		
		4963590	NOV 27, 2007		
		5112861	MAY 12, 2009		
		6410054	DEC 08, 2019	U-3 NCE	SEP 27, 2007
		6410524	NOV 05, 2019	U-467	
>ADD>		4559332	APR 09, 2004		
>ADD>		6410054	DEC 08, 2019	U-3 NCE	SEP 27, 2007
>ADD>		6410524	NOV 05, 2019	U-467	
>ADD>		4559332	APR 09, 2004		
>ADD>		6410054	DEC 08, 2019	U-3 NCE	SEP 27, 2007
>ADD>		6410524	NOV 05, 2019	U-467	
020738 006	EPROSARTAN MESYLATE; TEVETEN	4559332	APR 09, 2004		
		5185351	FEB 09, 2010	U-3	
		5656650	AUG 12, 2014	U-3	
		5656650	AUG 12, 2014	U-3	
>ADD>		5656650	AUG 12, 2014	U-3	
>ADD>		5968902	JUN 02, 2015	U-453	
>ADD>		5747447	MAY 05, 2015		
020718 002	EPTIFIBATIDE; INTEGRILIN	5968902	JUN 02, 2015	U-453	
		5747447	MAY 05, 2015		
021323 001	ESCITALOPRAM OXALATE; LEXAPRO	RE34712	JUN 08, 2009		
		RE34712*PED	DEC 08, 2009		
021323 002	ESCITALOPRAM OXALATE; LEXAPRO	RE34712	JUN 08, 2009		
		RE34712*PED	DEC 08, 2009		
021323 003	ESCITALOPRAM OXALATE; LEXAPRO	RE34712	JUN 08, 2009		
		RE34712*PED	DEC 08, 2009		
021153 001	ESOMEPRAZOLE MAGNESIUM; NEXIUM	6369085	MAY 25, 2018	U-469	
		6428810	NOV 03, 2019		
021153 002	ESOMEPRAZOLE MAGNESIUM; NEXIUM	6369085	MAY 25, 2018		
		6428810	NOV 03, 2019		
020655 001	ESTRADIOL; ALORA	5122383	MAY 17, 2011		
>ADD>		5227169	MAY 17, 2011		
>ADD>		5212199	MAY 17, 2011		
>ADD>		5164190	DEC 11, 2010		
				I-351	APR 05, 2005
				I-351	APR 05, 2005
				I-351	APR 05, 2005
				I-351	APR 05, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021129 001	GABAPENTIN; NEURONTIN	6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
021061 001	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015		NCE	DEC 17, 2004
021061 002	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015		NCE	DEC 17, 2004
021062 001	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015			
021062 002	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015			
020622 001	GLATIRAMER ACETATE; COPAXONE	6342476	MAY 24, 2014	U-441		
		6362161	MAY 24, 2014	U-441		
>ADD>	GLIPIZIDE; METAGLIP				NC	OCT 21, 2005
>ADD>	GLIPIZIDE; METAGLIP				NC	OCT 21, 2005
>ADD>	GLIPIZIDE; METAGLIP				NC	OCT 21, 2005
>ADD>	GLYBURIDE; GLUCOVANCE				I-368	SEP 30, 2005
>ADD>	GLYBURIDE; GLUCOVANCE				I-368	SEP 30, 2005
>ADD>	GLYBURIDE; GLUCOVANCE				I-368	SEP 30, 2005
>ADD>	GRANISETRON HYDROCHLORIDE; KYTRIL				I-369	AUG 16, 2005
>ADD>	GRANISETRON HYDROCHLORIDE; KYTRIL				I-369	AUG 16, 2005
>ADD>	GRANISETRON HYDROCHLORIDE; KYTRIL				I-369	AUG 16, 2005
020125 001	HYDROCHLOROTHIAZIDE; ACCURETIC	4886808	DEC 20, 2007	U-105		
		4344949	OCT 03, 2002	U-3	NC	DEC 28, 2002
		4743450	FEB 24, 2007		PED	JUN 28, 2003
020125 002	HYDROCHLOROTHIAZIDE; ACCURETIC	4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		4743450	FEB 24, 2007			
		4344949	OCT 03, 2002	U-3		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
020125 003	HYDROCHLOROTHIAZIDE; ACCURETIC	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
020758 001	HYDROCHLOROTHIAZIDE; AVALIDE	5270317	SEP 30, 2011			
020758 002	HYDROCHLOROTHIAZIDE; AVALIDE	5270317	SEP 30, 2011			
020758 003	HYDROCHLOROTHIAZIDE; AVALIDE	5270317	SEP 30, 2011			
020818 001	HYDROCHLOROTHIAZIDE; DIOVAN HCT	6294197	JUN 18, 2017	U-3		
020818 002	HYDROCHLOROTHIAZIDE; DIOVAN HCT	6294197	JUN 18, 2017	U-3		
020387 001	HYDROCHLOROTHIAZIDE; HYZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009			
		5608075	MAR 04, 2014			
020387 002	HYDROCHLOROTHIAZIDE; HYZAAR	5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010	U-3		
		5153197*PED	APR 06, 2010			
		5608075*PED	SEP 04, 2014			
		5138069	AUG 11, 2009	U-3		
		5153197	OCT 06, 2009			
		5608075	MAR 04, 2014			
		5138069*				

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS EXCLUS CODE	EXPIRES
020729 003	HYDROCHLOROTHIAZIDE; UNIRETIC	4743450	FEB 24, 2007			
020716 001	HYDROCODONE BITARTRATE; VICOPROFEN	6348216	JUN 10, 2017			
021374 001	IBUPROFEN; ADVIL COLD AND SINUS	5071643	DEC 10, 2008			
		5071643*PED	JUN 10, 2009			
		5360615	DEC 10, 2008			
		5360615*PED	JUN 10, 2009			
021373 001	IBUPROFEN; CHILDREN'S ADVIL COL					
075874 001	IFOSFAMIDE; IFOSFAMIDE/MESNA KIT	5618913	APR 08, 2014		NP	AUG 01, 2003
075874 002	IFOSFAMIDE; IFOSFAMIDE/MESNA KIT	5866538	JUN 20, 2017		PED	FEB 01, 2004
020986 001	INSULIN ASPART; NOVOLOG	5547930	SEP 28, 2013		PC	OCT 05, 2002
		5834422	SEP 28, 2013	U-471		
		5948751	JUN 19, 2017			
		5840680	SEP 28, 2013	U-471		
		5618913	APR 08, 2014			
		4396598	DEC 30, 2002	U-31		
		4396598	DEC 30, 2002	U-30		
		4396598	DEC 30, 2002	U-29		
		4396598	DEC 30, 2002	U-29		
		4396598	DEC 30, 2002	U-30		
		4396598	DEC 30, 2002	U-464		
		4396598	DEC 30, 2002	U-28		
		4396598	DEC 30, 2002	U-29		
		4396598	DEC 30, 2002	U-463		
		4396598	DEC 30, 2002	U-62		
		4396598	DEC 30, 2002	U-464		
		4396598	DEC 30, 2002	U-465		
019710 003	IOVERSOL; OPTIRAY 160					
019710 002	IOVERSOL; OPTIRAY 240					
019710 004	IOVERSOL; OPTIRAY 300					
019710 001	IOVERSOL; OPTIRAY 320					
019710 005	IOVERSOL; OPTIRAY 350					
020757 001	IRBESARTAN; AVAPRO					
020757 002	IRBESARTAN; AVAPRO					
020757 003	IRBESARTAN; AVAPRO					
020571 001	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR					
018662 002	ISOTRETINOIN; ACCUTANE					
018662 003	ISOTRETINOIN; ACCUTANE					
018662 004	ISOTRETINOIN; ACCUTANE					
020657 001	ITRACONAZOLE; SPORANOX					
020966 001	ITRACONAZOLE; SPORANOX					
019700 001	KETOROLAC TROMETHAMINE; ACULAR					
020811 001	KETOROLAC TROMETHAMINE; ACULAR					
020564 001	LAMIVUDINE; EPIVIR					
		6407079	JUN 18, 2019	U-449	M-12	MAY 02, 2005
		6407079	JUN 18, 2019		PED	NOV 02, 2005
					M-12	MAY 02, 2005
					PED	NOV 02, 2005
					M-12	MAY 02, 2005
					PED	NOV 02, 2005
					M-16	FEB 08, 2005
					M-16	FEB 08, 2005
					D-2	JUN 24, 2005

PRESCRIPTION AND OTC DRUGS PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES
021249 001	LOVASTATIN; ADVICOR	6080428	MAY 27, 2017	U-447	
		6129930	SEP 20, 2013	U-448	
		6406715	OCT 31, 2017	U-450	
021249 002	LOVASTATIN; ADVICOR	6080428	MAY 27, 2017	U-447	
		6129930	SEP 20, 2013	U-448	
		6406715	OCT 31, 2017	U-450	
021249 003	LOVASTATIN; ADVICOR	6080428	MAY 27, 2017	U-447	
		6129930	SEP 20, 2013	U-448	
		6406715	OCT 31, 2017	U-450	
021316 001	LOVASTATIN; ALTOCOR	5916595	DEC 12, 2017	NDF	JAN 30, 2005
		6080778	MAR 23, 2018	U-456	
021316 002	LOVASTATIN; ALTOCOR	5916595	DEC 12, 2017	NDF	JAN 30, 2005
		6080778	MAR 23, 2018	U-456	
021316 003	LOVASTATIN; ALTOCOR	5916595	DEC 12, 2017	NDF	JAN 30, 2005
		6080778	MAR 23, 2018	U-456	
021316 004	LOVASTATIN; ALTOCOR	5916595	DEC 12, 2017	NDF	JAN 30, 2005
		6080778	MAR 23, 2018	U-456	
019643 002	LOVASTATIN; MEVACOR			PED	AUG 14, 2005
				I-350	FEB 14, 2005
019643 003	LOVASTATIN; MEVACOR			PED	AUG 14, 2005
				I-350	FEB 14, 2005
019643 004	LOVASTATIN; MEVACOR			PED	AUG 14, 2005
				I-350	FEB 14, 2005
020652 001	MANGAFODIPIR TRISODIUM; TESLASCAN	4933456	NOV 27, 2011	PC	NOV 03, 2002
076175 001	MEFLOQUINE HYDROCHLORIDE; MEFLOQUINE HCL			NCE	APR 13, 2005
020938 002	MELOXICAM; MOBIC				
020922 001	MEQUINOL; SOLAGE	6353029	AUG 24, 2020	NDF	MAR 21, 2005
020855 001	MESNA; MESNEX				
013217 001	METAXALONE; SKELAXIN	6407128	DEC 03, 2021	U-189	
013217 003	METAXALONE; SKELAXIN	6407128	DEC 03, 2021	U-189	
020357 001	METFORMIN HYDROCHLORIDE; GLUCOPHAGE			PED	JUN 15, 2004
				I-320	DEC 15, 2003
				W	DEC 15, 2003
				W	JUN 15, 2004
020357 002	METFORMIN HYDROCHLORIDE; GLUCOPHAGE			PED	JUN 15, 2004
				I-320	DEC 15, 2003
				W	DEC 15, 2003
				W	JUN 15, 2004
020357 003	METFORMIN HYDROCHLORIDE; GLUCOPHAGE			PED	JUN 15, 2004
				I-320	DEC 15, 2003
				W	DEC 15, 2003
				W	JUN 15, 2004
020357 004	METFORMIN HYDROCHLORIDE; GLUCOPHAGE			PED	JUN 15, 2004
				I-320	DEC 15, 2003
				W	DEC 15, 2003
				W	JUN 15, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE	6475521	MAR 19, 2018			JUN 15, 2004
>ADD>		4519801	JUL 12, 2002		I-320	DEC 15, 2003
		4612008	SEP 16, 2003		W	DEC 15, 2003
		4783337	SEP 16, 2003		W	JUN 15, 2004
>ADD>		5082668	SEP 16, 2003	U-372		
>ADD>		6344215	OCT 27, 2020			
>ADD>		5837284	MAY 15, 2016			
>ADD>		6228398	MAY 01, 2019	U-472		JUN 07, 2005
>ADD>		5837284	MAY 15, 2016			
>ADD>		6228398	MAY 01, 2019	U-472		JUN 07, 2005
>ADD>		5837284	MAY 15, 2016			
>ADD>		6228398	NOV 01, 2019	U-472		JUN 07, 2005
020415 001	MIRTAZAPINE; REMERON				M-18	APR 09, 2005
020415 002	MIRTAZAPINE; REMERON				M-18	APR 09, 2005
020415 003	MIRTAZAPINE; REMERON				M-18	APR 09, 2005
019297 001	MITOXANTHONE HYDROCHLORIDE;NOVANTRONE				ODE	OCT 13, 2007
020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX				I-360	JUL 17, 2005
021409 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012		PED	JAN 17, 2006
		5565473*	PED AUG 03, 2012		NDF	JUL 26, 2005
					PED	JAN 26, 2006
					NCE	FEB 26, 2006
021260 001	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017			FEB 20, 2003
021260 002	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017			AUG 20, 2003
021260 003	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017			MAR 20, 2005
021260 004	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017			MAR 20, 2005
020763 001	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	JUL 07, 2010			MAR 20, 2005
020763 002	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	JUL 07, 2010			MAR 20, 2005
020152 001	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	MAR 16, 2003			
		4338317*	PED APR 28, 2012			
020152 002	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664*	PED SEP 16, 2003			
		4338317*	PED OCT 28, 2012			
		4338317	MAR 16, 2003			
		5256664	MAR 16, 2003			
		4338317*	PED APR 28, 2012			
		5256664*	PED SEP 16, 2003			
020152 003	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
		5256664	MAR 16, 2003			
		4338317*	PED APR 28, 2012			
		5256664*	PED SEP 16, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES
020152 004	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		
		5256664	APR 28, 2012		
		4338317*PED	SEP 16, 2003		
		5256664*PED	OCT 28, 2012		
020152 005	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		
		5256664	APR 28, 2012		
		4338317*PED	SEP 16, 2003		
		5256664*PED	OCT 28, 2012		
020152 006	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		
		5256664	APR 28, 2012		
		4338317*PED	SEP 16, 2003		
		5256664*PED	OCT 28, 2012		
020778 001	NELFINAVIR MESYLATE; VIRACEPT	6162812	OCT 07, 2013	U-248	
020779 001	NELFINAVIR MESYLATE; VIRACEPT	6162812	OCT 07, 2013	U-248	
020381 001	NIACIN; NIASPAN	6406715	OCT 31, 2017	U-450	
020381 002	NIACIN; NIASPAN	6406715	OCT 31, 2017	U-450	
020381 003	NIACIN; NIASPAN	6406715	OCT 31, 2017	U-450	
020381 004	NIACIN; NIASPAN	6406715	OCT 31, 2017	U-450	
020381 005	NIACIN; NIASPAN TITRATION ST	6406715	OCT 31, 2017	U-450	
		6129930	SEP 20, 2013	U-354	
021330 001	NICOTINE POLACRILEX; COMMIT			NDF	OCT 31, 2005
021330 002	NICOTINE POLACRILEX; COMMIT			NDF	OCT 31, 2005
020076 004	NICOTINE; HABITROL			D-71	NOV 12, 2002
020076 005	NICOTINE; HABITROL			D-71	NOV 12, 2002
020076 006	NICOTINE; HABITROL			D-71	NOV 12, 2002
020555 001	NIZATIDINE; AXID AR				
021008 001	OCTREOTIDE ACETATE; SANDOSTATIN LAR	4375547	APR 12, 2002		
021286 001	OLMESARTAN MEDOXOMIL; BENICAR	6395292	JAN 30, 2017		
021286 003	OLMESARTAN MEDOXOMIL; BENICAR				
021286 004	OLMESARTAN MEDOXOMIL; BENICAR				
019810 001	OMEPRAZOLE; PRILOSEC				
019810 002	OMEPRAZOLE; PRILOSEC				
019810 003	OMEPRAZOLE; PRILOSEC				
020766 001	ORLISTAT; XENICAL				
021492 001	OXALIPLATIN; ELOXATIN				
021492 002	OXALIPLATIN; ELOXATIN				
021285 001	OXCARBAZEPINE; TRILEPTAL				
		6166213	OCT 09, 2018		
		6166213*PED	APR 09, 2019		
		4598089	JUN 18, 2009		
		5420319	APR 07, 2013		
		5338874	APR 07, 2013		
		5290961	JAN 12, 2013		
		5420319	APR 07, 2013		
		5338874	APR 07, 2013		
		5290961	JAN 12, 2013		
		6166213*PED	APR 09, 2019		
		6166213	APR 09, 2019		
		6166213	OCT 09, 2018		
		6166213*PED	APR 09, 2019		
		4598089	JUN 18, 2009		
		5420319	APR 07, 2013		
		5338874	APR 07, 2013		
		5290961	JAN 12, 2013		
		5420319	APR 07, 2013		
		5338874	APR 07, 2013		
		5290961	JAN 12, 2013		
		6166213*PED	APR 09, 2019		
		6166213	APR 09, 2019		
		6166213	OCT 09, 2018		
		6166213*PED	APR 09, 2019		
		4598089	JUN 18, 2009		
		5420319	APR 07, 2013		
		5338874	APR 07, 2013		
		5290961	JAN 12, 2013		
		5420319	APR 07, 2013		
		5338874	APR 07, 2013		
		5290961	JAN 12, 2013		
		6166213*PED	APR 09, 2019		
		6166213	APR 09, 2019		
		6166213	OCT 09, 2018		
		6166213*PED	APR 09, 2019		
		4598089	JUN 18, 2009		
		5420319	APR 07, 2013		
		5338874	APR 07, 2013		
		5290961	JAN 12, 2013		
		5420319	APR 07, 2013		
		5338874	APR 07, 2013		
		5290961	JAN 12, 2013		
		6166213*PED	APR 09, 2019		
		6166213	APR 09, 2019		
		6166213	OCT 09, 2018		
		6166213*PED	APR 09, 2019		
		4598089	JUN 18, 2009		
		5420319	APR 07, 2013		
		5338874	APR 07, 2013		
		5290961	JAN 12, 2013		
		5420319	APR 07, 2013		
		5338874	APR 07, 2013		
		5290961	JAN 12, 2013		

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE CODE	EXCLUS EXCLUS CODE	EXPIRES	EXPIRES
020553 001	OXYCODONE HYDROCHLORIDE; OXYCONTIN	4970075			AUG 29, 2006	
		5266331			OCT 26, 2007	
		5549912			OCT 26, 2007	
		5508042	U-443		APR 16, 2013	
		5656295	U-443		OCT 26, 2007	
020553 002	OXYCODONE HYDROCHLORIDE; OXYCONTIN	4970075			AUG 29, 2006	
		5266331			OCT 26, 2007	
		5549912			OCT 26, 2007	
		5508042	U-443		APR 16, 2013	
		5656295	U-443		OCT 26, 2007	
020553 003	OXYCODONE HYDROCHLORIDE; OXYCONTIN	4970075			AUG 29, 2006	
		5266331			OCT 26, 2007	
		5549912			OCT 26, 2007	
		5508042	U-443		APR 16, 2013	
		5656295	U-443		OCT 26, 2007	
020553 004	OXYCODONE HYDROCHLORIDE; OXYCONTIN	4970075			AUG 29, 2006	
		5266331			OCT 26, 2007	
		5549912			OCT 26, 2007	
		4970075	U-443		AUG 29, 2006	
		5266331	U-443		OCT 26, 2007	
020553 005	OXYCODONE HYDROCHLORIDE; OXYCONTIN	4970075			AUG 29, 2006	
		5266331			OCT 26, 2007	
		5549912			OCT 26, 2007	
		4970075	U-443		AUG 29, 2006	
		5266331	U-443		OCT 26, 2007	
020987 001 020987 002	PANTOPRAZOLE SODIUM; PROTONIX PANTOPRAZOLE SODIUM; PROTONIX	4758579	U-443		JUL 19, 2005	I-356 APR 19, 2005 I-356 APR 19, 2005 I-330 JUN 12, 2004 NCE I-261 FEB 02, 2005 I-326 MAY 17, 2002 I-345 APR 13, 2004 PED DEC 14, 2004 PED OCT 13, 2004 PED JUN 14, 2005 PED NOV 17, 2002
		4721723	U-12		DEC 29, 2006	
020031 001	PAROXETINE HYDROCHLORIDE; PAXIL	5872132			MAY 19, 2015	
		5900423			MAY 19, 2015	
		5789449			JAN 06, 2009	
		6063927			APR 23, 2019	
		6080759			MAY 19, 2015	
		6113944			DEC 14, 2014	
		6121291			MAR 17, 2017	
		6133289			MAY 19, 2015	
		6172233			JAN 15, 2018	
		6121291			MAR 17, 2017	
		4721723*PED			JUN 29, 2007	
		5789449*PED			JUL 06, 2009	
		5872132*PED			NOV 19, 2015	
		5900423*PED			NOV 19, 2015	
		6063927*PED			OCT 23, 2019	
6080759*PED			NOV 19, 2015			
6113944*PED			JUN 14, 2015			
6121291*PED			SEP 17, 2017			
6133289*PED			NOV 19, 2015			
6172233*PED			JUL 19, 2005			
U-286						
U-431						
U-12						
U-285						
U-286						
U-358						
U-431						
U-12						
U-285						
U-286						
U-431						
U-358						

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES
020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-261 MAY 17, 2002
		5872132	MAY 19, 2015		I-326 APR 13, 2004
		5900423	MAY 19, 2015		I-345 DEC 14, 2004
		5789449	JAN 06, 2009		PED OCT 13, 2004
		6063927	APR 23, 2019		PED JUN 14, 2005
		6080759	MAY 19, 2015		PED NOV 17, 2002
		6113944	DEC 14, 2014		
		6121291	MAR 17, 2017		
		6133289	MAY 19, 2015		
		6172233	JAN 15, 2018		
		6121291	MAR 17, 2017		
		4721723*PED	JUN 29, 2007		
		5789449*PED	JUL 06, 2009		
		5872132*PED	NOV 19, 2015		
		5900423*PED	NOV 19, 2015		
		6080759*PED	NOV 19, 2015		
		6113944*PED	JUN 14, 2015		
6121291*PED	SEP 17, 2017				
6121291*PED	SEP 17, 2017				
6133289*PED	NOV 19, 2015				
6172233*PED	JUL 15, 2018				
020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261 MAY 17, 2002
		5872132	MAY 19, 2015		I-326 APR 13, 2004
		5900423	MAY 19, 2015		I-345 DEC 14, 2004
		5789449	JAN 06, 2009		PED OCT 13, 2004
		6063927	APR 23, 2019		PED JUN 14, 2005
		6080759	MAY 19, 2015		PED NOV 17, 2002
		6113944	DEC 14, 2014		
		6121291	MAR 17, 2017		
		6133289	MAY 19, 2015		
		6172233	JAN 15, 2018		
		6121291	MAR 17, 2017		
		4721723*PED	JUN 29, 2007		
		5789449*PED	JUL 06, 2009		
		5872132*PED	NOV 19, 2015		
		5900423*PED	NOV 19, 2015		
		6080759*PED	NOV 19, 2015		
		6113944*PED	JUN 14, 2015		
6121291*PED	SEP 17, 2017				
6121291*PED	SEP 17, 2017				
6133289*PED	NOV 19, 2015				
6172233*PED	JUL 15, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES	
020031 004	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	I-261	MAY 17, 2002	
		5872132	MAY 19, 2015	I-326	APR 13, 2004	
		5900423	MAY 19, 2015	I-345	DEC 14, 2004	
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6133289	MAY 15, 2015	U-358		
		6121291	MAR 17, 2017	U-286		
		6121291	MAR 17, 2017	U-431		
		6172233	JAN 15, 2018	U-12		
		4721723*PED	JUN 29, 2007	U-285		
		5789449*PED	JUL 06, 2009			
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
6133289*PED	NOV 19, 2015	U-358				
6172233*PED	JUL 15, 2018					
4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002		
5872132	MAY 19, 2015		I-326	APR 13, 2004		
5900423	MAY 19, 2015		I-345	DEC 14, 2004		
5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004		
6063927	APR 23, 2019		PED	JUN 14, 2005		
6080759	MAY 19, 2015		PED	NOV 17, 2002		
6113944	DEC 14, 2014					
6121291	MAR 17, 2017	U-286				
6133289	MAY 15, 2015	U-358				
6172233	JAN 15, 2018					
6121291	MAR 17, 2017	U-431				
4721723*PED	JUN 29, 2007	U-12				
5789449*PED	JUL 06, 2009					
5872132*PED	NOV 19, 2015					
5900423*PED	NOV 19, 2015					
6063927*PED	OCT 23, 2019					
6080759*PED	NOV 19, 2015					
6113944*PED	JUN 14, 2015					
6121291*PED	SEP 17, 2017	U-286				
6121291*PED	SEP 17, 2017	U-431				
6133289*PED	NOV 19, 2015	U-358				
6172233*PED	JUL 15, 2018					
4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002		
5872132	MAY 19, 2015		I-326	APR 13, 2004		
5900423	MAY 19, 2015		I-345	DEC 14, 2004		
5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004		
6063927	APR 23, 2019		PED	JUN 14, 2005		
6080759	MAY 19, 2015		PED	NOV 17, 2002		
6113944	DEC 14, 2014					
6121291	MAR 17, 2017	U-286				
6133289	MAY 15, 2015	U-358				
6172233	JAN 15, 2018					
6121291	MAR 17, 2017	U-431				
4721723*PED	JUN 29, 2007	U-12				
5789449*PED	JUL 06, 2009					
5872132*PED	NOV 19, 2015					
5900423*PED	NOV 19, 2015					
6063927*PED	OCT 23, 2019					
6080759*PED	NOV 19, 2015					
6113944*PED	JUN 14, 2015					
6121291*PED	SEP 17, 2017	U-286				
6121291*PED	SEP 17, 2017	U-431				
6133289*PED	NOV 19, 2015	U-358				
6172233*PED	JUL 15, 2018					

PRESCRIPTION AND OTC DRUG PRODUCT
 NAME, TRADENAME AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL. USE EXPIRES	EXCL. CODE	EXCL. CODE	EXCL. EXPIRES	
020936 001	PAROXETINE HYDROCHLORIDE; PAXIL CR	5872132	MAY 19, 2015		1-358	FEB 12, 2005	
		4839177	JUN 13, 2006		PED	AUG 12, 2005	
		5422123	JUN 06, 2012				
		4721723	DEC 29, 2006				
		5900423	MAY 19, 2015	U-286			
		5789449	JAN 06, 2009				
		6063927	APR 23, 2019				
		6080759	MAY 19, 2015				
		6121291	MAR 17, 2017	U-286			
		6133289	MAY 19, 2015	U-286			
		6172233	JAN 15, 2018				
		4721723*	JUN 29, 2007				
		4839177*	DEC 13, 2006				
		5422123*	DEC 06, 2012				
		5789449*	JUL 06, 2009				
		5872132*	NOV 19, 2015	U-286			
		5900423*	NOV 19, 2015				
		6063927*	OCT 23, 2019				
		6080759*	NOV 19, 2015	U-286			
		020936 002	PAROXETINE HYDROCHLORIDE; PAXIL CR	6121291*	SEP 17, 2017		
6133289*	NOV 19, 2015						
6172233*	JUL 15, 2018						
5872132	MAY 19, 2015				I-358	FEB 12, 2005	
4839177	JUN 13, 2006				PED	AUG 12, 2005	
5422123	JUN 06, 2012						
4721723	DEC 29, 2006						
5900423	MAY 19, 2015			U-286			
5789449	JAN 06, 2009						
6063927	APR 23, 2019						
6080759	MAY 19, 2015						
6121291	MAR 17, 2017			U-286			
6133289	MAY 19, 2015			U-286			
6172233	JAN 15, 2018						
4721723*	JUN 29, 2007						
4839177*	DEC 13, 2006						
5422123*	DEC 06, 2012						
5789449*	JUL 06, 2009						
5872132*	NOV 19, 2015	U-286					
5900423*	NOV 19, 2015						
6063927*	OCT 23, 2019						
6080759*	NOV 19, 2015	U-286					
6121291*	SEP 17, 2017						
6133289*	NOV 19, 2015						
6172233*	JUL 15, 2018						

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020865 002	RIZATRIPTAN BENZOATE; MAXALT-MLT	5298520	JUN 29, 2012	U-240	I-353	APR 11, 2005
021042 001	ROFECOXIB; VIOXX	5691374	MAY 18, 2015	U-266	I-353	APR 11, 2005
021042 002	ROFECOXIB; VIOXX	6063811	MAY 06, 2017	U-266	I-353	APR 11, 2005
021042 003	ROFECOXIB; VIOXX	5691374	MAY 18, 2015	U-266	I-353	APR 11, 2005
021052 001	ROFECOXIB; VIOXX	6063811	MAY 06, 2017	U-266	I-353	APR 11, 2005
021052 002	ROFECOXIB; VIOXX	5691374	MAY 18, 2015	U-266	I-353	APR 11, 2005
020658 001	ROPINIROLE HYDROCHLORIDE; EQUIP	6063811	MAY 06, 2017	U-266	I-353	APR 11, 2005
020658 002	ROPINIROLE HYDROCHLORIDE; EQUIP	4452808	DEC 07, 2007			
020658 003	ROPINIROLE HYDROCHLORIDE; EQUIP	4452808	DEC 07, 2007			
020658 004	ROPINIROLE HYDROCHLORIDE; EQUIP	4452808	DEC 07, 2007			
020658 005	ROPINIROLE HYDROCHLORIDE; EQUIP	4452808	DEC 07, 2007			
020658 006	ROPINIROLE HYDROCHLORIDE; EQUIP	4452808	DEC 07, 2007			
020658 007	ROPINIROLE HYDROCHLORIDE; EQUIP	4452808	DEC 07, 2007			
020692 001	SALMETEROL XINAFOATE; SEREVENT	4452808	DEC 07, 2007			
020828 001	SAQUINAVIR; FORTOVASE	6352717	NOV 16, 2019		I-348	MAR 22, 2005
021209 001	SECRETIN; SECREFO	6008228	JUN 06, 2015			
019839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U-12	NP	APR 04, 2005
		4536518*PED	JUN 30, 2006	U-12	ODE	APR 04, 2009
		5248699	AUG 13, 2012		I-355	MAY 16, 2005
		5248699*PED	FEB 13, 2013			
		5744501	FEB 13, 2013	U-461		
		5789449	JAN 06, 2009	U-460		
019839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG 13, 2012	U-12		
		5248699*PED	FEB 13, 2013	U-12		
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		5248699	AUG			

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019839 005	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
		6444859	JAN 27, 2017			
		6444859*PED	JUL 27, 2017			
		4746680	JUN 11, 2007	U-439		
		5436272	JUL 25, 2012			
		4746680	JUN 11, 2007	U-439		
		5436272	JUL 25, 2012			
		4746680	JUN 11, 2007	U-439		
		5436272	JUL 25, 2012			
		6469012	OCT 22, 2019	U-155		
		5250534	MAR 27, 2012	U-155		
		6469012	OCT 22, 2019			
		5250534	MAR 27, 2012	U-155		
		6469012	OCT 22, 2019			
		5250534	MAR 27, 2012	U-155		
>ADD>						
>ADD>						
>ADD>						
>ADD>						
>ADD>						
>ADD>						
>ADD>						
>ADD>						
>ADD>						
>ADD>						
019766 001	SIMVASTATIN; ZOCOR					
019766 002	SIMVASTATIN; ZOCOR					
019766 003	SIMVASTATIN; ZOCOR					
019766 004	SIMVASTATIN; ZOCOR					
019766 005	SIMVASTATIN; ZOCOR					
021196 001	SODIUM OXYBATE; XYREM					
020572 001	SODIUM PHENYLBUTYRATE; BUPHENYL	4457942	AUG 20, 2004	U-136		
020573 001	SODIUM PHENYLBUTYRATE; BUPHENYL	4457942	AUG 20, 2004	U-136		
021075 001	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5912015	MAR 12, 2012			
021075 002	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5912015	MAR 12, 2012			
021075 003	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5912015	MAR 12, 2012			
020604 004	SOMATROPIN RECOMBINANT; SEROSTIM					
020677 001	SPARFLOXACIN; ZAGAM	4795751	FEB 04, 2010	U-160		
020132 001	SUMATRIPTAN SUCCINATE; IMITREX	6368627	MAR 02, 2012	U-444		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020132 002	SUMATRIPTAN SUCCINATE; IMITREX	6368627	MAR 02, 2012	U-444		
020132 003	SUMATRIPTAN SUCCINATE; IMITREX	6368627	MAR 02, 2012	U-444		
017970 001	TAMOXIFEN CITRATE; NOLVADEX	4536516	AUG 20, 2002		M-20	AUG 30, 2005
		4536516*	PED FEB 20, 2003		PED	MAR 01, 2006
017970 002	TAMOXIFEN CITRATE; NOLVADEX	4536516	AUG 20, 2002			
		4536516*	PED FEB 20, 2003			
>ADD>					NP	SEP 30, 2005
021184 003	TAZAROTENE; AVAGE	4452774	DEC 21, 2004			
019785 001	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE	4452774	DEC 21, 2004			
019785 003	TECHNETIUM TC-99M SESTAMIBI KIT; MTRALUMA	5510353	APR 26, 2013	U-466	NCE	JUL 24, 2007
021200 001	TEGASEROD MALEATE; ZELNORM	5510353	APR 26, 2013	U-466	NCE	JUL 24, 2007
021200 002	TEGASEROD MALEATE; ZELNORM	5510353	APR 26, 2013			
021029 001	TEMZOLOMIDE; TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*	PED MAY 09, 2011		ODE	AUG 11, 2006
>ADD>					PED	FEB 11, 2005
>ADD>					PED	FEB 11, 2007
>ADD>					NCE	AUG 11, 2004
>ADD>					ODE	AUG 11, 2006
>ADD>					PED	FEB 11, 2005
>ADD>					PED	FEB 11, 2007
021029 002	TEMZOLOMIDE; TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*	PED MAY 09, 2011		ODE	AUG 11, 2006
>ADD>					PED	FEB 11, 2005
>ADD>					PED	FEB 11, 2007
021029 003	TEMZOLOMIDE; TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*	PED MAY 09, 2011		ODE	AUG 11, 2006
>ADD>					PED	FEB 11, 2005
>ADD>					PED	FEB 11, 2007
021029 004	TEMZOLOMIDE; TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*	PED MAY 09, 2011		ODE	AUG 11, 2006
>ADD>					PED	FEB 11, 2005
>ADD>					PED	FEB 11, 2007
020846 001	TERBINAFINE; LAMISIL	4755534	DEC 30, 2006	U-445		
		4680291	JUL 14, 2004	U-445		
020791 001	TESTOSTERONE; TESTODERM TTS	6348210	NOV 10, 2019	U-440		
020785 001	THALIDOMIDE; THALOMID	6315720	OCT 23, 2020	U-442		
021447 001	TIZANIDINE HYDROCHLORIDE; ZANAFLEX	6455557	NOV 28, 2021			
021447 002	TIZANIDINE HYDROCHLORIDE; ZANAFLEX	6455557	NOV 28, 2021			
021447 003	TIZANIDINE HYDROCHLORIDE; ZANAFLEX	6455557	NOV 28, 2021			
020697 001	TOLCAPONE; TASMAR	5236952	JAN 29, 2012			
020697 002	TOLCAPONE; TASMAR	5236952	JAN 29, 2012			
021228 001	TOLTERODINE TARTRATE; DETROL LA	5559269	NOV 05, 2013	U-318		
021228 002	TOLTERODINE TARTRATE; DETROL LA	5559269	NOV 05, 2013	U-318		
020671 001	TOPOTECAN HYDROCHLORIDE; Hycamtin	5004758	MAY 28, 2010			
		5004758*	PED NOV 28, 2010			
>ADD>					PC	FEB 17, 2003
>ADD>					PC	DEC 10, 2002
>ADD>					PC	DEC 07, 2002
>ADD>					PC	DEC 10, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 * PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES
021267 001	VORICONAZOLE; VFEND	6294572	DEC 15, 2014	NCE	MAY 24, 2007
021036 001	ZANAMIVIR; RELENZA	6150366	MAY 27, 2019		
020825 001	ZIPRASIDONE HYDROCHLORIDE; GEODON	6150366	MAY 27, 2019		
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	6150366	MAY 27, 2019		
020825 003	ZIPRASIDONE HYDROCHLORIDE; GEODON	6150366	MAY 27, 2019		
020825 004	ZIPRASIDONE HYDROCHLORIDE; GEODON	6150366	MAY 27, 2019		
020919 001	ZIPRASIDONE MESYLATE; GEODON	6399777	APR 01, 2017	NCE	FEB 05, 2006
		4831031	MAR 02, 2007	NDF	JUN 21, 2005
		6110918	MAR 26, 2017		
		6232304	APR 01, 2017		
021223 001	ZOLEDRONIC ACID; ZOMETA	5466699	NOV 14, 2012	I-361	FEB 22, 2005
021231 001	ZOLMITRIPTAN; ZOMIG-ZMT	6342515	DEC 21, 2018	NCE	NOV 25, 2002
020789 001	ZONISAMIDE; ZONEGRAN			U-438	

ALPHABETICALLY BY TITLE

DUE TO S
DEVELOP
EDITION F
AND PAT

W

D-71
D-72
D-73
D-74
D-75

D-76

D-77

I-348

I-349
I-350

I-351
I-352

I-353
I-354
I-355
I-356

I-357
I-358
I-359
I-360

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 22ND EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

- W EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.3 OF SUPPLEMENT WAIVED EXCLUSIVITY

REFERENCES

NEW DOSING SCHEDULE

- D-71 EIGHT WEEK DOSING REGIMEN
 D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
 D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
 D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
 D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
 D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
 D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)

NEW INDICATION

- I-348 LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
 I-349 ACUTE CORONARY SYNDROME
 I-350 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
 I-351 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
 I-352 ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
 I-353 TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
 I-354 MANAGEMENT OF POST HERPETIC NEURALGIA
 I-355 PREMENSTRUAL DYSPHORIC DISORDER
 I-356 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
 I-357 TREATMENT OF COMPLICATED SINUS AND SKIN STRUCTURE INFECTIONS
 I-358 TREATMENT OF PANIC DISORDER
 I-359 TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
 I-360 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE

- I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
- I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
- I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
- I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
- I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-367 COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
- I-368 USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
- I-369 PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING

U-455
U-456
U-45
U-458
U-459
U-460
U-461
U-462
U-463
U-464
U-465
U-466
U-467

MISCELLANEOUS EXCLUSIVITY CODES

- M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
- M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
- M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
- M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
- M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
- M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
- M-21 COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
- M-22 CHANGE IN TIME TO ONSET OF ACTION

U-468
U-469
U-470
U-471
U-472

PATENT USE CODES

- U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
- U-439 TREATMENT OF OBESITY
- U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
- U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
- U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
- U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- U-444 METHOD OF TREATING
- U-445 USE AS AN ANTIMYCOTIC AGENT
- U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
- U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
- U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
- U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-452 USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
- U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
- U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A

U-473
U-474
U-475
U-476
U-477
U-478

- CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
- U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
- U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
- U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
- U-458 METHOD OF USE OF IMAGENT
- U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
- U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
- U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
- U-463 VENOGRAPHY
- U-464 PERIPHERAL ARTERIOGRAPHY
- U-465 CT IMAGING OF THE HEAD
- U-466 TREATMENT OF IRRITABLE BOWEL SYNDROME
- U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
- U-468 METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
- U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
- U-470 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
- U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
- U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
- U-473 TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
- U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
- U-475 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
- U-477 METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
- U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B

VISA

DP, and the

your order!

(2008)